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SUMMARY 
The inner cellular lining of all blood vessels consists of a monolayer of endothelial 
cells (ECs) that have a low proliferation rate in healthy tissue. Under pathological 
conditions such as wound healing, inflammation and in growing tumors, the 
proliferation rate of ECs is elevated. Radiotherapy is commonly used for the local 
control of solid tumors. During radiotherapy of patients with thoracic tumors, the 
surrounding healthy tissue including ECs of heart and lung may become damaged 
which in turn can change the proliferation rate of these resting ECs. This damage 
may increase the risk to develop cardiac diseases in patients after thoracic 
irradiation at later time-points. It is hypothesized that the protein profile of resting 
and growing primary ECs is different. To address this question, viable primary ECs 
are required. Established methods allow the isolation of ECs only from very young 
mice at low yields and purities. The analysis of late radiation-induced effects on 
primary ECs requires the availability of primary ECs from old mice. 
I succeeded to establish a novel method for the isolation of viable primary ECs at 
high purity from non-proliferating (heart from young and old mice), proliferating 
benign (repair blastema) and malignant (tumor) tissues at high yields. These ECs 
were characterized phenotypically, functionally and with respect to their gene 
expression profiling under static and physiological flow conditions. 
The expression density of proliferation markers such as endoglin and VE-cadherin 
is higher on isolated ECs of proliferating tissues from repair blastema and tumor 
compared to non-proliferating normal tissues from heart and lung. The expression 
density of the progenitor marker mucosialin is elevated on tumor-derived ECs, but 
not on those of repair blastemas. The inflammatory markers PECAM-1, ICAM-1 
and ICAM-2 were found to be elevated on ECs of repair blastema and tumor 
compared to ECs from heart and lung. Further, I could show that tumor ECs are 
larger, have a significantly higher migration capacity and distribute in a more 
chaotic pattern in cell culture compared to ECs derived from normal tissues. Tube 
formation assays showed that tumor ECs have a smaller number of branching 
points and loops compared to that of normal ECs. In contrast to normal tissue 
ECs, tumor-derived ECs show no tendency to align under flow conditions. The 
results suggest that increased expression of surface molecules on ECs in 
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proliferating tissues contributes to a loss of EC function that might be responsible 
for a chaotic tumor vasculature. 
In contrast to the short-term effects in tumors and repair blastemas induced by 
proliferation, irradiation can cause long-term effects in heart and lung ECs. Local 
thorax irradiation of mice resulted in a temporary and differential up-regulation of 
proliferation markers such as HCAM, integrin β3, endoglin, VE-cadherin and 
VEGFR-2 on ECs after 8 Gy at later time-points. The progenitor marker mucosialin 
is increased on lung ECs 15 to 20 weeks after irradiation. Inflammatory markers 
such as PECAM-1, ICAM-1, ICAM-2 and VCAM-1 started to increase 10 weeks 
after thorax irradiation with 8 Gy. Interestingly, ICAM-1 and VCAM-1 remained up-
regulated even 20 weeks after thorax irradiation on heart and lung ECs. The 
persistent increase of both markers ICAM-1 and VCAM-1 after irradiation may 
suggest a predisposition for the development of atherosclerotic plaques in heart 
and lung ECs at later time points. 
Shear stress on ECs induced by blood flow is disturbed in heart capillaries with 
atherosclerotic plaques as well as in tumor vasculature. mRNA expression 
analysis of genes from heart ECs under normal flow conditions and pathological 
static conditions in vitro show significant changes related to extracellular 
organisation, cell membrane function, signaling, hemostasis, metabolism and 
smooth muscle contraction. Moreover, it was observed that mRNA expression of 
the inflammation markers Pecam1, Icam1 and Icam2 was higher on heart ECs 
under static conditions. The protein expression of these inflammatory markers was 
also elevated on ECs from pathologic conditions. These results provide the basis 
for subsequent investigations on the role of irradiation on gene expression profiles 
of ECs derived from normal and tumor tissues. 
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Zusammenfassung 
Die innere Oberfläche aller Blutgefäße besteht aus einer einschichtigen Lage aus 
Endothelzellen, die im gesunden Gewebe eine niedrige Vermehrungsrate 
aufweisen. Unter pathologischen Bedingungen wie Wundheilung, Entzündung und 
wachsenden Tumoren ist die Vermehrungsrate von Endothelzellen erhöht. Für die 
lokale Kontrolle von soliden Tumoren wird allgemein die Strahlentherapie 
verwendet. Während der Strahlentherapie von Patienten mit einem Tumor im 
Thorax-Bereich kann benachbartes gesundes Gewebe einschließlich 
Endothelzellen des Herzens und der Lunge beschädigt werden, wodurch sich die 
Vermehrungsrate dieser ruhenden Endothelzellen verändern kann. Diese 
Beschädigung kann das Risiko einer auftretenden Herzerkrankung nach Thorax-
Bestrahlung zu späteren Zeitpunkten erhöhen. Es wird angenommen, dass das 
Proteinprofil von ruhenden und wachsenden primären Endothelzellen 
unterschiedlich ist. Für diese Fragestellung sind lebensfähige primäre 
Endothelzellen erforderlich. Etablierte Methoden erlauben die Isolierung von 
Endothelzellen nur von sehr jungen Mäusen mit geringer Ausbeute und Reinheit. 
Die Analyse von späten bestrahlungs-induzierten Effekten von primären 
Endothelzellen erfordert die Verfügbarkeit von primären Endothelzellen von alten 
Mäusen. 
Mir ist es gelungen, eine neue Methode für die Isolierung von lebensfähigen 
primären Endothelzellen mit hoher Reinheit aus nicht wachsenden (Herz von 
jungen und alten Mäusen), wachsenden benignen (Reparatur-Blastem) und 
malignen (Tumor) Geweben mit hoher Ausbeute zu etablieren. Diese 
Endothelzellen wurden phänotypisch, funktionell und hinsichtlich ihrer 
Genexpressionsprofile unter statisch und physiologischen Flussbedingungen 
charakterisiert. 
Die Expressionsdichte der Proliferations-Marker wie Endoglin und VE-Cadherin ist 
höher auf isolierten Endothelzellen von wachsenden Geweben aus Reparatur-
Blastem und Tumor im Vergleich zu nicht wachsendem, normalem Gewebe aus 
Herz und Lunge. Die Expressionsdichte des Vorläufer-Markers Mucosialin ist 
erhöht auf Endothelzellen aus dem Tumor, aber nicht auf denen aus dem 
Reparatur-Blastem. Die Entzündungsmarker PECAM-1, ICAM-1 und ICAM-2 
waren erhöht auf Endothelzellen aus dem Reparatur-Blastem und Tumor im 
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Vergleich zu Endothelzellen aus Herz und Lunge. Des Weiteren konnte ich zeigen, 
dass die Tumor-Endothelzellen größer sind, eine signifikant höhere 
Migrationskapazität und eine chaotische Verteilung in Zellkultur im Vergleich zu 
Endothelzellen aus normalem Gewebe aufweisen. Tube-Bildungs-Versuche 
zeigten, dass Tumor-Endothelzellen eine geringere Anzahl von 
Verzweigungspunkten und Schlaufen im Vergleich zu normalen Endothelzellen 
aufweisen. Im Gegensatz zu normalen Endothelzellen zeigen Tumor-
Endothelzellen keine Ausrichtung unter Flussbedingungen. Diese Ergebnisse 
legen nahe, dass eine erhöhte Expression von Oberflächenmolekülen auf 
Endothelzellen in wachsenden Geweben an einem Verlust der Endothelzellen-
Funktion mitwirkt, die für die chaotische Tumor-Vaskularisierung verantwortlich 
sein könnte. 
Im Gegensatz zu den durch das Wachstum bedingten kurzfristigen Auswirkungen 
in Reparatur-Blastemen und Tumoren, kann Bestrahlung langfristige 
Auswirkungen in Endothelzellen des Herzens und der Lunge verursachen. Lokale 
Thorax-Bestrahlung von Mäusen mit 8 Gy führt zu einer vorübergehenden und 
unterschiedlichen Hochregulierung der Proliferations-Marker HCAM, Integrin β3, 
Endoglin, VE-Cadherin und VEGFR-2 auf Endothelzellen zu späteren Zeitpunkten. 
Der Vorläufer-Marker Mucosialin ist auf Lungen-Endothelzellen 15−2 0 Wochen 
nach Bestrahlung erhöht. Entzündungs-Marker wie PECAM-1, ICAM-1, ICAM-2 
und VCAM-1 waren ab 10 Wochen nach Thorax-Bestrahlung mit 8 Gy erhöht. 
Interessanterweise blieben 20 Wochen nach Thorax-Bestrahlung ICAM-1 und 
VCAM-1 auf Herz- und Lungen-Endothelzellen hochreguliert. Die anhaltende 
Erhöhung der beiden Marker ICAM-1 und VCAM-1 nach Bestrahlung legt eine 
Prädisposition für die Entwicklung von arteriosklerotischen Plaques in Herz- und 
Lungen-Endothelzellen zu späteren Zeitpunkten nahe. 
Die durch Blutfluss verursachte Scherbelastung auf Endothelzellen ist in Herz- 
Kapillaren mit arteriosklerotischen Plaques sowie in Tumorgefäßen gestört. 
mRNA-Expressionsanalysen von Genen aus Herz-Endothelzellen unter normalen 
Fluss- und pathologisch statischen Bedingungen in vitro zeigen signifikante 
Veränderungen bezüglich extrazellulärer Organisation, Funktionen der 
Zellmembran, Signalgebung, Blutstillung, Stoffwechsel und Kontraktion der glatten 
Muskulatur. Zudem wurde festgestellt, dass die mRNA-Expression von 
Entzündungs-Markern Pecam1, Icam1 und Icam2 unter statischen Bedingungen 
Zusammenfassung 
XII 
 
höher auf Herz-Endothelzellen war. Die Protein-Expression dieser Entzündungs-
Marker war ebenfalls auf Endothelzellen aus pathologischen Bedingungen erhöht. 
Diese Ergebnisse liefern die Basis für weitere Untersuchungen über die Wirkung 
der Bestrahlung auf Genexpressionsprofile von Endothelzellen aus normalen und 
Tumorgeweben. 
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1. INTRODUCTION 
The inner cellular lining of all blood vessels consists of a monolayer of endothelial 
cells (ECs). This monolayer (endothelium) has direct contact with the blood and 
the circulating cells (Feletou 2011). The diffusion limit of oxygen from the 
endothelium to non-vascular tissue in the body ranges from 100 to 200 µm 
(Hoeben et al. 2004). Therefore, a dense network of blood vessels is necessary 
for an adequate supply of each cell with oxygen and nutrients in the whole body. In 
adult organisms, the vascular system is fully developed. The proliferation rate of 
these resting ECs is commonly low. In contrast, under pathological conditions 
such as wound healing, inflammation and tumors the proliferation rate is high. The 
induce formation of new blood vessel from existing vessels is one of the hallmarks 
for the development of tumors (Hanahan and Weinberg 2011).  
Thoracic radiotherapy is commonly used for the treatment of Hodgkin's lymphoma 
and breast cancer patients (Gabriels et al. 2012). However, surrounding healthy 
tissue including the heart also may receive radiation doses. The pathological 
consequences of radiation-induced heart disease are myocardial fibrosis, 
cardiomyopathy, coronary artery disease, valvular disease and pericardial disease 
(Taunk et al. 2015). Experimental studies of radiation-induced heart diseases have 
shown major functional changes in the microvasculature of the myocardium, 
particularly to microvascular ECs (Schultz-Hector and Trott 2007). In a mouse 
model, it was shown that local heart irradiation with single doses of 2 and 8 Gy led 
to a significant temporary increase in microvascular density after 20 weeks 
(Seemann et al. 2012). 
The high proliferation rate of ECs in tumors and hearts after irradiation represent 
pathological hallmarks. It has therefore been assumed that proteins expressed in 
ECs of resting and growing tissues may be different.  
 
1.1 Vasculature 
1.1.1 Structure and function 
Although the endothelium shows organ specific variability, arteries and veins have 
a general structure consisting of three layers: the tunica interna (intima), the tunica 
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media (media) and the tunica externa (adventitia) (Figure 1) (Martinez-Lemus 
2012)). The tunica interna consists mostly of ECs, the tunica media consists 
mainly of smooth muscle cells and the tunica externa is composed mostly of 
collagen fibers and extra-cellular matrix. In capillaries, the endothelial monolayer 
with the basal lamina is the only cell barrier between blood and intercellular space, 
stroma and parenchymal cells (Bolender 1974). In healthy tissue, ECs are 
surrounded with external pericytes in a ratio between 1:1 and 10:1 (Armulik et al. 
2011). Pericytes play an important role in the regulation of capillary barriers, 
capillary diameter and endothelial proliferation. In healthy tissue, ECs are typically 
flat and align in the direction of blood flow as response to fluid shear stress 
(Resnick et al. 2003; Aird 2007). Shear stress is the force per unit area created 
when a tangential force of blood flow acts on the endothelium (Pan 2009). 
 
 
 
Figure 1: Schematic representation of the vascular wall (arteriole) (Martinez-Lemus 2012). 
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The endothelium plays an important role not only as a supply system or cell barrier 
but also in many physiological functions, including vascular permeability, leukocyte 
trafficking, hemostasis and the regulation of vasomotor tone (Aird 2007). The 
endothelium is semipermeable and allows the transport of fluids and solutes into 
and out of the blood. Tight junctions and adherens junctions are recognized as 
intercellular junctions in the endothelium. Tight junctions are located in the most 
apical position toward the vessel lumen and strictly control permeability. Adherent 
junctions are ubiquitously distributed. The transfer of solutes and fluids between 
blood and underlying tissue occurs by different mechanisms and depends on the 
organ. In continuous non-fenestrated endothelium (heart, lung, skin, brain), water 
and solutes (<3 nm) are able to pass between ECs, whereas larger solutes pass 
through ECs via channels or caveolae. Caveolae are particularly present in heart 
capillaries and rare in brain capillaries due to the blood-brain barrier. Continuous 
fenestrated endothelium is characterized by greater permeability (70 nm) to water 
and solutes via diaphragms and is observed in tissue with increased filtration 
(exocrine and endocrine glands, gastric and intestinal mucosa). Discontinuous 
endothelium has larger fenestrations (100-200 nm) without diaphragms and is 
found predominantly in the liver, but also in the spleen and bone marrow (Aird 
2007; Feletou 2011). The passage of leukocytes from blood to underlying tissue is 
performed by an adhesion cascade that includes attachment, rolling and 
transmigration with the help of different endothelial adhesion molecules. The 
accumulation of lymphocytes, monocytes, macrophages and neutrophils is an 
important step in the inflammatory response of the immune system. ECs are also 
involved in hemostasis. On the pro-coagulant side, ECs synthesize tissue factors 
(TF), plasminogen activator inhibitor, von Willebrand factor (vWF) and protease 
activated receptors (PARs). The synthesis of endothelial vWF and PARs induces 
the adhesion of thrombocytes to the endothelium (Sadler 1998; Alberelli and De 
Candia 2014). TP is involved in the blood clotting due to the formation of fibrin 
(Mackman 2009). On the anti-coagulant side, ECs express tissue factor inhibitor, 
heparin, thrombomodulin, endothelial protein C receptor, tissue plasminogen 
activator (t-PA), ecto-ADPase, prostacyclin, and nitric oxide (NO) (Aird 2007). 
Endothelial heparin acts as a cofactor for antithrombin, which inhibits pro-
coagulant enzymes (Olson and Chuang 2002). Prostacyclin (PGLI2
Weiss and Turitto 1979
) inhibits the 
adhesion of thrombocytes ( ). The synthesis of t-PA 
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activates fibrinolysis. Thrombomodulin is expressed on the surface of ECs and 
inactivates thrombin. Maintenance of the physiologic laminar shear stress is 
known to be crucial for normal vascular function (Cunningham and Gotlieb 2005). 
Steady laminar shear stress promotes the release of factors from ECs (NO, PGL2
Traub and Berk 1998
, 
t-PA, thrombomodulin) that inhibit coagulation, migration of leucocytes and smooth 
muscle proliferation. Low or disturbed shear stress shift the profile of factors in a 
situation that leads to the opposite effects ( ). 
 
1.1.2 Origin and neovascularisation 
Vessel density results from the metabolic needs of oxygen and nutrients (Bergers 
and Benjamin 2003). The development of new blood vessels can occur by 
vasculogenesis and angiogenesis (Buschmann and Schaper 1999). During 
embryonic vasculogenesis, blood vessels are formed from endothelial progenitor 
cells (angioblasts) that assemble into a primitive network. The extension in a 
complex vascular system occurs by angiogenesis (Bergers and Benjamin 2003). 
In this way new blood vessels are formed from preexisting ECs which are 
stimulated by a variety of factors. A less established formation is the 
arteriogenesis, which describes the proliferation of collateral arteries from 
preexisting ECs and which is stimulated by shear stress even in the absence of 
hypoxia (Heil et al. 2006). In adults, the vasculature is usually quiescent and the 
turnover rate of ECs is generally low. 
The neovascularisation is the formation of new blood vessels in adult organism. In 
healthy tissue, the formation occurs only in wound healing, in the female 
reproductive cycle and during pregnancy (Reynolds and Redmer 2001; Hoeben et 
al. 2004). During vasculogenesis, endothelial progenitor cells can be mobilized 
from the bone marrow and transported through the blood-flow to incorporate in 
growing vessels. The angiogenesis starts with vasodilation and an increased 
vascular permeability, followed by extravasation of plasma proteins and loosening 
of pericytes (Figure 2). After degradation of the vascular basement membrane, 
ECs proliferate and migrate towards chemotactic angiogenic stimuli and form a 
column in the perivascular space. The association of a new basal lamina and 
pericytes leads to an intact blood vessel (Bergers and Benjamin 2003).  
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Figure 2: New blood vessel formation (A) Blood vessels arise from pre-existing capillaries. (B) 
First, pericytes (green) detach and blood vessels dilate before (C) the basement membrane and 
extracellular matrix is degraded. (D) After degradation, ECs (red) proliferate and migrate towards 
chemotactic stimuli and form a column in the perivascular space. (E) ECs from two growing 
columns adhere to each other and create a lumen. Little is known about this fusion mechanism 
(Bergers and Benjamin 2003). 
 
1.2 Endothelial cells 
1.2.1 Isolation methods 
All EC isolation methods generally consist of the generation of a single cell 
suspension from the corresponding tissue and the separation of ECs from all other 
cells. Tissue digestion was performed often with collagenase and trypsin, 
occasionally with pronase, dispase and hyaluronidase. The first isolation methods 
that are still commonly used were derived from the human umbilical vein (Jaffe et 
al. 1973; Gimbrone et al. 1974). This endothelium is large and can easily be 
obtained. In this case, high purities of macrovascular ECs can be obtained by 
clamping the vein and performing short enzymatic digestion. Alternatively, large 
arteries were also useful. Here, macrovascular ECs can be obtained by gentle 
scraping of the intimal surface (Ryan et al. 1980; Gajdusek and Schwartz 1983). 
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Unfortunately, these simple methods are not suitable for the isolation of 
microvascular ECs from a complex organ. In this case, ECs must be separated 
from all other cells. 
Early methods relied on the morphology of ECs after seeding. The cells become 
adherent and proliferate in the following days. Initially, the development of 
capillaries or the removal of the endothelium from the vessels was the basis for 
successful EC isolation (White and Parshley 1951; Maruyama 1963). This was 
replaced by the observation that ECs show a typical cobblestone morphology at 
confluence in vitro (Ryan 1984; Marks et al. 1985; Davies et al. 1987; Launder et 
al. 1987). Contaminated cells show often spindle-shaped morphology and also 
become strongly adherent and must be separated early in culture from ECs to 
ensure that ECs are not overgrown. In addition, ECs and contaminated cells tend 
to change their morphology and behavior depending on the growth medium, with 
the result that it is not possible to distinguish between them. Some manual 
techniques include removal of contaminating colonies using a needle or cell 
scraper (Marks et al. 1985; King et al. 2004). Other procedures perform the 
removal of ECs from their contaminants. Once identified, the ECs are 
encapsulated and detached from their environment with the help of cloning 
rings/discs or glass beads (King et al. 2004; Teng et al. 2006). Although this 
procedure is still used, magnetic beads are generally used for successful 
separation. In this case, beads are coated with a specific molecule or antibody, 
which recognizes ECs. After incubation, the cells with bound beads are separated 
with the help of a magnet. The method of MACS (Magnetic Activated Cell Sorting) 
separates cells with bound beads in a column placed in a magnet (Bussolati et al. 
2003; Hida et al. 2004). Cells without bound beads are in the flow-through 
whereas cells with bound beads stick to the column and can be eluted when the 
column is removed from the magnet. A refinement of this method is the use of 
magnetic beads without a column. Thereby, a blockage of the column can be 
prevented. The cells with bound beads are collected inside a tube in a magnetic 
field. Unbound material is simply removed by aspiration. After washing steps, the 
tube is removed from the magnetic field and the bead-bound cells can be used 
(DeCarlo et al. 2008; Sobczak et al. 2010; Jin et al. 2012; Mackay et al. 2013). A 
further method is the use of FACS (Fluorescence Activated Cell Sorting) after 
labelling ECs with a specific antibody conjugated with a fluorescent dye (Kevil and 
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Bullard 2001; Huang et al. 2003; Okaji et al. 2004; Fehrenbach et al. 2009; 
Pratumvinit et al. 2013). Generally, the separation of cells via FACS is only 
successful if target cells comprise more than 30 % of the cell population (Scott and 
Bicknell 1993). Culturing ECs for a longer period of time with subsequent changing 
of medium can enrich the EC proportion due to the removal of blood and dead 
cells. Another possibility is the use of percoll or dextran gradient centrifugation 
(Grimwood et al. 1995; Kallmann et al. 2002; Wu et al. 2003; Cha et al. 2005). In 
this case, the EC fraction appears in a distinct layer within the gradient and can be 
collected without the majority of contaminated cells. 
During the last 40 years, many investigators have used different methods for EC 
isolation. The isolation of ECs from heart, lung or tumors is a particular challenge. 
Not only a high level of purity but also a gentle isolation procedure is necessary to 
obtain viable ECs. Very often purification steps were repeated or performed after 
time-consuming culture in vitro to obtain high purity of ECs (Table 1). Whatever 
the method might be, most important is the full characterization of the isolated 
cells as ECs. This can prevents the possibility to come under criticism for studies 
on ECs, which may consist more probably of mesothelial cells (Scott and Bicknell 
1993).  
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Table 1: Isolation, purification and identification of murine ECs isolated from heart, lung or tumor. 
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Table 1 continued: Isolation, purification and identification of murine ECs isolated from heart, lung 
or tumor. 
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1.2.2 Cell surface markers 
It is necessary not only to prove the purity of isolated cells, but also to prove that 
these cells are indeed ECs. An identification of ECs directly after isolation would 
be the best to avoid long-term culture effects which can influence the behavior of 
ECs. ECs express specific markers that can be used for identification in vivo and 
in vitro. In many cases, these molecules have been discovered by monoclonal 
antibodies directed against ECs (Garlanda and Dejana 1997). Some of the EC 
markers are constitutively expressed and are presented in the endothelium of all 
tissues. Other molecules are expressed only after stimulation by inflammatory 
cytokines or growth factors. Unfortunately, markers will not only be expressed by 
ECs, but also by different other cell types. Table 2 shows a (not definitive) 
summary of constitutively expressed EC markers. Traditional constitutive markers 
are the van Willebrand factor (vWF/factor VIII-related antigen) and the angiotensin 
converting enzyme (ACE). The vWF has been shown to be highly expressed on 
ECs from large vessels, but is not or marginally expressed in some capillary ECs 
(Kuzu et al. 1992). Another problem is that mesothelial cells can also express ACE 
and vWF (Chung-Welch et al. 1989). Mesothelial cells form a monolayer that line 
the body’s serous cavities and internal organs (pleura, pericardium, peritoneum 
and male/female reproductive organs) (Mutsaers 2002). Further markers include 
the staining with lectin (Griffonia simplicifolia for mouse ECs) and the uptake of dil-
Ac-LDL. Lectin can also be bound by epithelial cells and fibroblasts (Marelli-Berg 
et al. 2000; Fehrenbach et al. 2009), and mesothelial cells and fibroblasts are also 
able to uptake dil-Ac-LDL (Lou et al. 1998; Fehrenbach et al. 2009). Mucosialin is 
mainly expressed by hematopoietic progenitor cells and by ECs. Endoglin is 
expressed on ECs and several different normal and tumor cell types (Postiglione 
et al. 2005). VE-cadherin is mainly located at junctions between ECs, but also 
expressed by lymph node sinus macrophages (Lampugnani et al. 1992; 
Vestweber 2008). Thrombomodulin is expressed on ECs and mesothelial cells 
(Verhagen et al. 1996). Endothelial adhesion molecules which are involved in the 
attachment of leukocytes on the endothelium during leukocytes recruitment or 
inflammation are more suitable for the identification of ECs. Endothelial adhesion 
molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), intercellular 
adhesion molecule-2 (ICAM-2), vascular cell adhesion molecule-1 (VCAM-1) and 
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E-selectin are involved in the passage of leukocytes from blood to underlying 
tissue. Whereas PECAM-1 and ICAM-2 are constitutively expressed on all ECs, 
ICAM-1 and VCAM-1 are less distributed and E-selectin is absent on the EC 
surface and must be induced. However, ICAM-1 and VCAM-1 may also be 
induced by contaminating mesothelial cells. PECAM-1 and ICAM-2 are also 
expressed by lymphocytes, platelets and monocytes. The EC identification can 
also be conducted by their cobblestone morphology and functional assays 
including tube formation in matrigel and the aligment in flow direction. Neither the 
cobblestone nor the tube formation is absolutely specific for ECs. Mesothelial cells 
can also display cobblestone morphology (Dong et al. 1997). It is also reported 
that ECs isolated from heart or tumor did not exhibit the typically tight cobblestone 
formation at confluence (Modzelewski et al. 1994; McDouall et al. 1996). 
In conclusion, the clear identification of ECs remains a critical factor. These data 
indicate that the identification of ECs requires the staining of cells with more than 
just one or two antibodies. The best means for EC identification could be using as 
many markers as possible or examining a series of unique markers to make an 
assessment leading to the unambiguous identification of ECs. 
 
Table 2: Endothelial cell markers. 
Marker Cell type Reference 
Angiotensin-converting 
enzyme 
ECs, epithelial cells, fibroblasts, 
macrophages, T-lymphocytes 
(Smallridge et al. 1986; 
Chung-Welch et al. 1989; 
Belloni and Tressler 1990) 
Uptake of acetylated LDL 
ECs, epithelial cells, fibroblasts, 
macrophages, smooth muscle cells, 
pericytes 
(Voyta et al. 1984; Lou et al. 
1998; Fehrenbach et al. 
2009) 
Lectin (Griffonia 
simplicifolia) ECs, epithelial cells, fibroblasts 
(Laitinen 1987; Marelli-Berg 
et al. 2000; Fehrenbach et 
al. 2009) 
Factor VIII-related 
antigen/ von Willebrand 
factor (Weibel-Palade 
bodies) 
ECs, epithelial cells, platelets, 
megakaryocytes 
(Chung-Welch et al. 1989; 
Belloni and Tressler 1990; 
Kuzu et al. 1992) 
PECAM-1 
ECs, platelets, megakaryocytes, B 
and T lymphocyte subsets, 
monocytes, neutrophils, tumor cells 
(Tang et al. 1993; DeLisser 
et al. 1994; Vecchi et al. 
1994; Scholz and Schaper 
1997) 
Mucosialin ECs, hematopoietic progenitor cells, tumor cells 
(Lin et al. 1995; Krause et al. 
1996; Natkunam et al. 2000) 
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Table 2 continued: Endothelial cell markers. 
 
ICAM-1 (up-regulated by 
cytokine) 
ECs, leukocytes, epithelial cells, 
fibroblasts 
(Dustin et al. 1986; Springer 
1990; de Fougerolles et al. 
1991) 
ICAM-2 ECs, lymphocytes, monocytes, platelets 
(Springer 1990; de 
Fougerolles et al. 1991) 
Endoglin ECs, macrophages, B lymphocytes, syncytiotrophoblasts, tumor cells 
(Gougos and Letarte 1988; 
Duff et al. 2003; Postiglione 
et al. 2005; Fonsatti et al. 
2010) 
VE-cadherin ECs, trophoblasts, lymph node sinus macrophages 
(Lampugnani et al. 1992; 
Bulla et al. 2005; Vestweber 
2008) 
Thrombomodulin ECs, smooth muscle cells, mesothelial cells 
(Esmon 1995; Verhagen et 
al. 1996; Rabausch et al. 
2005) 
VCAM-1 (up-regulated by 
cytokine) 
ECs, macrophages, mesothelial 
cells 
(Springer 1990; Mutsaers 
2002) 
 
 
Further markers such as CD36, MUC18 (CD146), Tie-2, Sca-1, VEGFR-2, 
endothelial cell specific adhesion molecule (ESAM) and P-selectin (inducible) are 
rare described for primary mouse ECs and their use as marker is still not clear 
(Kobayashi et al. 2005; Lim and Luscinskas 2006; Kajimoto et al. 2010; Sobczak 
et al. 2010; Pratumvinit et al. 2013).  
 
1.3 Shear stress on heart endothelial cells 
The cultivation of primary heart and tumor ECs under shear stress due to liquid 
flow (medium) allows the physiological conditions in blood vessels to be simulated. 
The response of ECs to shear stress is closely linked to the regulation of vascular 
tone, blood coagulation and fibrinolysis, angiogenesis and vascular remodeling 
and plays an important role in maintaining the homoeostasis of the circulatory 
system (Ando and Yamamoto 2013). Impairment of the EC response to shear 
stress leads to the development of vascular diseases such as hypertension, 
thrombosis, aneurysms and atherosclerosis. The intensity of shear stress mainly 
depends on the diameter of blood vessels. Under physiological conditions, shear 
stress ranges from 2-12 dyn/cm2 for aorta and veins, whereas shear stress ranges 
from 20-40 dyn/cm2 Kamiya et al. 1984 for arterioles and capillaries ( ; Papaioannou 
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and Stefanadis 2005). A variety of shear-induced molecular responses in ECs was 
identified as candidates for shear stress sensors: Ion channels, receptors, 
adhesion molecules and glycocalyx (which are expressed in the cell membrane), 
primary cilia and caveolae (which constitute membrane microdomains), and actin-
containing stress fibers, other cytoskeletal components and the lipid bilayer 
membrane (which support cell structures) (Figure 3) (Yamamoto and Ando 2011; 
Ando and Yamamoto 2013). 
 
 
 
 
 
 
 
 
 
 
Figure 3: Candidates for shear stress sensors (Ando and Yamamoto 2013). 
 
Shear stress is known to activate a variety of ion channels on ECs. Studies have 
demonstrated that flow activates Ca2+-channels and K+
Olesen et al. 1988
-channels, which leads to 
the hyperpolarization of ECs ( ; Hutcheson and Griffith 1994; 
Helmlinger et al. 1996; Yamamoto et al. 2000). The depolarization of ECs is 
executed by activation of Cl− Barakat et al. 1999-channels ( ; Nilius and Droogmans 
2001). Shear stress also activates receptor tyrosin kinases and GTP binding 
protein-coupled receptors (GPCRs). As a result, receptor-tyrosin kinases VEGFR 
and Tie-2 or the membrane-bound G-protein can be activated even in the absence 
of their ligands VEGF and angiopoietin (Gudi et al. 1998; Shay-Salit et al. 2002; 
Lee and Koh 2003). Protein kinases, including extracellular signal-regulated 
kinase (ERK) are activated through the small G-protein Ras, which leads to the 
activation of NO synthase and inhibition of apoptosis (Jin et al. 2003). Shear stress 
due to liquid flow also leads to tyrosin phosphorylation of PECAM-1 in ECs, which 
positively regulates the Ras signalling pathways, leading to ERK activation 
(Osawa et al. 1997; Fujiwara et al. 2001; Ando and Yamamoto 2013). It was 
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shown that VE-cadherin forms a complex with PECAM-1 and VEGFR2 in which 
PECAM-1 transfers mechanical force (Tzima et al. 2005). These results indicate 
that PECAM-1 and VE-cadherin may play important roles in sensing shear stress 
generated by liquid flow. The surface of ECs is lined with a layer of membrane-
bound glycocalyx, which contains proteoglycan and glycosaminoglycan including 
heparan sulfate, chondroitin sulfate and hyaluronic acid (van den Berg et al. 2003; 
Fu and Tarbell 2013; Alphonsus and Rodseth 2014). Shear stress affects the 
conformation of the glycocalyx, which influences the signal transduction by 
changing the local concentration of ions, enzymes, growth factors and cytokines 
(Siegel et al. 1996; Tarbell and Pahakis 2006). Enzymatic degradation of heparan 
sulfate with heparinase inhibits NO production in bovine aortic ECs in response to 
shear stress, suggesting a role of the glycocalyx plays in the intervention of shear 
stress-induced NO production (Florian et al. 2003). The presence of primary cilia 
was shown in embryonic ECs, HUVECs and human aortic ECs (Iomini et al. 
2004). The bending of primary cilia by shear stress induces cytoskeleton 
deformation and activates the Ca2+
Nauli et al. 2008
-channels polycystin-1 (PC1) and polycystin-2 
(PC2) ( ; AbouAlaiwi et al. 2009). Caveolae are small (50−100 nm) 
membrane invaginations below the surface of ECs that are rich in caveolins, 
cholesterol and sphingolipids (Shaul and Anderson 1998). They are involved in 
shear stress signal transduction using various receptors, ion channels and protein 
kinases (Anderson 1993; Rizzo et al. 1998; Rizzo et al. 2003). Treatment of ECs 
with caveolin-1 antibody has been shown to suppress the ERK activation in 
response to shear stress (Park et al. 2000). Living cells stabilize their structure and 
shape by the use of an interconnected network of cytoskeleton components that 
includes microfilaments, microtubules and intermediate filaments. The endothelial 
cytoskeleton changes in response to shear stress and is able to bind directly or 
indirectly shear stress receptors (Helmke and Davies 2002). This leads to a 
reorientation of actin microfilaments to form stress fibers (Noria et al. 2004). Shear 
stress also changes the physical components of the endothelial lipid bilayer 
membrane (Lenaz 1987). It was shown that shear stress increased the membrane 
fluidity in HUVECs and bovine aortic ECs (Haidekker et al. 2000; Butler et al. 
2001). The lipid bilayer membrane itself may act as sensor for shear stress. 
Additionally, it was shown that blood flow may determine the vessel size. A 
reduction of blood flow leads to a decrease in the vessel diameter (Langille and 
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O'Donnell 1986), which confirmed the physiological significance of blood flow 
detection by ECs. 
In order to explore differences of the molecular phenotype of ECs under static and 
shear stress conditions at the transcriptome level microarray analysis is the tool of 
choise. In the living cardiovascular system, shear stress may present the normal 
situation. The absence of shear stress may present the pathological situation 
(Chen et al. 2001). The information of cardiovascular gene expression between 
both situations can be used to direct the attention to previously unknown or 
ignored genes/pathways. However, differences between the origin of ECs (e.g. 
different organism and tissue) and experimental conditions (e.g. different flow rate 
and duration) make the comparison between data sets difficult and limit their 
interpretation. Although limited, studies suggest three patterns of gene expression 
(Resnick et al. 2003). First, the immediate induction of gene expressions within 
seconds or minutes followed by a decrease to static levels; second, the immediate 
induction or suppression with sustained expression levels last for several hours; 
and third, the delayed induction or suppression of genes several hours after the 
onset of shear stress with sustained expression levels during flow condition. It 
seems that the first two conditions play a role in the activation of ECs and may be 
found in regions of inflammation or atherosclerosis, whereas the third condition 
plays a role in inhibition of proliferation, adhesion, thrombogenesis and 
inflammation (Resnick et al. 2003). Most data regarding flow transduction have 
been obtained during the first hours of flow exposure (Ando and Yamamoto 2013). 
Several pathways may be involved at later points in time, but later data for shear 
stress-regulated molecules and mechanisms are missing. Not only the change of 
gene expression from static to flow conditions is important, but also the gene 
expression under continuous flow, which is more representative for the functional 
status of normal ECs in vivo. This will lead to a better understanding of blood flow-
dependent events, including angiogenesis, vascular remodeling and 
atherosclerosis, which may contribute to the development of new therapies for 
patients with vascular diseases. 
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1.4 Tumor angiogenesis 
The origin of a tumor, i.e. the transformation of a normal cell into a tumor cell, can 
be explained by oncogene activation, tumor-suppressor mutation, high levels of 
telomerase or the induction of aneuploidy (Duesberg et al. 1999; Hahn and 
Weinberg 2002; Shay and Wright 2011). Normal and tumor tissue are dependent 
on an adequate supply of oxygen and nutrients. When the growing tissue reaches 
a certain size, in which the supply is no longer sufficient via diffusion, the tumor 
needs the connection to the existing normal vascular system. The induction of 
tumor vasculature is called angiogenic switch. The angiogenic balance is tightly 
regulated by pro- and anti-angiogenic signals. In normal physiological 
angiogenesis, new vessels rapidly mature and become stable. Pro- and anti-
angiogenic factors are in balance. During tumor angiogenesis, the balance tips to 
the direction of pro-angiogenic factors. In adult organs, in vivo experiments 
showed that the normal EC turnover rate was very long. With a doubling time of 
years, normal ECs are among the longest-lived cells in the body outside the 
central nervous system. Only 1 in every 10,000 ECs (0.01 %) is in the cell division 
cycle at any given time. In contrast, about 14 % of normal intestinal epithelial cells 
are in the cell division cycle (Hanahan and Folkman 1996). The ECs doubling time 
in tumors is very short and is measured in days and may even be the limiting 
factor for tumor growth. Beside the low turnover rate, tumor blood vessels are also 
different in their architecture compared to normal blood vessels (Figure 4). Tumor 
blood vessels are not organized into definitive arterioles, venules and capillaries. 
Instead, tumor vessels show a chaotic vasculature (Denekamp and Hill 1991; 
McDonald and Choyke 2003; Jain 2005). Tumor ECs are irregularly shaped and 
tortuous, show variable diameters and have fewer branches. The tumor 
vasculature is often leaky and perivascular cells, usually in close contact to ECs, 
are often loosely associated or less common than in normal tissue. All this leads to 
dysfunctional capillaries with slower and sometimes oscillating blood flow. 
In conclusion, in normal tissue, the vessel density is dynamically controlled by the 
metabolic needs of nutrients and oxygen. The vasculature is quiescent. In tumor 
tissue, as soon as the increased tissue mass outgrows the ability of existing 
vasculature to provide sufficient nutrients, the angiogenic switch is induced. The 
vasculature is able to produce capillaries. Obviously the excessive production of 
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tumor ECs leads to dysfunction of tumor vessels. The structural and functional 
abnormalities in tumor vessels reflect the pathological nature of their induction. 
 
 
Figure 4: Luminal surface of a normal blood vessel (left, mouse mammary gland) and a tumor 
blood vessel (right, mouse mammary carcinoma) by scanning electron microscopy. In contrast to 
normal ECs tumor ECs are irregularly shaped and tortuous, show variable diameters and have 
fewer branches (arrows) (McDonald and Choyke 2003). 
 
1.5 Irradiation effects on endothelial cells 
Radiotherapy is commonly used for the local treatment of solid tumors residing in 
the thorax. However, radiotherapy may also induce delayed damage in 
surrounding healthy tissue, including the heart and lung. Although the volume 
exposure is kept as low as possible in adjustment of radiotherapy for breast 
cancer patients, parts of the heart still may receive radiation doses between 10-
40 Gy, with a mean dose of few Gy (Andratschke et al. 2011; Darby et al. 2013). 
Experimental studies on the pathogenesis of radiation-induced heart diseases 
have demonstrated major functional changes in the microvasculature of the 
myocardium, particularly in microvascular ECs (Schultz-Hector and Trott 2007). 
Radiation exposure of a large lung volume may induce lung fibrosis leading to 
pulmonary hypertension, which can also participate to cardiac dysfunction (Marcus 
et al. 2008; Ghobadi et al. 2012). The risk for radiation-induced heart diseases 
increases significantly 10 years after radiation therapy (Darby et al. 2010). 
Radiation effects on ECs have been analyzed by commercially available cell lines 
such as human umbilical vein endothelial cells (HUVECs), human dermal 
microvascular endothelial cells (HDMECs), human pulmonary microvascular 
endothelial cells and by in vitro experiments (Gaugler et al. 1997; Heckmann et al. 
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1998; Quarmby et al. 1999; Quarmby et al. 2000; Gaugler et al. 2004). However, 
results may not be important to the pathogenesis of late radiation damage due to 
the high proliferation rate of these ECs in vitro (Sievert et al. 2015). In contrast, 
primary ECs in healthy tissue show a very low proliferation rate (Hobson and 
Denekamp 1984). Recently, the mechanisms of radiation induced heart 
dysfunction in mice after low and high doses were investigated by the European 
Cardiovascular Radiation Risk Research Project CARDIORISK. The development 
of vascular damage after irradiation was found to be dose- and time-dependent 
(Seemann et al. 2012; Azimzadeh et al. 2013). After 20 weeks, local heart 
irradiation with single doses of 2 and 8 Gy led to a significant increase in 
microvascular density, co-occurring with an increased epicardial thickness after 
8 Gy. After 40 weeks, microvascular density returned to normal and decreased at 
60 weeks (Seemann et al. 2012). These temporary changes were presumably 
based on stimulated proliferation of ECs in response to radiation-induced damage. 
It was shown that total body irradiation resulted in depletion and reduced 
vasculogenesis of endothelial progenitor cells (Lee et al. 2012). Injection of bone 
marrow-derived endothelial progenitor cells in mice 16 and 28 weeks after heart 
irradiation with 16 Gy revealed no repair of microvascular damage at 40 weeks 
(Seemann et al. 2014). However, studies which investigate the role of endothelial 
progenitor cells after local heart irradiation are rare. 
While it is widely recognized that adhesion molecules of ECs are involved in 
inflammation and atherosclerotic lesions (Davies et al. 1993), their contribution to 
radiation-induced microvascular heart diseases remains unclear. 
Immunohistochemistry showed that ICAM-1 in the endothelium of mouse carotid 
arteries was decreased 1 and 4 weeks after local irradiation with 14 Gy (Hoving et 
al. 2012). Immunofluorescence staining of the Arteria saphena demonstrated an 
increased expression of PECAM-1, ICAM-1 and VCAM-1 3−6 months after local 
irradiation with 2−10 Gy (Patties et al. 2014). However, immunofluorescence 
staining of heart tissue indicated no alteration in PECAM-1 and VCAM-1 
expression 20 weeks after local irradiation with 2 and 8 Gy (Patties et al. 2015). 
Recently, a proteomic study on isolated cardiac microvascular ECs showed 
significantly increased expression levels of ICAM-1 and ICAM-2 16 weeks after 
local heart irradiation with 8 Gy (Azimzadeh et al. 2015). However, a causal 
relationship between an increased expression of inflammatory proteins and late 
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radiation-induced diseases in heart and lung has not been proven and thus 
remains speculative (Sievert et al. 2015). 
 
1.6 Aim of the study 
Previous isolation methods of primary ECs from the heart and tumor of mice were 
based on collagenase digestion followed by purification techniques, such as 
magnetic bead separation or FACS-sorting using an antibody, such as PECAM-1, 
which is directed against ECs. In both cases, very often the purification step 
needed to be repeated to remove contaminating cells (Table 1). This resulted in 
low yields of primary ECs. Furthermore, magnetic beads which remain bound to 
isolated ECs represent a steric hindrance and prevents the attachment of freshly 
isolated primary ECs in cell culture (Gargett et al. 2000; Cha et al. 2005). 
Additionally, the use of hearts from mice which are older than 28 weeks resulted in 
ECs, that did not become adherent. These cells could not be maintained or 
expanded in cell culture, and underwent apoptotic cell death within a few days. 
ECs isolated from young mice, which are not fully grown yet, have the capacity to 
proliferate and therefore have the ability to get rid of the attached beads with 
sustained cell division. However, the results obtained by this analysis using in vitro 
cultured ECs may not be representative for the functional status of ECs of adult 
animals in vivo. The doubling time of ECs in vitro (days) does not reflect the very 
low proliferation rate (years) of ECs in healthy tissues of adult mice. 
Based on the problems which appeared with the previously described isolation 
methods for ECs, the goal of my work was the analysis and characterization of 
isolated primary ECs from normal non-proliferating and proliferating benign and 
malignant tissue. For that a new method is necessary that provides high yields of 
vital ECs not only from young mice (proliferating tissue) but also from old mice 
(quiescent tissue). Importantly, the isolated ECs should be free of contaminating 
cells and free of magnetic beads which are bound to the cells. The absence of 
contaminating cells avoids a further purification step and thus results in higher 
yields. The isolation of bead-free ECs allows not only that these cells get adherent 
in vitro but also provide the possibility to analyze them directly after isolation by 
flow cytometry. This immediate analysis reflects much better the in vivo status of 
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primary ECs compared to those cells which were cultured in vitro. Furthermore, 
the identification of primary ECs should be demonstrated with more than two or 
three markers.  
Based on the newly established method, a specific aim was to explore the 
difference between normal quiescent ECs and malignant proliferating ECs. In this 
context it was intended to analyse the expression of different cell surface markers, 
morphology and functions like migration, tube formation and alignment under liquid 
flow. The results should provide a clarification of organ-specific immunological 
interactions and functional changes in the interplay of existing and evolving ECs 
from benign and malignant tissue. 
An additional aim was to examine the cardiovascular gene expression of ECs 
under physiological shear stress compared to pathological static conditions. This 
should improve the understanding of blood flow-dependent events, including 
angiogenesis, vascular remodeling and atherosclerosis, which may contribute to 
the development of new therapies for patients with vascular diseases. 
Furthermore, it was an important aim of this thesis to investigate the development 
of late radiation damage in the microvasculature using this novel method. The 
analysis of primary heart ECs after local irradiation in vivo should provide 
evidences to clarify the long clinical development and progression of radiation 
heart damage in situ. 
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2. MATERIALS AND METHODS 
All materials and methods used in this study are described below. Commonly used 
methods, materials and devices are not listed separately. 
 
2.1 Materials 
2.1.1 Devices and consumable materials 
Table 3: Used devices and their producer 
device producer 
4 °C refrigerator profi line Liebherr, Biberach an der Riß, Germany 
-20 °C Comfort Liebherr, Biberach an der Riß, Germany 
-80 °C Herafreeze Basic Thermo Fisher Scientific, Waltham, USA 
Agilent Bioanalyzer 2100 Agilent Technologies, Waldbronn, Germany 
autoclav Systec VX-150 Systec, Linden, Germany 
cryogenic storage system Biosafe® Cryotherm, Kirchen/Sieg, Germany 
cryostat Leica CM 1950 Leica, Wetzlar, Germany 
direct-Q3 ultrapure water system Merck Millipore, Billerica, USA 
DNA-microarray scanner Agilent Technologies, Waldbronn, Germany 
dry bottle with silicate ibidi, Martinsried, Germany 
external humidifier column ibidi, Martinsried, Germany 
FACS Calibur instrument BD Bioscience, Heidelberg, Germany 
Fluidic Unit ibidi, Martinsried, Germany 
Fresco 21 centrifuge Thermo Fisher Scientific, Waltham, USA 
Gulmay RS225A xstrahl, Camberley, United Kingdom 
heated lid and heated plate ibidi, Martinsried, Germany 
heating block Haep Labor Consult, Bovenden, Germany 
ibidi air pressure pump ibidi, Martinsried, Germany 
ice machine MF22 Scotsman, Milan, Italy 
incubator BBD 6220 Thermo Fisher Scientific, Waltham, USA 
incubator Heracell 240i Thermo Fisher Scientific, Waltham, USA 
intelli-mixer RM-2L Elmi, Riga, Latvia 
laminar flow safe 2020 Thermo Fisher Scientific, Waltham, USA 
lead plate with 9x13 and 15x18 mm2 own fabrication  windows  
Magnetic Particle Concentrator DynaMag Thermo Fisher Scientific, Waltham, USA 
magnetic stirrer RCT basic IKA, Staufen, Germany 
megafuge 16R centrifuge Thermo Fisher Scientific, Waltham, USA 
Mikro-Dismembrator S Sartorius Stedim Biotech, Göttingen, Germany 
microscope 40C Zeiss, München, Germany 
microscope observer.Z1 Zeiss, München, Germany 
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Table 3 continued: Used devices and their producer 
microscope Primo Vert Zeiss, München, Germany 
mouse jig own fabrication 
Mr. FrostyTM Thermo Fisher Scientific, Waltham, USA  Freezing Container 
NanoDrop spectrophotometer Thermo Fisher Scientific, Waltham, USA 
PCR-unit (GeneAmp®PCR System 9700) Thermo Fisher Scientific, Waltham, USA 
plate reader EL808 BioTek, Bad Friedrichshall, Germany 
RNase Thermo Fisher Scientific, Waltham, USA 
scale Kern ew 420 Kern, Balingen, Germany 
sonograph GE Healthare, Fairfield, USA 
temperature controller HT200 ibidi, Martinsried, Germany 
The BRICK, active gas mixer ibidi, Martinsried, Germany 
 
Table 4: Use consumable materials and their producer 
consumable material producer 
cell culture flask 12.5 mm BD Bioscience, Heidelberg, Germany 2 
cell culture flask 25, 75, 162 mm Corning B.V. Life Sciences, Amsterdam, the Netherlands 
2 
cell culture plate 6, 12 well Corning B.V. Life Sciences, Amsterdam, the Netherlands 
cell strainer 70 µm BD Bioscience, Heidelberg, Germany 
chamber slide (2, 4, 8 well) Thermo Fisher Scientific, Waltham, USA 
cover slip (round, 15x15 mm, 24x50 mm) Gerhard Menzel, Braunschweig, Germany 
cryo tube 20 TPP Techno Plastic Products, Trasadingen, Switzerland 
needle 18Gx2, 20Gx1½, 27Gx¾, 30Gx½ B.Braun, Melsungen, Germany 
perfusion set, 50 cm, ID 0.8 mm ibidi, Martinsried, Germany 
phase lock gel tube Eppendorf, Hamburg, Germany 
pipette tips 10, 100, 1000 µl Sarstedt, Nümbrecht, Germany 
quadriperm® cell culture vessel Sigma-Aldrich, Steinheim, Germany 
reaction tubes 1.5 ml Sarstedt, Nümbrecht, Germany 
reservoir set, 10 ml ibidi, Martinsried, Germany 
safe-lock tubes 0.5 ml Eppendorf, Hamburg, Germany 
single-use pipettes 1, 2, 5, 10, 25, 50 ml Greiner Bio-One, Frickenhausen, Germany 
slide-A-Lyzer G2 Dialysis Cassette Thermo Fisher Scientific, Waltham, USA 
syringes 1, 2, 3, 10 ml B.Braun, Melsungen, Germany 
syringe filter 0.22 µm TPP Techno Plastic Products, Trasadingen, Switzerland 
tissue culture dishes 22.1 cm TPP Techno Plastic Products, Trasadingen, Switzerland 
2 
tissue culture test plates 96U TPP Techno Plastic Products, Trasadingen, Switzerland 
tubes 15, 50 ml Greiner Bio-One, Frickenhausen, Germany 
tubes 5 ml for flow cytometry Sarstedt, Nümbrecht, Germany 
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Table 4 continued: consumable materials and their producer 
µ-Dish 35mm, low Culture-Insert, ibiTreat ibidi, Martinsried, Germany 
µ-Slide Angiogenesis ibidi, Martinsried, Germany 
µ-slideI0.2 Luer, µ-slideI0.4 ibidi, Martinsried, Germany  Luer 
µ-Slide VI0.4 ibidi, Martinsried, Germany  Luer, ibiTreat 
 
2.1.2 Chemicals 
Table 5: Used chemicals and their sources 
chemical source 
pure acetic acid Merck, Darmstadt, Germany 
acetone Sigma-Aldrich, Steinheim, Germany 
Aqueous Mount Zytomed Systems, Berlin, Germany 
Biotin-Nick Translation Mix Sigma-Aldrich, Steinheim, Germany 
bovine serum albumin (BSA) Sigma-Aldrich, Steinheim, Germany 
chloroform Merck, Darmstadt, Germany 
collagenase A Roche Diagnostics, Mannheim, Germany 
dextran sulfate Serva, Heidelberg, Germany 
Dig-Nick Translation Mix Sigma-Aldrich, Steinheim, Germany 
dimethyl sulfoxide (DMSO) Sigma-Aldrich, Steinheim, Germany 
di-sodium hydrogen phosphate dihydrate Merck, Darmstadt, Germany 
Dulbecco's modified Eagle's medium (DMEM) Sigma-Aldrich, Steinheim, Germany 
phosphate buffered saline (PBS) Sigma-Aldrich, Steinheim, Germany 
ethylenediaminetetraacetic acid ( EDTA) Merck, Darmstadt, Germany 
Endothelial Cell Growth Medium 2 (EGM2) PromoCell, Heidelberg, Germany 
eosin y-solution Merck, Darmstadt, Germany 
ethanol Merck, Darmstadt, Germany 
ethidium Bromide Sigma-Aldrich, Steinheim, Germany 
fixogum Marabu, Tamm, Germany 
FACS Clean BD Bioscience, Heidelberg, Germany 
FACS Rinse BD Bioscience, Heidelberg, Germany 
FACS Flow BD Bioscience, Heidelberg, Germany 
fetal bovine serum (FSC) Sigma-Aldrich, Steinheim, Germany 
forene 100% Abbott, Wiesbaden, Germany 
formamide Sigma-Aldrich, Steinheim, Germany 
Freund's adjuvant, incomplete Sigma-Aldrich, Steinheim, Germany 
gelatine Merck, Darmstadt, Germany 
glucose Sigma-Aldrich, Steinheim, Germany 
isoamyl alcohol Sigma-Aldrich, Steinheim, Germany 
Hanks' Balanced Salt Solution (HBSS) Thermo Fisher Scientific, Waltham, USA 
hematoxylin Merck, Darmstadt, Germany 
herring sperm DNA Sigma-Aldrich, Steinheim, Germany 
LB Broth USB, High Wycombe, United Kingdom 
L-glutamine 200 mM Sigma-Aldrich, Steinheim, Germany 
lysozyme-solution (5 mg/ml) Sigma-Aldrich, Steinheim, Germany 
β-mercaptoethanol 50 mM Thermo Fisher Scientific, Waltham, USA 
marker 1kb Thermo Fisher Scientific, Waltham, USA 
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Table 5 continued: Used chemicals and their sources 
matrigel BD Bioscience, Heidelberg, Germany 
methanol Merck, Darmstadt, Germany 
mouse Cot-1 DNA Thermo Fisher Scientific, Waltham, USA 
non-essential amino acid solution Sigma-Aldrich, Steinheim, Germany 
Nonidet P 40 Sigma-Aldrich, Steinheim, Germany 
penicillin-streptomycin Sigma-Aldrich, Steinheim, Germany 
pepsin Thermo Fisher Scientific, Waltham, USA 
phenol Sigma-Aldrich, Steinheim, Germany 
potassium chloride (KCl) Merck Millipore, Billerica, USA 
primary antibody diluent AbD Serotec, Puchheim, Germany 
propidium iodide (PI) Merck, Darmstadt, Germany 
Roswell Park Memorial Institute (RPMI) 1640 
medium Sigma-Aldrich, Steinheim, Germany 
salt acid (1N) (HCl) Merck, Darmstadt, Germany 
skimmed milk powder BioRad Laboratories, München, Germany 
sodium azide Merck, Darmstadt, Germany 
sodium bicarbonate Sigma-Aldrich, Steinheim, Germany 
sodium chloride (NaCl) Merck, Darmstadt, Germany 
sodium dodecylsulfate (SDS) Merck, Darmstadt, Germany 
sodium hydrogen phosphate monohydrate Merck, Darmstadt, Germany 
sodium hydroxide (NaOH) Merck, Darmstadt, Germany 
Tissue-Tek Sakura Finetek, Alphen aan den Rijn, the Netherlands 
tris Merck, Darmstadt, Germany 
tri-sodium citrate Merck, Darmstadt, Germany 
trypan Blue solution Sigma-Aldrich, Steinheim, Germany 
trypsin-EDTA solution Sigma-Aldrich, Steinheim, Germany 
ultrasound gel Dahlhausen, Köln, Germany 
Vectashield mounting medium with DAPI Vector Laboratories, Burlingame, USA 
 
2.1.3 Buffers and solutions 
• carnoy's Fixative 
pure acetic acid (1 part) 
methanol (3 parts) 
 
• glucose-buffer 
6 g glucose (50 mM) 
3.73 g EDTA (10 mM) 
3.03 g tris (25 mM) 
ad 1 liter with double distilled water 
 
• LB-medium 
20 g LB Broth 
ad 1liter with double distilled water 
autoclave 
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• phosphate buffer with Nonidet P 40, 0.1% (PN-buffer) 
142.39 g di-sodium hydrogen phosphate dihydrate in 8 liter distilled water 
set pH 8 with 6.9 g sodium hydrogen phosphate monohydrate in 500 ml distilled water 
add 0.1 % Nonidet P 40 
 
• phosphate-Nonidet P 40-skimmed milk (PNM-buffer) 
5 g skimmed milk powder 
0.02 g sodium azide 
ad 100 ml with PN-buffer, incubation at 37 °C for several hours 
next day centrifugation (3000 g, 10 minutes), sterile filtration of supernatant 
storage at  −20 °C 
 
• NaOH/SDS-solution 
200 µl NaOH (1 M) 
40 µl sodium dodecylsulfate 
ad 1 liter with double distilled water 
 
• mastermix 
5 ml formamide deionized 
1 g dextran sulfate 
1 ml 20x SSC pH 7 
mix, heating at 70 °C to solve dextran sulfate, set pH 7 
ad 7 ml with double distilled water 
 
• sodium acetate (3 M) 
246 g sodium acetate 
ad 1 liter  with double distilled water, set pH 4.8 
autoclave 
 
• saline sodium citrate buffer (20x) (SSC) 
175.3 g/l (3M) NaCl 
88.2 g/l (0.3 M) tri-sodium citrate 
set pH 7, ad 1 liter with double distilled water 
 
• tris-EDTA-buffer (TE-buffer) 
1.2 g Tris (10 mM) 
0.37 g EDTA (1 mM) 
ad 1 liter with double distilled water, set pH 7.5 
autoclave 
 
• tris-EDTA-Saline-buffer (TES-buffer) 
1.21 g tris (10 mM) 
0.58 g NaCl (10 mM) 
0.37 g EDTA (1 mM) 
ad 1 liter with double distilled water, set pH 7.6 
autoclave 
 
• sodium dodecylsulfate 
250 g sodium dodecylsulfate in 600 ml double distilled water, heating at 60−100 °C 
cool down and ad 1 liter with double distilled water 
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2.1.4 Antibodies 
Table 6: Used antibodies (clon, host, isotype, conjugation) and their sources for FACS 
antigen clon host and isotype conjugation source 
Isotype HybIgG2a mouse IgG2a FITC abcam, Cambridge, United Kingdom 
Isotype R35-95 rat IgG2a,κ FITC BD Bioscience, Heidelberg, Germany 
Isotype A19-3 hamster IgG1,κ FITC BD Bioscience, Heidelberg, Germany 
Isotype A110-1 rat IgG1,λ FITC BD Bioscience, Heidelberg, Germany 
Isotype R35-95 rat IgG2a,κ PE BD Bioscience, Heidelberg, Germany 
Isotype R35-38 rat IgG2b,κ PE BD Bioscience, Heidelberg, Germany 
Isotype R3-34 rat IgG1,κ PE BD Bioscience, Heidelberg, Germany 
Isotype A95-1 rat IgG2b,κ APC BD Bioscience, Heidelberg, Germany 
PECAM-1/ 
CD31 MEC 13.3 rat IgG2a,κ PE 
BD Bioscience, Heidelberg, 
Germany 
PECAM-1/ 
CD31 MEC 13.3 rat IgG2a,κ unconjugated 
BD Bioscience, Heidelberg, 
Germany 
Mucosialin/ 
CD34 RAM34 rat IgG2a,κ FITC 
eBioscience, Frankfurt am Main, 
Germany 
HCAM/ 
CD44 IM7 rat IgG2b,κ PE 
BD Bioscience, Heidelberg, 
Germany 
CD45 30-F11 rat IgG2b,κ APC BD Bioscience, Heidelberg, Germany 
ICAM-1/ 
CD54 3E2 hamster IgG1,κ FITC 
BD Bioscience, Heidelberg, 
Germany 
ICAM-2/ 
CD102 3C4 rat IgG2a,κ FITC 
BD Bioscience, Heidelberg, 
Germany 
Integrin β3/ 
CD61 2C9.G2 hamster IgG1,κ FITC 
BD Bioscience, Heidelberg, 
Germany 
E-selectin/ 
CD62E 10E9.6 rat IgG2a,κ PE 
BD Bioscience, Heidelberg, 
Germany 
Endoglin/ 
CD105 MJ7/18 rat IgG2a,κ PE 
eBioscience, Frankfurt am Main, 
Germany 
VCAM-1/ 
CD106 M/K-2 rat IgG1,κ PE 
life technologies, Darmstadt, 
Germany 
Prominin-1/ 
CD133 13A4 rat IgG1,κ FITC 
eBioscience, Frankfurt am Main, 
Germany 
VE-cadherin/ 
CD144 11D4.1 rat IgG2a,κ PE 
BD Bioscience, Heidelberg, 
Germany 
VEGFR-2/ 
CD309 
Avas 
12alpha1 rat IgG2a,κ PE 
BD Bioscience, Heidelberg, 
Germany 
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Table 7: Used antibodies (clon, host, isotype, conjugation) and their sources for 
immunofluorescence microscopy 
antigen host and isotype conjugation source 
anti-rat Goat, IgG Alexa Fluor 594 Thermo Fisher Scientific, Waltham, USA 
Isolectin B4 Griffonia Simplicifolia FITC 
Vector Laboratories, Burlingame, 
USA 
 
Table 8: Used antibodies, sources and dilutions for FISH 
antibody source antibody solution [µl] 
PNM-
buffer 
[µl] 
Streptavidin-Avidin Jackson ImmunoResearch, Newmarket, United Kingdom 10 240 
anti-Digoxigenin-Cy3 Jackson ImmunoResearch, Newmarket, United Kingdom 4 496 
Biot-anti-Streptavidin Vector Laboratories, Burlingame, USA 10 240 
Rat-anti-mouse-Cy3 Jackson ImmunoResearch, Newmarket, United Kingdom 10 240 
Mouse-anti-rat-Cy3 Jackson ImmunoResearch, Newmarket, United Kingdom 10 240 
 
2.1.5 BAC clones 
Table 9: Used murine BAC clones for FISH 
Name BAC reference reference sources labeling 
RP23-289I3 Chromosome 1 www.ensembl.org Digoxigenin 
RP23-257F12 Chromosome 4 www.ensembl.org Biotin 
RP23-154G18 Chromosome 14 www.ensembl.org Digoxigenin 
RP23-154G18 Chromosome 14 www.ensembl.org Biotin 
 
2.1.6 Kits 
Table 10: Used kits and their sources 
kits source 
DSB-XTM Thermo Fisher Scientific, Waltham, USA  Biotin protein labeling kit 
Dynabeads FlowCompTM Thermo Fisher Scientific, Waltham, USA  Flexi, part A 
MycoAlertTM Lonza, Basel Switzerland  mycoplasma detection kit 
PierceTM Thermo Fisher Scientific, Waltham, USA  BCA Protein Assay kit 
DNA Clean and Concentrator kit Zymo Research, Irvine, USA 
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Table 10 continued: Used kits and their sources 
RNA 6000 Nano Assay kit Agilent Technologies, Waldbronn, Germany 
RNeasy Micro kit Qiagen, Hilden, Germany 
two-color microarray-based gene expression 
analysis kit Agilent Technologies, Waldbronn, Germany 
 
2.1.7 Software 
Table 11: Used software and their sources 
software source 
Adobe Photoshop CS4 Version 11 Adobe Systems Incorporated, USA 
AxioVision Zeiss, München, Germany 
Cell Quest Pro BD Bioscience, Heidelberg, Germany 
Feature Extraction software Agilent Technologies, Waldbronn, Germany 
Gen5 BioTek, Bad Friedrichshall, Germany 
ibidi CamControl 0.1 ibidi, Martinsried, Germany 
ibidi PumpControl 1.5 ibidi, Martinsried, Germany 
ImageJ 1.48v Wayne Rasband National Institutes of Health, USA 
Isis MetaSystems, Altlussheim, Germany 
Microsoft Office Microsoft Corporation, Redmond, USA 
SigmaPlot 11 Systat Software, wpcubed, Germany 
TMPGEnc Video Mastering Works 5 Pegasys Inc., Tokyo, Japan 
WimTaxis Wimasis, München, Germany 
WimTube Wimasis, München, Germany 
 
2.1.8 Cell lines and primary cells 
Table 12: Used cell lines and their sources (incl. reference) 
cells line source reference 
H5V Immortalized heart ECs from C57Bl/6-mice (Dr. Chrisou Kanthou, University of Sheffield) 
(Garlanda et 
al. 1994) 
CT26 Colon adenocarcinoma cells from BALB/c-mice (CT26.WT; ATCC CRL-2638) 
(Brattain et 
al. 1980; 
Wang et al. 
1995) 
B16-F0 Melanoma cells from C57Bl/6-mice (B16-F0; ATCC CRL-6322) (Fidler 1973; Fidler 1975) 
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Table 13: Used primary cells and their sources (incl. reference) 
primary cells source reference 
heart endothelial cells this laboratory from mouse heart (Sievert et al. 2014) 
lung endothelial cells this laboratory from mouse lung (Sievert et al. 2014) 
repair blastema endothelial cells this laboratory from mouse repair blastema (Sievert et al. 2014) 
CT26 endothelial cells this laboratory from mouse tumor (CT26) (Sievert et al. 2014) 
B16-F0 endothelial cells this laboratory from mouse tumor (B16-F0) (Sievert et al. 2014) 
 
2.1.9 Laboratory animals 
Female/male BALB/c and C57Bl/6 mice (Charles River) within an age range of 4 
to 100 weeks were used for the experiments. Mice were housed in single, 
ventilated cages under pathogen-free conditions. Experiments were in agreement 
with German law on animal experiments and welfare. 
 
Table 14: Used pharmaceuticals and their sources  
pharmaceutical source 
Medetomidine  Pfizer, Berlin, Germany 
Midazolam Ratiopharm, Ulm, Germany 
Fentanyl  Jansen-Cilag, Neuss, Germany 
Atipamezole Pfizer, Berlin, Germany 
Flumazenil  Insera Arzneimittel, Freiburg, Germany 
Naloxone Insera Arzneimittel, Freiburg, Germany 
 
The anesthesia was performed by MMF (Medetomidin (0,50 mg/kg) + Midazolam 
(5,0 mg/kg) + Fentanyl (0,05 mg/kg)). The antagonist consists of AFN (Atipamezol 
(2,5 mg/kg) + Flumazenil (0,5 mg/kg) + Naloxon (1,2 mg/kg)). 
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2.2 Methods 
2.2.1 Cell biological methods 
2.2.1.1 Cell culture of cell lines and primary cells 
Cells were regularly cultivated under sterile conditions in cell culture flasks at 
37 °C, 95 % relative humidity and 5 % CO2
2.2.1.2 Cell number and viability 
 in an incubator. Cell culture was 
performed under a laminar flow. Briefly, the adherent cells were washed twice with 
PBS and treated with trypsin-EDTA solution at 37 °C for detachment from the 
flask. The cells were seeded in adequate dilution with medium in new flask. All cell 
lines were passaged twice weekly to maintain them under exponential growth 
conditions. Cell lines were regularly screened and confirmed to be free from 
mycoplasma contaminations. CT26 cells were cultured in RPMI 1640 medium 
containing 5 % (v/v) heat-inactivated fetal calf serum, 2 mM L-glutamine, 
antibiotics (100 IU/ml penicillin and 100 µg/ml streptomycin), 50 µM β-
mercaptoethanol and non-essential amino acids (1x). B16-F0 cells and the heart 
endothelial cell line H5V were cultured in DMEM containing 10 % (v/v) heat-
inactivated fetal calf serum and antibiotics (100 IU/ml penicillin and 100 µg/ml 
streptomycin. 
Freshly isolated primary microvascular PECAM-1 positive ECs from different 
tissue were counted and viable cells were seeded in gelatin coated (2 %) culture 
flasks with EGM2 (supplemented with 10 % FCS, streptomycin (100 µg/ml) and 
penicillin (100 U/ml)). The medium was exchanged every third day and cells were 
passaged when 90 % confluence were reached. For further functional assays, 
primary ECs in the first or second passage were used. 
 
Viable cells were determined by the trypan blue exclusion test. Only non-viable 
cells absorbed trypan blue and appeared blue. Briefly, a dilution (1:2) of cell 
suspension and trypan blue was loaded in a Neubauer chamber and viable 
unstained cells were counted under the microscope. The dilution of the cell 
suspension was regulated with the result that approximately 100 cells could be 
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counted (statistical significance). The total number of cells was calculated as 
follows: 
 
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑐𝑐𝑐𝑐𝑡𝑡𝑡𝑡𝑐𝑐 = 𝑐𝑐𝑡𝑡𝑐𝑐𝑐𝑐𝑡𝑡𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑡𝑡𝑡𝑡𝑐𝑐 𝑥𝑥 104
𝑐𝑐𝑐𝑐𝑛𝑛𝑛𝑛𝑐𝑐𝑛𝑛 𝑞𝑞𝑐𝑐𝑡𝑡𝑐𝑐𝑛𝑛𝑡𝑡𝑐𝑐𝑡𝑡𝑐𝑐  𝑐𝑐𝑑𝑑𝑡𝑡𝑐𝑐𝑡𝑡𝑑𝑑𝑡𝑡𝑐𝑐 
 
2.2.1.3 Cryopreservation of cells 
For permanent storage the cells were cryopreserved in liquid nitrogen. After 
centrifugation (500 g, 5 minutes) at 4 °C, the cell pellet (2 x 106
2.2.1.4 Cell alignment assay 
) was solved in cold 
medium/FCS/DMSO (50/40/10 %). DMSO prevents crystallization in the cells. The 
cell suspension was aliquoted into cryo tubes (1.8 ml) and continuously frozen in 
freezer container (to -80 °C). After 24 hours the cells were transferred into liquid 
nitrogen. For new cultivation, the cells were defrosted, centrifuged (400 g, 5 
minutes) at 4 °C and seeded in culture flask. After 24 hours the medium was 
exchanged to remove dead cells.  
 
For the analysis of heart and tumor ECs with permanent shear stress, ECs were 
used directly after their isolation. 4 x 105 cells in 50 µl medium were seeded into a 
channel of a µ-slideVI0.4 (area per channel: 0.6 cm2). For the mRNA expression 
analysis, more heart ECs were necessary. Therefore 1.8 x 106 heart ECs in 50 µl 
or 100 µl medium were seeded into a channel of a µ-slideI0.2 or µ-slideI0.4 (area per 
channel 2.5 cm2). The µ-slideI0.2 Luer (height of the channel: 200 µm) allows the 
use of high shear stress, but is not recommended for static culture longer than 6 
hours. For static condition, the µ-slideI0.4 Luer (height of the channel: 400 µm) was 
used. After filling both ends of the channel with medium and incubation under 
static conditions at 37 °C, cells were exposed to flow conditions. A pump system, 
Fluidic Unit, gas mixer, temperature controller and heating system guaranteed 
constant conditions. In this way, simultaneous culture and observation of cells 
under perfusion were possible. First, the slide was connected with the perfusion 
set, which contains both syringe reservoirs and the branching tubes (Figure 5). All 
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tubes were filled with preheated medium. Then, reservoirs and tubes were 
connected with the Fluidic Unit. The pump generates a constant pressure and 
pumps the medium from one reservoir to the other and back. The flow rate of the 
medium is dependent by the pressure applied, viscosity of the medium and the 
flow resistance of the slide. The calibrated flow rate (ml/min) causes a wall shear 
stress (dyn/cm2) to which the cells are exposed. A PumpControl software 
controlled the pump and the Fluidic Unit. The Fluidic Unit switched synchronously 
two four way valves. In this way, a continuous flow through the slide with minimal 
consumption of medium was possible. A gas mixer was connected to the incubator 
to provide the medium with 5 % CO2
 
. The temperature controller and the heating 
system guaranteed a temperature of 37 °C inside the slide. Representative 
microscopy pictures of ECs were taken using an Axiovert 40C microscope. 
 
 
Figure 5: Principle of the ibidi pump (www.ibidi.com) 
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2.2.1.5 Cell migration assay 
10,000 ECs were seeded into m-dishes 35 mm, low with culture-insert in a volume 
of 70 µl EGM2 medium supplemented with 10 % FCS, Streptomycin (100 µg/ml) 
and Penicillin (100 U/ml). Cells were allowed to become adherent. The migration 
of heart and tumor ECs was captured on a video and analyzed. Films were 
analyzed with WimTaxis for quantitative evaluation of cell tracking. 
 
2.2.1.6 Tube formation assay 
For tube formation, each well of a µ-slide Angiogenesis was filled with 10 µl chilled 
matrigel. After incubation for 30 minutes at 37 °C, H5V cells (10,000 cells/well), 
primary heart ECs (80,000 cells/well) or tumor ECs (20,000 cells/well) in passage 
1 were added in 50 µl medium. After 6 hours, pictures were recorded with an 
Axiovert 40C microscope. For quantitative evaluation, representative images were 
analyzed with WimTube. The total number of branching points and loops per 
image was determined. 
 
2.2.2 Molecular biological methods 
2.2.2.1 Isolation of RNA 
The isloation of endothelial RNA was performed by RNeasy Micro kit, which is 
based on the selective binding properties of a silica-based membrane followed by 
centrifugation. Cells in the µ-slideI were lysed and homogenized with 350 µl 
guanidine-thiocyanate-containing RLT-buffer. After adding of 350 µl ethanol (70%), 
the mixture was transferred on a spin column, centrifuged and washed with 350 µl 
RW1-buffer (8000 g for 15 seconds). DNA was removed by DNase treatment (10 
µl DNase + 70 µl RDD-buffer) for 15 minutes on the spin column. After washing 
and drying steps, the RNA was eluted with 10 µl RNase-free water and stored at 
−80°C. This procedure allows the purifications of RNA molecules longer than 200 
nucleotides, leading to mRNA enrichment due to exclusion of RNA molecules 
smaller than 200 nucleotides (5S-rRNA, 5.8S-rRNA, tRNA). 
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2.2.2.2 Quantification and qualification of RNA 
The quantification and qualification of endothelial RNA was performed by Agilent 
Bioanalyzer 2100 and RNA 6000 Nano Assay Kit. Briefly, a chip was loaded with 
gel-dye mix, RNA marker, denatured RNA ladder (70°C for 2 minutes) and 
denatured samples to be tested. The dye molecules intercalate into RNA and were 
electrophoretically separated. The Bioanalyzer detects the fluorescence of RNA 
fragments and generates an electropherogram (Figure 6). The results provide 
information about the length distribution of the RNA fragments reflecting the 
integrity of the RNA sample. Beside the control peak, two distinct ribosomal peaks 
(18S-rRNA and 28S-rRNA) are detectable. A proprietary algorithm (Agilent) 
analyses the electropherogram and calculates the so-called RNA Integrity Number 
(RIN) which ranges from 1 (RNA completely degraded) to 10 (RNA not degraded 
at all). Samples with RINs higher than 7 are generally accepted to be used in 
microarray analysis. 
 
 
 
 
Figure 6: Representative electropherogram for quality control of RNA isolated from ECs 7 days 
under static conditions. The concentration of RNA was 52 ng/µl and the RNA Integrity Number was 
9.1 (1: RNA marker, 2: 18S-RNA peak, 3: 28S-RNA peak). 
 
2.2.2.3 Global mRNA expression analysis 
The analysis of global gene expression was performed using the mouse one-color 
microarray-based gene expression analysis kit (Agilent Whole Genome Mouse 
1 
2 3 
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8x60k, AMADID: 28005). Briefly, 25 ng heart endothelial RNA was amplified, 
labelled and purified and subjected to hybridization on the array. After washing, 
slides were scanned using the Agilent DNA Microarray Scanner (G2505C). 
Fluorescence intensities of hybridised microarray spots were extracted from 
scanned images using the Agilent Feature Extraction software and the output was 
written to text files. Subsequent bioinformatics analysis was performed within the 
Integrative Biology Group (Research Unit Radiation Cytogenetics, Helmholtz 
Zentrum München) together with Dr. Kristian Unger. Briefly, text files were 
imported into the R statistical platform (R Core Team, 2015 (https://www.r-
project.org/)) using the Bioconductor package Agi4x44PreProcess 
(http://www.bioconductor.org/packages//2.10/bioc/html/Agi4x44PreProcess.html), 
quality filtered and normalised using the RMA algorithm. Differential expression 
was calculated using functions of the Bioconductor package limma 
(https://bioconductor.org/packages/release/bioc/html/limma.html). 
 
2.2.3 Protein biochemical methods 
2.2.3.1 Dialysis 
A dialysis cassette was used to remove sodium azide from the antibody PECAM-
1. For the purification, 300 µl of the antibody was loaded in the cassette via 
20Gx1½ needle and dialyzed first twice for 2 hours and then over night in PBS. 
 
2.2.3.2 Protein concentration 
The protein determination was performed by Pierce BCA protein assay. 
Colorimetric detection of proteins is based on the biuret reaction, linked to the 
sensitive reagent bicinchoninacid. For quantification of proteins, different 
concentrations of BSA (25−2000 µg/ml) act as standard. Samples and standards 
were incubated in a 96-well plate at 37 °C for at least 30 minutes. The absorbance 
was measured at 550 nm via plate reader EL808. 
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2.2.3.3 Biotinylation 
The biotinylation of PECAM-1 was performed by DSB-XTM
2.2.4 Immunological methods 
 Biotin protein labeling 
kit. Briefly 200 µl of the antibody were mixed with 20 µl sodium bicarbonate and 
2 µl DSB-X biotin for 1½ hours at room temperature. DSB-X-conjugated antibody 
and free DSB-X biotin were separated using a spin column. 
 
2.2.4.1 Immunofluorescence microscopy 
For the PECAM-1 staining, primary ECs were seeded into chamber slides. After 
washing with PBS and fixation with cold acetone (4 °C), dried cells were incubated 
with PECAM-1 (1:100 in primary antibody diluent) for 1 hour at 23 °C. After 
repeating washing and drying step, cells were stained with Alexa Fluor 594-
labeled secondary antibody (1:200 in PBS) for 1 hour at 37 °C. For the isolectin 
staining, cells were blocked with PBS/BSA (0.2 %) and incubated with isolectin-
FITC-labeled antibody (1:50 in PBS/BSA 0.2 %) for 30 minutes at 4 °C. For both 
stainings, cell nuclei were co-stained via Mounting medium with Dapi. Samples 
were analyzed using a fluorescence microscope equipped with 10x, 20x and 100x 
objective and standard filters. Image procession was performed with Axiovision 
and Photoshop. 
 
2.2.4.2 Flow cytometry analysis 
The fluorescence activated cell sorting (FACS) is a method for the quantitative 
identification of cell surface markers. The antigens were detected by specific 
fluorescence-labeled antibodies. Appropriately labeled isotype-matched 
immunoglobulins in the same concentration were used as negative controls. 
Briefly, after a washing step in PBS/FCS (10 %) 0.1x106 viable cells were 
incubated on ice with antibodies for 30 minutes in the dark. Following a further 
washing step in PBS/FCS (10 %), cells were analyzed on the FACS Calibur 
instrument and evaluated with Cell Quest Pro. Dead cells were excluded from the 
analysis by a propidium iodide co-staining and gating strategy. The percentage of 
positive stained cells was calculated as the number of specific-stained cells minus 
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the number of unspecific-stained cells. The mean fluorescence intensity (mfi) was 
calculated by subtraction the mean for unspecific fluorescence intensity from the 
mean for specific fluorescence intensity. 
 
2.2.5 Histopathology and immunohistochemistry 
2.2.5.1 Preparation of histological cryosection 
The isolated mouse tissue was frozen in Tissue-Tek with the help of dry ice and 
stored at -80 °C. For cryo slices, the blocks were pre-cooled at -20 °C and 
consecutive slices (5−8 µm thickness) were cut and collected on glass slides. After 
drying, the slides were stored at -20 °C. 
 
2.2.5.2 Hematoxylin and eosin staining 
For the HE staining, the slides were dried at room temperature and covered with 
cold acetone for 10 minutes at 4 °C for fixation. After drying and washing in PBS 
for 10 minutes, the slides were stained in hematoxylin for 1 minute. Then the 
slides were washed with warm flowing tap water for 10 minutes and stained in 
200 µl eosin added with two drops acetic acid (100 %) for 2 minutes. After washing 
with flowing tap water for 5 minutes, the slides were embedded with Aqueous 
Mount and cover slips freed from air bubbles. 
 
2.2.6 Fluorescence in situ hybridization 
The method of fluorescence in situ hybridization (FISH) is based on 
complementary base pairing of single-strand fluorescence labeled probe DNA with 
single-stranded target DNA in metaphases and interphases. In this study, the 
signals were detected by indirect markers with biotin and digoxigenin. These 
haptens were coupled on nucleotides and would integrate into the DNA. The 
detection was performed by fluorescence labeled antibodies against biotin and 
digoxigenin. In this study, FISH was used for the analysis of the ploidy level of 
primary heart and tumor ECs. It was considered that only interphases can be 
analyzed because of the low proliferation rate of primary ECs in vitro. The labeling 
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of all mouse chromosomes (2x19, X, Y) cannot be evaluated due to the multiplicity 
of signals. Therefore only three chromosomes were labeled (Figure 7).  
 
 
Figure 7: Schematic figure of the FISH principle with three different probes for chromosome 1 
(red), chromosome 4 (green) and chromosome 14 (orange). The haploid, diploid and triploid ploidy 
levels are illustrated in metaphases and interphases. 
 
Chromosome 1 was labeled with digoxigenin (red signal), chromosome 4 was 
labeled with biotin (green signal) and chromosome 14 was labeled with 
digoxigenin and biotin (orange signal). The results of these three chromosomes 
have been used to determine the ploidy level of the cells. 
 
2.2.6.1 BAC DNA isolation 
Bacterial Artificial Chromosome (BAC) is an artificial chromosome from bacteria, 
based on components of F-plasmid from E. coli. This cloning vector can contain 
foreign DNA up to a size of 300 kb. A BAC-vector contains regulatory genes for 
unidirectional replication (oriS and repE) and genes (parA and parB), which limit 
the copying rate per cell around one or two. Further, the BAC-vector contains an 
antibiotic resistance marker and a cloning segment, into which the foreign DNA 
can be inserted. 
Based on the transformation of such vectors in bacterium cells and their culturing, 
a larger quantity of foreign DNA can be harvested. The BACs used in this study 
are listed in table 9. 
For the proliferation of bacteria, 10 ml LB-medium were mixed with 
chloramphenicol (20 µg/ml) and the corresponding bacteria. The bacteria were 
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transferred from glycerin stock in LB-medium with the help of an inoculation loop. 
If the medium was cloudy after 16 hours at 37 °C in an incubator shaker, the cell 
suspension was centrifuged (6000 rpm) at 4 °C for 30 minutes. The supernatant 
was discarded and the cell pellet was washed with 5 ml TES-buffer (6000 rpm, 
10 minutes, 4 °C) and resuspended in 2 ml glucose-buffer and 2 ml lysozyme-
solution. After incubation at room temperature for 5 minutes, 4 ml NaOH/SDS and 
immediately 3 ml sodium acetate (ice cold) were added. The compound was 
mixed and incubated on ice for 15 minutes. After centrifugation (6000 rpm, 10 
minutes, 4 °C), the supernatant was filtered and mixed with the double volume of 
ethanol (100 %). The mixture was incubated at room temperature for 10 minutes 
and centrifuged (13.000 rpm) at 4 °C for 30 minutes. The supernatant was 
discarded and the pellet was dried and solved in 1 ml TE-buffer at 4 °C over night. 
On the next day, the RNA-digestion was processed. The sample was separated in 
2 tubes (500 µl), 5 µl RNase A solution were added and incubated at 37 °C for 1 
hour in a heating block. Afterwards the sample was transferred in phase lock gel 
tube, which was previously centrifuged (13.000 rpm) at room temperature for 3 
minutes. A mixture of 500 µl phenol/chloroform/isoamyl alcohol (25+24+1) was 
added, mixed and centrifuged (13.000 rpm) at room temperature for 5 minutes. 
This last step was repeated. After centrifugation, the upper phase was transferred 
in new phase lock gel tube. A mixture of 500 µl chloroform/isoamyl alcohol (24+1) 
was added, mixed and centrifuged (13.000 rpm) at 4 °C for 5 minutes. The upper 
phase was transferred in a new tube. The plasmid-DNA was precipitated by 
adding the double volume of ethanol (100 %, ice cold) at -20 °C over night. On the 
next day, the tube was centrifuged (13.000 rpm) at 4 °C for 30 minutes. The 
supernatant was discarded and the DNA-pellet was washed with 500 µl ethanol 
(70 %, 4 °C). After centrifugation (13.000 rpm, 20 minutes, 4 °C), the pellet was 
dried and solved in 100 µl double distilled water at 4 °C over night. 
 
2.2.6.2 Purification of plasmid-DNA 
The purification was performed by DNA Clean and Concentrator kit. Briefly, the 
plasmid-DNA was mixed with the double volume of binding buffer and transferred 
on the column. After centrifugation (16.000 g, 30 seconds), the flow rate was 
discarded and the column was washed twice with 200 µl wash buffer. For the 
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elution, 35 µl double distilled water were added on the column, incubated at room 
temperature for 5−10 minutes and centrifuged (16.000 g) for 30 seconds. 
 
2.2.6.3 Concentration of plasmid-DNA 
The isolated plasmid-DNA concentration was measured by NanoDrop 
spectrophotometer according to manufacturer's instructions. Briefly, 1 μl of the 
DNA-solution to be measured was placed on the sample position of the 
spectrophotometer. At a wavelength of 260 nm, the optical density of the solution 
was measured. The ratio of absorbance at 260 and 280 nm was used to assess 
the DNA purity. A ratio between 1.8 and 2 is generally accepted for high level of 
purity. 
 
2.2.6.4 Labeling of probe-DNA via nick translation 
The probe-DNA was labeled with Biotin-16-dUTP and Digoxigenin-dUTP. The 
enzyme DNase I generated randomly single-strand breaks (nicks) in double-strand 
DNA at low enzyme concentration in the presence of MgCl2
 
. The resulting 3' ends 
were elongated by DNA-polymerase I and the template was reduced via 5'->3' 
exonuclease activity. For the reconstruction of the DNA-strand, new nucleotides 
were used. One of them was conjugated with Biotin-dUTP or Digoxigenin-dUTP, 
which are detected by antibodies. 
For the nick translation 1 µg of the probe-DNA, 4 µl of the translation-mix and 
double distilled water were mixed on ice in a total volume of 20 µl and incubated at 
15 °C for 45 minutes in the PCR-unit. The adequate size of the fragments were 
controlled by agarose gel electrophoresis (Figure 8). For that, 3 µl of the sample 
were mixed with 7 µl loading buffer and filled in 1.5 % agarose gel (50 ml TAE-
buffer and 2.5 µl ethidium bromide). When the fragment size between 500 and 
1000 bp was reached, the enzymes were inactivated by incubation at 65 °C for 10 
minutes. 
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Figure 8: Presentation of agarose gel electrophoresis after nick translation. The adequate size of 
fragments between 500 and 1000 bp was reached for chromosome 1 (ch1), chromosome 4 (ch4) 
and chromosome 14 (ch14). 
 
2.2.6.5 Precipitation of probe-DNA 
After labeling, the probe-DNA was precipitated in the presence of herring sperm 
DNA and mouse Cot-1 DNA. The excess of Cot-1 DNA l blocked non-specific 
hybridisation and resulted in saturation of high repetitive sequences. In this way, 
false positive signals were avoided. 
For the precipitation, biotin and digoxigenin labeled probe DNA (10 µl RP23-289I3-
Dig, 10 µl RP23-257F12-Bio, 5 µl RP23-154G18-Dig, 5 µl RP23-154G18-Bio), 
53 µl Cot-1 DNA, 8.8 µl herring sperm DNA and sodium acetate (1/10 volume) 
were mixed. Then, ethanol (2.5 x volume, 100 %, -20 °C) was added and 
incubated at -20 °C over night. 
Afterwards, the sample was centrifuged (13.000 UpM) at 4 °C for 30 minutes. The 
supernatant was removed and 500 µl ethanol (70 %, ice cold) were added. After 
repeated centrifugation (13.000 UpM) at 4 °C for 20 minutes and removal of 
supernatant, the DNA-pellet was dried. The pellet was resolved in 12 µl double 
distilled water and 28 µl mastermix 1.0 at 37 °C for at least 3 hours with the help of 
a shaker (550 rpm). The probe DNA was stored at -20 °C. The binding specificity 
was checked by hybridisation on metaphases from normal spleen cells. The 
1000 bp 
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isolation of spleen cells was kindly performed by Katrin-Janine Goldmann and 
metaphase preparations were provided for the experiments. 
 
2.2.6.6 Fixation of cells 
The cells were seeded in adequate dilution with medium on a glass slide and 
incubated in quadriperm cell culture dish in an incubator. When 20−30 % 
confluence was reached, the medium was removed and replaced by hypotonic 
solution KCl. After incubation at 37 °C for 15 minutes, carnoy's fixative 
(methanol/acetic acid, (4:1) -20 °C) was added and incubated on ice for 20 
minutes. The removing and adding of new carnoy's fixative for 20 minutes was 
repeated twice. After drying, the glass slide was stored at room temperature at 
least for 1 week before starting with denaturation and hybridization. 
 
2.2.6.7 RNase and pepsin digestion 
For the RNase digestion, the sample was incubated in 2xSSC at room 
temperature for 5 minutes. The glass slide was covered with 200 µl RNase 
(50 µg/ml), followed by a plastic film and incubated in a metal box with high 
humidity at 37 °C. B16-F0 and heart ECs were incubated for 5 minutes. Tumor 
ECs were incubated for 7 minutes. Afterward, the slides were washed three times 
in 2xSSC for 2 minutes. 
For the pepsin digestion, the sample was incubated in PBS at room temperature. 
The glass slide was incubated in pepsin solution (10 µg/ml) at 37 °C. B16-F0 and 
heart ECs were incubated for 1 minute. Tumor ECs were incubated for 2 minutes. 
Afterward, the glass slides were washed at room temperature twice in PBS for 5 
minutes, incubated in MgCl2 solution for 5 minutes, rinsed in PBS, incubated in 
formaldehyde (1 %) for 4 minutes, rinsed in PBS and washed twice in PBS for 5 
minutes. 
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2.2.6.8 Denaturation, hybridization and detection 
The FISH probe (3−5 µl) was denatured at 76 °C for 7 minutes and incubated at 
37 °C for at least 30 minutes. The target glass slide was incubated at 72 °C in 
70 % formamide/2xSSC for 2 minutes and incubated in an ethanol series (70, 90 
and 100 %) each time for 2 minutes. After drying on a heating plate at 37 °C for 5 
minutes, the sample was covered with the FISH probe (3 µl or 10 µl) followed by a 
cover slip (round or 15x15 mm). This area was marked and sealed with fixogum. 
After drying on the heating plate at 37 °C for at least 15 minutes, the glass slide 
was incubated at 37 °C in a metal box for 48 hours. After hybridization, the 
fixogum and the cover slip were removed. The glass slide was washed at 42 °C in 
2xSSC for 10 minutes, three times in 50 % formamide/2xSSC for 15 minutes, 
shortly in 2xSSC, in 2xSSC for 15 minutes and in PN-buffer for 15 minutes. After 
this, the glass slide was washed in PN-buffer at room temperature for 15 minutes. 
The sample was covered with PNM-buffer and plastic film and incubated in a 
metal box with high humidity at 37 °C for 20 minutes. After blocking, the sample 
was treated in series with 100 µl Streptavidin-Avidin/anti-Digoxigenin-Cy3 (1:2), 
100 µl Biot-anti-Streptavidin/rat-anti-mouse-Cy3 (1:2) and 100 µl Streptavidin-
Avidin/mouse-anti-rat-Cy3 (1:2) in a metal box with high humidity at 37 °C for 20 
minutes. After each incubation, the sample was washed twice in PN-buffer for 5 
minutes to remove excess antibodies. Afterward, the slide was washed shortly 
three times in double distilled water and dried. The glass slide was covered with 
Vectashield Mounting Medium (with Dapi), followed by a cover slip (24x50 mm) 
and stored at 4 °C. 
 
2.2.7 Animal model 
2.2.7.1 Tumor implantation 
In order to establish tumors in vivo, 1x105
 
 viable CT26 or B16-F0 cells in 50 µl 
medium were injected s.c. into the shaven backs of anesthetized 10 weeks old 
BALB/c or C57Bl/6 mice. For the intraperitoneal injection (27Gx¾) of the 
anesthetic MMF, the mice were weighted and immobilized in the hand. The 
anesthesia was finished with AFN 30 minutes after tumor injection. 
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2.2.7.2 Tumor growth measurements 
One week after tumor injection, tumor diameters were measured without 
anesthetic at least three times per week by ultrasonography. Therefore the 
subcutaneously tumor was covered with ultrasound gel and the diameters of the 
tumor was determined (height, width, depth). Tumor volumes were determined by 
using the formula for an ellipsoid (π/6abc, where a, b and c are the measured 
diameters of the tumors). Mice were sacrificed when the tumor had reached a 
volume ranging between 0.3 and 0.4 cm3
 
 (Figure 9). 
 
Figure 9: Representative macroscopic and ultrasound pictures of a subcutaneous murine tumor 
CT26 (A, B) and B16-F0 (C, D). 
 
2.2.7.3 Induction of repair blastema 
PBS and sterile incomplete Freund’s adjuvant (1:1) were mixed via Mikro-
dismembrator with the help of a chromium steel ball in a shaking tube at 3000 rpm 
twice for two minutes. The resulting emulsion was transferred in a 3 ml syringe. To 
induce a repair blastema, 0.5 ml sterile air and 0.5 ml sterile incomplete Freund’s 
adjuvant/PBS-emulsion were injected (27Gx¾) s.c. into the shaven backs of 
anesthetized 10 weeks old C57Bl/6 mice. For the intraperitoneal injection (27Gx¾) 
of the anesthetic MMF, the mice were weighted and immobilized in the hand. The 
anesthesia was finished with AFN 10 minutes after emulsion injection. Three 
weeks after injection the repair blastema was dissected. 
 
2.2.7.4 Procedure of heart and thorax irradiation of mice 
Each mouse was immobilized without anesthetic in a specially designed jig. 
Preceding the exposure, the position of the heart and thorax inside the jig was 
localized by digital radiographs (Figure 10). 
A B C D 
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10 weeks old male C57Bl/6 mice received local heart irradiation with a single X-ray 
dose of 8 or 16 Gy (200 kV, 10 mA); age-related control mice received sham 
irradiation. The heart irradiation field consisted of a 9 x 13 mm2 window in a 2 mm 
thick lead plate. The mice were sacrificed by cervical dislocation 16 weeks after 
heart irradiation. 
10 weeks old female C57Bl/6 mice received local thorax irradiation with a single X-
ray dose of 2 or 8 Gy (200 kV, 10 mA); age-related control mice received sham 
irradiation. The thorax irradiation field consisted of a 15 x 18 mm2
 
 window in the 
lead plate. The mice were sacrificed by cervical dislocation 5, 10, 15 and 20 weeks 
after thorax irradiation. 
 
Figure 10: Representative pictures of mouse heart and thorax irradiation. (A) Fixed mouse in the 
jig (top view), (B) lead for thorax irradiation with 15 x 18 mm2 window, (C) radiograph shows the 
position of the thorax (arrow), (D) fixed mouse in the jig (bottom view) after heart irradiation; a 
gafchromic film below the mouse presents the irradiation field due to the colour change from light 
blue to dark blue, (E) lead for heart irradiation with 9 x 13 mm2
2.2.8 Statistics 
 window, (F) radiograph show the 
position of the heart (arrow).  
 
Analysis of the number of positively stained cells (proportion of cells) and the 
mean fluorescence intensity (mfi) (expression density of protein per cell) were 
performed by CellQuest software. Comparative analysis of the data was carried 
out using the Student’s t-test (two paired and unpaired). The significance levels 
were p* < 0.05 (5 %); p** < 0.01 (1 %) and p*** < 0.001 (0.1 %). Data were 
presented as means of the number (n) of indicated experiments. 
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3. RESULTS  
It has been assumed that surface markers on ECs from normal resting and 
growing tissues may be different. The establishment of my new EC-isolation 
method allows the analysis of primary ECs directly after their isolation. Thereby 
the physiological status of EC surface markers in resting and growing tissue can 
be determined without previous long-term in vitro cell culture. For isolation of ECs 
from non-proliferating tissue, heart and lung of the mice were used. For the 
isolation of ECs from proliferating benign and malignant tissue, repair blastema 
and tumors (B16-F0 melanoma and CT26 colon carcinoma) were used.  
Heart irradiation is known to lead to a change in the microvascular density. After a 
temporary increase, the microvascular density was found to be decreased. This 
effect results in late radiation-induced heart diseases. 
Based on the newly established method, the differences between non-proliferating 
and proliferating ECs could be investigated. Selected surface markers which differ 
in ECs derived from non-proliferating (normal tissues) and proliferating tissues 
(tumors) may provide possible targets in the future that could be used for 
therapeutic intervention for patients with tumors or for patients that have to 
undergo a thoracic irradiation therapy. 
 
3.1 Isolation of primary endothelial cells 
A new method for the isolation of primary ECs was established (Sievert et al. 
2014). For each isolation procedure, one to four mice were sacrificed by 
craniocervical dislocation. Heart, lung, repair blastema and tumors were collected 
under aseptic conditions. The left and right atria were surgically removed from the 
heart to reduce contaminations with macrovascular ECs. After washing in ice-cold 
PBS and mechanical mincing with a sterile scalpel blade, tissue fragments with a 
size of 1 mm3 were transferred into 10 ml of pre-warmed (37 °C) digestion solution 
consisting of collagenase A (0.5 units/ml) diluted in HBSS/10 % FCS. The tissues 
were incubated for 45 minutes at 37 °C under gentle rotation (2 rpm). Afterwards 
the suspension was dispersed by forcing it through a sterile 18 G injection needle 
10 times. The single cell suspension was filtered through a 70 µm cell strainer and 
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washed twice in 50 ml HBSS/10 % FCS solution at 4 °C (400xg for 10 minutes). 
The cell pellet was resuspended in 600 µl ice-cold isolation buffer and DSB-X 
biotin-labeled anti-mouse PECAM-1-antibody (25 µl; 0.5 mg/ml) was added. After 
incubation for 10 minutes at 4 °C under gentle rotation (3 rpm) and washing in ice-
cold isolation buffer (2 ml), the cell pellet was resuspended in 1 ml cold isolation 
buffer. Magnetic dynabeads coated with streptavidin (75 µl) were added and 
incubated for 15 minutes at 4 °C under gentle rotation (3 rpm). Afterwards the tube 
was placed in the magnetic separator. After 2 minutes, the bead-free, unbound 
PECAM-1-negative cells were removed from the cell suspension by pipetting. 
PECAM-1-positive cells immobilized in the DSB-X-streptavidin-bead-complex, 
remained on the wall of the tube due to the magnetic field. After at least 5 washing 
steps with isolation buffer (1 ml), cells attached to beads were resuspended in 1 ml 
release buffer and incubated for 2 minutes at 21 °C. By pipetting the cell 
suspension 10 times, the cells were detached from the beads by biotin-streptavidin 
competition. Then the tube was placed in the magnetic separator. After 1 minute, 
bead-free PECAM-1-positive ECs could be isolated, whereas the magnetic beads 
remained on the wall of the tube (Figure 11) (Sievert et al. 2014). 
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3.1.1 Quality control experiment 
To test the efficiency of the new method, a PECAM-1-positive mouse EC line 
(H5V) and a PECAM-1-negative mouse colon cancer cell line (CT26) were mixed 
at a ratio of 1:20. After a simulated digestion with collagenase (Figure 12A, second 
column) and magnetic bead separation (Figure 12A, third column) according to the 
method described in Figure 11, the percentage of PECAM-1 positively stained 
H5V cells remained unchanged compared to that of untreated H5V cells. The 
mean surface expression density of PECAM-1 (which remained high after 
collagenase digestion (Figure 12B, second column)) decreased to 17 % (mfi: 
31±4) following PECAM-1-biotin-streptavidin competition (Figure 12B, third 
column). Despite the low expression density of free PECAM-1 molecules on the 
cell surface of H5V cells after PECAM-1-biotin-streptavidin competition, the 
recovery rate of H5V cells was more than 70 % after the separation procedure 
(Figure 12C). It is assumed that the recovery rate of primary ECs is higher 
because the mean cell surface density of PECAM-1 on heart, repair blastema and 
tumor ECs (mfi: 85±8, 479±14, 211±67) is higher compared to that of H5V cells 
(mfi: 31±4). Analysis by flow cytometry revealed that no contaminating PECAM-1-
negative tumor (CT26) cells were present in the PECAM-1-positive EC fraction. 
This result demonstrates that it is possible to recover PECAM-1-positive ECs from 
a mixture of different cells with high efficiency and purity (Sievert et al. 2014). 
  
 
   
Figure 12: Control experiment for the new isolation method of ECs: Separation of PECAM-1-
positive H5V cells mixed with PECAM-1-negative CT26 tumor cells at a ratio of 20:1. (A) The 
percentage of PECAM-1-positive H5V cells remained unchanged after a simulated digestion and 
after separation. (B) The fluorescence intensity (mfi) remained stable after digestion (second 
column), but decreased to 17 % (mfi: 31) after separation (third column). (C) The recovery rate of 
H5V cells after separation was higher than 70 %. 
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3.2 Endothelial cells from different tissue 
3.2.1 Distribution in vivo and yield after isolation 
To determine the distribution and density of capillaries and the fraction of necrotic 
and apoptotic areas, sections of hearts and tumors of mice were analyzed by 
PECAM-1 immunofluorescence and H&E staining (Sievert et al. 2014). Viable 
tumor tissue is characterized by compact tissue with high cell densities, whereas 
necrosis is characterized by increased eosin staining and a bulky extracellular 
matrix. In heart sections, capillaries and myocardial tissues were homogeneously 
distributed. PECAM-1-positive vessels were localized in close proximity to 
cardiomyocytes (Figure 13A, B). In contrast, the capillary densities in tumor 
sections were lower and vessels were predominantly localized in the viable outer 
borders, but not in the necrotic center of the tumor (Figure 13C, D). In line with 
these findings, the yield of ECs originated from heart and lung tissues was much 
higher compared to that of tumors and repair blastemas (Figure 14). 
 
 
Figure 13: Localization of necrosis/apoptosis fraction and capillaries in heart and tumor (B16-F0, 
size between 0.3–0.4 cm3). (A, C) H&E staining of heart and tumor, respectively. Arrows indicate 
the fraction of necrotic/apoptotic areas. (B, D) PECAM-1 immunostaining of heart and tumor, 
respectively. Arrows indicate PECAM-1-positive ECs (red). 
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An important feature of the newly established method is that similar amounts of 
viable, primary microvascular ECs that became adherent to plastic could be 
isolated from tumor and normal tissues of young (5 weeks old) and old mice (100 
weeks old) (Table 15) (Sievert et al. 2014).  
 
Table 15: Heart weight, number of viable heart ECs and EC adherence after two days as a 
function of mice age (n=2). 
age of mouse 
[weeks] sex 
weight of 
heart [g] 
ECs counts directly 
after isolation 
total adherent ECs after 2 
days 
5 f 0.07 350,000 60,000 
20 f 0.11 400,000 40,000 
50 f 0.12 490,000 40,000 
100 m 0.14 550,000 50,000 
 
It was possible to isolate approximately 0.45x106 PECAM-1-positive ECs from one 
heart, approximately 3x106 PECAM-1-positive ECs from one lung, approximately 
0.025x106 PECAM-1-positive ECs from one repair blastema and approximately 
0.1x106 Sievert et al. 2014 PECAM-1-positive ECs from one tumor (Figure 14) ( ). 
 
 
Figure 14: Weight of various tissues and counts of isolated ECs. (A) Summary of the total weight 
of separate tissues; weight of heart (n=10) and lung (n=3) taken from 13− 15 weeks old female 
mice; weight of repair blastemas (n=10) taken from a balloon which was induced by using Freund’s 
adjuvant/PBS-emulsion; weight of CT26 (n=10) and B16-F0 (n=10) tumors which were taken when 
their size was ranging between 0.3 and 0.4 cm3. (B) Corresponding isolated EC counts were 
calculated per 100 mg tissue. 
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3.2.2 Size of isolated ECs and number of bound beads 
After digestion and magnetic bead separation of PECAM-1-positive and PECAM-
1-negative cells, primary ECs were inspected under the microscope (Sievert et al. 
2014). In most cases, ECs isolated from the heart and lung bound 2–5 micro-
beads (Figure 15A), whereas ECs originated from repair blastema and tumors 
(CT26, B16-F0) bound more than 20 beads (Figure 15B, C). After biotin-
streptavidin competition, almost all ECs were completely separated from the 
magnetic beads (Figure 15D–F). The size of ECs from repair blastema and both 
tumors were twice the size of ECs derived from normal heart and lung tissues. The 
diameter of heart and lung ECs ranged between 1.5 and 2 µm, whereas that of 
repair blastema and tumor ECs ranged from 3 to 4 µm. Determination of the height 
of the forward scatter (FSC-height) by flow cytometry (Figure 16) confirmed that 
the mean FSC-height of ECs from repair blastema (350±7) and tumors (CT26: 
400±40, B16-F0: 437±17) was about twice the size of ECs derived from heart 
(225±6) and lung (189±6) tissues. The purity of ECs isolated from heart, lung and 
tumors was almost 100 %. 
 
 
Figure 15: Primary ECs isolated from different tissue. (A-C) Isolated ECs from heart, repair 
blastema and B16-F0 with bound dynabeads. Arrows indicate specific binding of corresponding 
PECAM-1-positive ECs to dynabeads. (D–F) Isolated ECs from heart, repair blastema and B16-F0 
after biotin-streptavidin competition without any bound dynabeads. 
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Figure 16: Size of primary ECs isolated from different tissue. Mean of the forward scatter (FSC) 
from PECAM-1 positive ECs isolated from heart (n=4), lung (n=3), repair blastema (n=2), CT26 
(n=4) and B16-F0 (n=4) measured using flow cytometry. Asterisk represent significantly different 
values (p** < 0.01; p*** < 0.001). 
 
3.2.3 Identification of primary endothelial cells 
Primary ECs isolated from heart, lung, repair blastema and tumors were 
characterized by flow cytometry using EC-specific antibodies directed against 
PECAM-1, endoglin, VE-cadherin, mucosialin, ICAM-1 and ICAM-2 (Sievert et al. 
2014). The leukocyte marker CD45, which was used as control, was not 
detectable on the population of separated ECs. A representative histogram of 
each antibody staining pattern is illustrated in Figure 17. The summary of the 
proportion of positively stained cells and the mean fluorescence intensity values 
are depicted in Figure 19A, B. The proportion of positive stained cells for PECAM-
1, endoglin, VE-cadherin, mucosialin, ICAM-1 and ICAM-2 is nearly 100 % (94±4 
%), independent of the origin of the tissue from which the ECs were generated. 
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Figure 17: Identification of ECs derived from different tissue using flow cytometry. Control EC line 
H5V and primary ECs isolated from heart, lung, repair blastema, CT26 and B16-F0 can be 
identified with EC-specific antibodies directed against PECAM-1, endoglin, VE-cadherin, 
mucosialin, ICAM-1 and ICAM-2. 
 
Comparative in vitro immunofluorescence studies showed that the fluorescence 
intensity of PECAM-1 and isolectin B4 was different between heart (Figure 18B, E) 
and tumor ECs (Figure 18C, F). Both markers were also used to stain the control 
murine endothelial cell line H5V (Figure 18A, D) (Sievert et al. 2014). 
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Figure 18: Identification of ECs derived from different tissue using immunofluorescence. (A-C) 
PECAM-1 staining (red) of H5V, primary heart and tumor (B16-F0) ECs. (D-F) Isolectin B4 staining 
(green) of H5V, primary heart and tumor (B16-F0) ECs. 
 
3.2.4 Surface markers of endothelial cells from normal and tumor 
tissue 
The proportion of positive stained cells for PECAM-1, endoglin, VE-cadherin, 
mucosialin, ICAM-1 and ICAM-2 is nearly 100 % (94±4 %) independent of the 
origin of the tissue from which the ECs were generated. In contrast, the proportion 
of the proliferation marker integrin β3 was low on heart ECs (30±7 %) and high on 
tumor ECs (96±4 %). For the analysis of ECs isolated from the repair blastema, all 
PECAM-1 negative cells were removed using a special gating strategy. Only 
PECAM-1 positive cells were illustrated in the histograms. In general, the cell 
surface expression density of typical EC markers is higher on ECs derived from 
tumors than that of normal heart and lung tissues, except for VE-cadherin. The 
marker densities of PECAM-1 (p=0.006), endoglin (p=0.0004), mucosialin 
(p=0.0005), ICAM-1 (p=0.03) and ICAM-2 (p=0.001) were all significantly 
increased (two to four-fold) in tumors as compared to ECs derived from normal 
tissue (Figure 19B). The expression density of PECAM-1 (p=0.007) on ECs 
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derived from repair blastema was six-fold higher and that of endoglin (p<0.001) 
twice as high as that found on normal heart and lung tissues. The expression 
density of mucosialin on ECs from repair blastema was similar to that found on 
heart or lung ECs, whereas the expression density of ICAM-2 was more similar to 
that seen in tumor ECs. Furthermore, ECs from the repair blastema show a two-
fold higher expression of VE-cadherin (p=0.01) and a five-fold higher expression 
density of ICAM-1 (p=0.1) compared to that of ECs from normal heart and lung 
tissues (Sievert et al. 2014). 
 
 
 
Figure 19: Identification and characterization of ECs derived from different tissue. (A) Percentage 
of positively stained cells and (B) mean fluorescence intensity (PECAM-1, integrin β3, endoglin, 
VE-cadherin, mucosialin, ICAM-1 and ICAM-2) of ECs isolated from heart (n=5), lung (n=3), repair 
blastema (n=2), CT26 (n=3) and B16-F0 (n=3). Asterisk represent significantly different values (p* 
< 0.05; p** < 0.01; p*** < 0.001). 
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3.2.5 Surface markers of heart endothelial cells in dependency of 
the age of mice 
Comparative flow cytometric analysis revealed that −  except for the case of VE-
cadherin (mean fluorescence intensity (mfi): 360±83 vs 244±6) −  the densities of 
typical cell surface markers of ECs such as PECAM-1 (mfi: 86±6 vs 87±2), 
endoglin (mfi: 153±11 vs 155±17), mucosialin (mfi: 22±1 vs 22±1), ICAM-1 (mfi: 
73±20 vs 84±11), ICAM-2 (mfi: 128±14 vs 137±18) were expressed at similar 
densities on heart ECs of young (5 weeks) and old (85 weeks) mice (Table 16). 
This suggests that expression patterns remain stable on ECs of young and old 
mice. The density of the EC marker VE-cadherin which enables tight junctions is 
substantially higher in ECs of young mice compared to that of old mice (Sievert et 
al. 2014).  
 
Table 16: Mean fluorescence intensity (mfi) of PECAM-1, endoglin, VE-cadherin, mucosialin, 
ICAM-1 and ICAM-2 of heart ECs in dependency of the age of mice (n=2). 
age of 
mice 
[weeks] 
mfi 
PECAM-1 
mfi 
endoglin 
mfi VE-
cadherin 
mfi 
mucosialin mfi ICAM-1 mfi ICAM-2 
5 86 ± 6 153 ± 11 360 ± 83 22 ± 1 73 ± 20 128 ± 14 
85 87 ± 2 155 ± 17 244 ± 6 22 ± 1 84 ± 11 137 ± 18 
 
3.2.6 Surface markers of tumor endothelial cells with different 
growth rate 
The B16-F0 tumors grow faster compared to CT26 tumors in vivo (Figure 20A). 
The mean doubling times for B16-F0 and CT26 tumors were 1.9 ans 3.6 days 
(p<0.001) (Figure 20B). The expression densities of the EC markers PECAM-1 (p= 
0.002), endoglin (p= 0.002) and mucosialin (p= 0.01) were higher on ECs derived 
from fast-growing B16-F0 tumors, whereas the expression densities of the cellular 
adhesion molecule ICAM-1 (p<0.05) and ICAM-2 (p= 0.008) were found to be 
elevated in the slow-growing CT26 tumor (Figure 20C) (Sievert et al. 2014). 
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Figure 20: Differences in expression of EC markers derived from slow- and fast-growing tumors 
(CT26 and B16-F0). (A, B) Growth curves and doubling times of CT26 (n=15) and B16-F0 (n=15) 
in vivo. (C) Mean fluorescence intensity values (PECAM-1, endoglin, VE-cadherin, mucosialin, 
ICAM-1 and ICAM-2) from slow-growing tumor ECs (CT26 (n=3)) and fast-growing tumor ECs 
(B16-F0 (n=3)). Asterisk represent significantly different values (p* < 0.05; p** < 0.01; p*** < 0.001). 
 
3.2.7 Morphology 
Primary ECs derived from normal (heart) and tumor (B16-F0) tissues became 
adherent 1−2 days after seeding (Figure 21A, B). The diameter of ECs increased 
over the following 5−7 days until the cells reached 100 % confluence (Figure 21C, 
D). Adherent tumor ECs were found to be larger, to spread faster and to distribute 
in a more chaotic pattern compared to ECs from normal tissues (Sievert et al. 
2014).  
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Figure 21: Phenotypic characteristics of heart and tumor (B16-F0) ECs. (A, B) Adherent heart and 
tumor ECs after 2 days. (C, D) Adherent heart and tumor ECs after 7 days. 
 
3.2.8 Migration, flow alignment and tube formation 
Although heart and tumor ECs became confluent, cell divisions were not 
detectable within 33 hours, as expected (Figure 22). The migratory capacity of 
heart ECs (134±68 µm, p<0.002) is significantly lower compared to that of tumor 
ECs (199±108 µm) (Figure 24A) (Sievert et al. 2014).  
 
 
 
 
 
 
heart ECs     tumor ECs 
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Figure 22: Migration of heart and tumor (B16-F0) ECs. After heart and tumor cells become 
adherent, the monitoring of the same place was started (A, B). Every minute a picture was taken. 
Although the confluence seems to be increased 33 hours later, cell divisions were not detectable 
(C, D). 
 
The cultivation of primary heart and tumor ECs under permanent shear stress 
allows the physiological conditions in blood vessels to be simulated. Therefore, 2 
days after allowing the cells to attach, ECs were cultured under constant flow 
conditions using the IBIDI system. To avoid detachment of cells, the flow was 
started at a rate of 2 ml/min (3.5 dyn/cm2) for the first day. After that, the flow was 
increased to 4 ml/min (7 dyn/cm2
Sievert et al. 2014
). After two days, heart ECs started to elongate in 
the direction of the flow. Four days later, most heart ECs showed an alignment in 
the direction of the flow (Figure 23A). In contrast, ECs derived from tumors did not 
align in the direction of the flow (Figure 23B) ( ). 
Due to the larger size of tumor ECs compared to normal tissue ECs (Figure 16), a 
higher number of heart (80,000 cells/well) than tumor (20,000 cells/well) ECs was 
heart ECs     tumor ECs 
C D 
B A 
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seeded into the matrigel. The numbers used mirror the minimum number of cells 
that are required to allow a tube formation within a defined area (Figure 23C, D). 
Tubes formed by tumor ECs show a significantly smaller number of branching 
points (n: 58±16, p<0.04) and loops (n: 15±6, p=0.02) per image compared to that 
of ECs derived from heart tissues (number of branching points: 176±6, number of 
loops: 68±8) (Figure 24B, C) (Sievert et al. 2014). 
 
 
 
Figure 23: Functional characteristics of heart and tumor (B16-F0) ECs. (A, B) Heart and tumor 
ECs under flow conditions (4 ml/min) after 4 days. Before starting the flow, cells were incubated for 
2 days under static conditions and 1 day under low flow conditions (2 ml/min). Arrows indicate flow 
direction. (C, D) Tube formation of heart and tumor ECs in matrigel. 
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Figure 24: Migration and functional characteristics of heart and tumor (B16-F0) ECs. (A) Migration 
of heart and tumor ECs. (B, C) Number of total branching points and total loops of heart and tumor 
ECs in matrigel.  Asterisk represent significantly different values (p* < 0.05; p** < 0.01). 
 
3.2.9 Ploidy level 
In this thesis, FISH was used for the determination of the ploidy level of primary 
heart and tumor ECs. It can be assumed that only interphases can be analyzed, 
because of the low proliferation rate of heart and tumor ECs in vitro. Therefore, 
three probes with different fluorescence dyes were used (Figure 7). The probe 
RP23-289I3 was labeled with digoxigenin and hybridized specific to chromosome 
1 (red signal), the probe RP23-257F12 was labeled with biotin and hybridized 
specific to chromosome 4 (green signal), the probe RP23-154G18 was labeled 
with digoxigenin and biotin and hybridized specific to chromosome 14 (orange 
signal). The frequency of these three signals have been used to detect the ploidy 
level of the cells (Figure 7). The specificity was controlled by metaphases from 
mouse spleen cells (Figure 25, upper line). As expected for normal cells, each 
chromosome exists twice. Additionally, B16-F0 tumor cells, from which the tumor 
ECs were isolated, were also investigated. Very often the metaphases from B16-
F0 showed a triploid ploidy level (Figure 25, bottom line). This underlines the need 
for an isolation method of primary ECs without contamination by tumor cells. 
In contrast to B16-F0 tumor cells, heart and tumor (B16-F0) ECs showed a normal 
diploid ploidy level (Figure 26, Table 17). 
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Figure 25: FISH-analysis for mouse spleen (upper line) and B16-F0 tumor (bottom line) cells with 
the probes for chromosome 1 (RP23-289I3, red signal), chromosome 4 (RP23-257F12, green 
signal) and chromosome 14 (RP23-154G18, orange signal). Arrows indicate the signals in 
metaphases. 
 
 
Figure 26: FISH-analysis for heart (upper line) and tumor (B16-F0) (bottom line) ECs with the 
probes for chromosome 1 (RP23-289I3, red signal), chromosome 4 (RP23-257F12, green signal) 
and chromosome 14 (RP23-154G18, orange signal). Arrows indicate the signals in interphases. 
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Table 17: Result of FISH-analysis for heart and tumor (B16-F0) ECs with the probes RP23-289I3 
(red signal), RP23-257F12 (green signal) and RP23-154G18 (orange signal). 
sample 
number of counted cell nucleus with associated signals 
result 
loss diploid loss and gain gain 
heart ECs 1x2r1g2o 46x2r2g2o 
1x2r3g1o 
1x3r1g1o 
1x5r5g5o diploid 
tumor ECs 1x2r1g2o 45x2r2g2o 2x2r3g1o 2x2r3g2o diploid 
g: green, o: orange, r: red 
 
3.3 mRNA expression of endothelial cells with high 
shear stress 
3.3.1 Flow−dependent alignment 
The cultivation of primary heart ECs under high permanent shear stress allows 
physiological conditions in capillaries to be simulated. Therefore, 2 days after 
allowing the cells to attach, ECs were cultured under constant flow conditions. To 
avoid detachment of cells, the flow was started at a rate of 0.68 ml/min 
(3.5 dyn/cm2) for 2 hours, followed by 0.97 ml/min (5 dyn/cm2) for 20 h and 1,95 
ml/min (10 dyn/cm2) for 2 hours. One day after starting flow, cells were exposed to 
a flow rate of 3.9 ml/min (20 dyn/cm2
 
). Four days later, most heart ECs showed an 
alignment in the direction of the flow (Figure 27B), contrary to ECs under static 
conditions (Figure 27A). ECs from this model were used for RNA isolation. 
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Figure 27: Heart ECs under static (A) and flow conditions (B) (20 dyn/cm2) after 4 days. Before 
being exposed to high flow (20 dyn/cm2), cells were incubated for 2 days under static conditions 
and 1 day under increasing flow conditions (3.5 dyn/cm2 for 2 hours, 5 dyn/cm2 for 20 hours, 10 
dyn/cm2 
3.3.2 Flow−dependent gene expression 
for 2 hours). Arrows indicate flow direction. 
 
The results of the mRNA microarray analysis showed 4,248 differently expressed 
genes (corrected p-value < 0.1/absolute log2 fold-change > 0.5) of heart ECs 
under flow conditions compared to static conditions. A heatmap of the top 50 
differentially expressed genes are shown in Figure 28. A clear separation of gene 
expression between static (A) and flow (B) conditions can be identified. Pathway 
enrichment analysis testing specific enrichment of all differentially genes identified 
in pathways of the Reactome interactome database (http://www.reactome.org/) 
resulted in 24 pathways (corrected p-value < 0.1, Table 18). The pathways can be 
assigned to different specific cell components and functions: Extracellular 
organisation, cell membrane, signal molecules, hemostasis, metabolism, 
developmental biology and smooth muscle contraction. The extracellular 
organisation includes the pathways "extracellular matrix organisation", "collagen 
formation", "assembly of collagen fibrils and other multimeric structures", "elastic 
fibre formation", "molecules associated with elastic fibres", "integrin cell surface 
interactions", "non-integrin membran-ECM interactions", "chondroitin sulfate/ 
dermatan sulfate metabolism" and "laminin interactions". The pathway "cholesterol 
biosynthesis" suggests specific involvement of the cell membrane. With regard to 
signaling, the pathways "signaling by Rho GTPase", "signaling by VEGF", 
"NRAGE signals death through JNK", "nitric oxide stimulates guanylate cyclase" 
A B 
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and signaling in angiogenesis such as "axon guidance", "signaling by NGF", 
"Netrin-1 signaling" and "semaphorin interactions" were shown to be specifically 
deregulated. The hemostasis includes the pathways "hemostasis", "platelet 
activation, signaling and aggregation" and "platelet homeostasis". The pathways 
"metabolism", "developmental biology" and "smooth muscle contraction" present 
specific own categories. 
 
 
Figure 28: Heatmap of top 50 differentially expressed gene-probes of heart ECs under static (A) 
and flow (B) conditions (20 dyn/cm2 for 4 days). Log2 transformed expression is reflected by the 
colour key as indicated on the top-left including the frequencies of each intensity (turquoise 
histogram line). 
 
 
 
 
 
Results 
67 
 
Table 18: Involved pathways based on differential gene expression in response to 4 days high 
shear stress (20 dyn/cm2). The pathways can be assigned to different specific cell components and 
functions (category (cat)): Extracellular organisation (A), cell membrane (B), signal molecules (C), 
hemostasis (D), metabolism (E), developmental biology (F) and smooth muscle contraction (G). 
Matches and %-match indicate the number and percentage of genes which are included in the 
corresponding pathway. Furthermore the corrected p-value (p-val < 0.1) and the false discovery 
rate (FDR < 0.1) are shown. 
pathway name cat genes in pathway matches 
%-
match p-val FDR 
Extracellular matrix 
organization A 263 91 34.6 9.6698E-10 1.4998E-06 
Assembly of collagen 
fibrils and other multimeric 
structures 
A 54 26 48.15 1.1018E-06 0.00056962 
Hemostasis D 475 132 27.79 7.5225E-07 0.00056962 
Cholesterol biosynthesis B 22 14 63.64 5.2106E-06 0.00161634 
Molecules associated with 
elastic fibres A 30 17 56.67 4.8617E-06 0.00161634 
Axon guidance C 318 91 28.62 1.2728E-05 0.00259808 
Elastic fibre formation A 41 20 48.78 1.4876E-05 0.00259808 
Signaling by Rho 
GTPases C 122 43 35.25 1.5076E-05 0.00259808 
Collagen formation A 86 33 38.37 2.0306E-05 0.00314947 
Developmental Biology F 498 128 25.7 6.1882E-05 0.00872533 
Signalling by NGF C 281 79 28.11 9.028E-05 0.01166875 
Metabolism E 1569 340 21.67 0.00011066 0.01320248 
Integrin cell surface 
interactions A 66 24 36.36 0.00066401 0.0650533 
NRAGE signals death 
through JNK C 45 18 40 0.00085215 0.0650533 
Netrin-1 signaling C 42 17 40.48 0.00100663 0.0650533 
Nitric oxide stimulates 
guanylate cyclase C 25 12 48 0.00093547 0.0650533 
Non-integrin membrane-
ECM interactions A 42 17 40.48 0.00100663 0.0650533 
Platelet homeostasis D 79 27 34.18 0.00095549 0.0650533 
Semaphorin interactions C 67 24 35.82 0.00085041 0.0650533 
Smooth Muscle 
Contraction G 22 11 50 0.00099631 0.0650533 
Platelet activation, 
signaling and aggregation D 205 57 27.8 0.00111354 0.06908398 
Chondroitin 
sulfate/dermatan sulfate 
metabolism 
A 50 19 38 0.00128611 0.0767217 
Laminin interactions A 23 11 47.83 0.0015837 0.09097492 
Signaling by VEGF C 106 33 31.13 0.00172045 0.09530074 
 
In order to study the putative functional role of genes that are known to be involved 
in endothelial adhesion and migration of leukocytes, Pecam1, Vcam1, Icam1 and 
Icam2 were investigated. mRNA expression analysis showed that Pecam1, Icam1 
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and Icam2 were higher expressed on heart ECs under static conditions compared 
to flow conditions (Table 19). Further Pecam1, Vcam1, Icam1 and Icam2 were 
investigated for correlation with all other genes of the gene expression microarray 
dataset. Positive correlations suggests an activating relationship and negative 
correlation an inhibitoy relationship. From the whole correlation network the top 5 
positively and top 5 negatively correlating genes were identified (Figure 29) 
according to the level of significance (e.g. their corrected p-values and correlation 
coeffecients). Next these genes were compared for significant differential 
expression between static (A) and flow (B) conditions. The level of significance is 
fulfilled, when logFC >0.5 or <-0.5, P.value <0.05 and adj.p.value <0.1. In contrast 
to Pecam1 and Vcam1 (table 20, 21), Icam1 fulfills the level of significance for all 
activated and inactivated genes relating to differential gene expression between 
static and flow condition (table 22). The functions of the genes include membrane-
trafficking (Syt17), internalization of ligand-activated EGFR (Ankrd13b), 
proliferation (Fgf2), loss of stress fibers (Basp1), migration (Plxna4), proteolysis 
(Grcc10, Psmb9, Bace2), morphogenesis (Nus1) and cytoskeletal reorganization 
(Ssh3). 
All gene probes from the Icam2 correlation network suggesting an activating 
relationship reached the level of significance, whereas only two gene probes from 
the Icam2 correlation network suggesting an inhibitoy relationship reached the 
level of significance (table 23). The functions of the activated gene-probes include 
pyrimidine metabolism (Cda), atheroprotective effects (Nos3), protein glycosylation 
(Galnt18), cell adhesion (Sh2b3) and maybe sensory receptor (Tmem44). The 
functions of the significant inactivated gene-probes include proteolysis (Rffl) and 
regulation of transcription (Zswim4). 
 
Table 19: Significant mRNA expression of Pecam1, Icam1 and Icam2 between flow (B) and static 
(A) conditions. The level of significance is fulfilled when logFC >0.5 or <-0.5, P.value <0.05 and 
adj.p.value <0.1. 
gene logFC P.Value adj.P.Val comp. B-A 
Pecam1 0.51 0.016 0.049 up 
Icam1 1.61 0.013 0.042 up 
Icam2 0.85 0.005 0.02 up 
Results 
69 
 
 
  Icam1 
 
  Syt17   
 
  Ankrd13b 
 
  Fgf2 
 
  Basp1 
 
  Plxna4 
 
  Bace2 
 
  Ssh3 
 
  Nus1 
 
  Psmb9 
 
  Grcc10 
 
  Vcam1 
 
  Slc18a8 
 
  Sh3pxd2a 
 
  Mgat2   
 
  Hmgxb3 
 
  Acbd5 
 
  Txnip 
 
  Hsf4 
 
  Cpne1 
 
  Sfrs18 
 
  Mrgprb1 
 
  Icam2 
 
  Cda 
 
  Nos3 
 
  Gaint18   
 
  Sh2b3 
 
  Tmem44 
 
  Clip1 
 
  Zswim4 
 
  Rffl 
 
  Sowahb 
 
  Snupn 
 
  Pecam1 
  Inpp5e 
 
  Iffo1 
 
  Stom   
 
  Bora 
 
  Zfp92 
 
  Rplp1 
 
  Timm17b 
 
  Bcl7a 
 
  Ctbs 
 
  Tctex1d2 
 
Figure 29: Functional correlation for Pecam1, Vcam1, Icam1 and Icam2. For each gene the top 5 
activated and inactivated gene-probes are shown. 
 
Table 20: Functional correlation of gene-probes with Pecam1. Five gene-probes with an activating 
and five gene-probes with an inactivating correlation are listed. In each group, gene-probes with 
the highest significance (p-val and coef) were selected. These gene-probes were compared for 
significant differential expression between static (A) and flow (B) conditions. When the level of 
significance (logFC >0.5 or <-0.5, P.value <0.05 and adj.p.value <0.1) is fulfilled, the gene is 
marked in green, otherwise the gene is marked in red. 
gene p-val coef logFC P. Value 
adj. 
P.Val function 
comp. 
A-B 
Inpp5e 3.6E-05 0.98  -0.31 0.02 0.05 phosphatase (Humbert et al. 2012) up 
Iffo1 6.7E-05 0.97 -0.47 0.01 0.03 
component of 
cytoskeleton (Herrmann et 
al. 2007) 
up 
Stom 0.00013 0.96 -0.27 0.02 0.05 
regulation of ion channels  
up and transporters 
(Rungaldier et al. 2013) 
Bora  0.00014 0.96  -0.25 0.03 0.08 cell division (Hutterer et al. 2006) up 
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Table 20 continued: Functional correlation of gene-probes with Pecam1. 
Zfp92 0.00018 0.96 -0.21 0.03 0.08 regulation of transcription (Papworth et al. 2006) up 
Rplp1 0.00019 -0.96 0.08 0.30 0.44 
structural component of 
ribosome (Ishii et al. 
2006) 
down 
Timm17b 0.00015 -0.96 0.26 0.04 0.09 
transport of proteins in 
mitochondrion (Shames et 
al. 2011) 
down 
Bcl7a 0.00011 -0.96 0.25 0.04 0.11 
B cell malignancy 
(Ramos-Medina et al. 
2013) 
down 
Ctbs 7.1E-05 -0.97 0.12 0.19 0.32 glycosidase (Liu et al. 1999) down 
Tctex1d2 4.5E-05 -0.97 0.27 0.02 0.06 ciliogenesis (Gholkar et al. 2015) down 
 
Table 21: Functional correlation of gene-probes with Vcam1. Five gene-probes with an activating 
and five gene-probes with an inactivating correlation are listed. In each group, gene-probes with 
the highest significance (p-val and coef) were selected. These gene-probes were compared for 
significant differential expression between static (A) and flow (B) conditions. When the level of 
significance (logFC >0.5 or <-0.5, P.value <0.05 and adj.p.value <0.1) is fulfilled, the gene is 
marked in green, otherwise the gene is marked in red. 
gene p-val coef logFC P. Value 
adj. 
P.Val function 
comp. 
A-B 
Slc16a8 2.1E-06 0.99 0.02 0.83 0.89 
monocarboxylate 
membrane transporter 
(Pinheiro et al. 2012) 
up 
Sh3pxd2a 6.5E-05 0.97 0.04 0.77 0.84 
extracellular matrix 
degradation (Stylli et al. 
2009) 
up 
Mgat2 0.00011 0.96 0.00 0.99 1.00 protein glycosylation (Tan et al. 1995) up 
Hmgxb3 0.00022 0.96 0.03 0.77 0.84 regulation of transcription (Stros et al. 2007) up 
Acbd5 0.00027 0.95 -0.45 0.02 0.06 cell metabolism (Fan et al. 2010) up 
Mrgprb1 7.8E-05 -0.97 0.00 0.97 0.98 G-protein-coppled sensory receptor (Liu et al. 2008) down 
Sfrs18 0.00014 -0.96 -0.07 0.73 0.82 processing of mRNA (Zimowska et al. 2003) down 
Cpne1  0.00016 -0.96  0.22 0.30 0.44 membrane-trafficking (Creutz et al. 1998) down 
Hsf4 0.00018 -0.96 0.00 1.00 1.00 heat shock proteins (Merath et al. 2013) down 
Txnip 0.00019 -0.96 0.13 0.54 0.66 redox homeostasis (Zhou and Chng 2013) down 
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Table 22: Functional correlation of gene-probes with Icam1. Five gene-probes with an activating 
and five gene-probes with an inactivating correlation are listed. In each group, gene-probes with 
the highest significance (p-val and coef) were selected. These gene-probes were compared for 
significant differential expression between static (A) and flow (B) conditions. When the level of 
significance (logFC >0.5 or <-0.5, P.value <0.05 and adj.p.value <0.1) is fulfilled, the gene is 
marked in green, otherwise the gene is marked in red. 
gene p-val coef logFC P. Value 
adj. 
P.Val function 
comp. 
A-B 
Syt17 3.6E-07 0.99 -0.60 0.01 0.03 membrane-trafficking (Schwarz 2004) up 
Ankrd13b 5.8E-07 0.99  -1.34 0.00 0.00 
internalization of ligand-
activated EGFR (Tanno et 
al. 2012) 
up 
Fgf2 1.9E-06 0.99 -0.50 0.02 0.06 proliferation (Wang et al. 2008a) up 
Basp1/ 
Cap-23 4.5E-06 0.99 -1.14 0.01 0.04 
loss of stress fibers 
(Wiederkehr et al. 1997) up 
Plxna4 5.9E-06 0.99 -1.62 0.00 0.00 migration (Waimey et al. 2008) up 
Grcc10 8.3E-07 -0.99 0.70 0.01 0.02 proteolysis (Lee et al. 2009) down 
Psmb9/ 
Lmp2 3.6E-06 -0.99 0.96 0.00 0.02 proteolysis (Powell 2006) down 
Nus1/ 
Ngbr 4.6E-06 -0.99 1.05 0.00 0.00 
morphogenesis (Miao et 
al. 2006) down 
Ssh3 5E-06 -0.99 0.61 0.02 0.05 cytoskeletal reorganization (Ohta et al. 2003) down 
Bace2 7.4E-06 -0.99 1.85 0.00 0.02 proteolysis (Bennett et al. 2000) down 
 
Table 23: Functional correlation of gene-probes with Icam2. Five gene-probes with an activating 
and five gene-probes with an inactivating correlation are listed. In each group, gene-probes with 
the highest significance (p-val and coef) were selected. These gene-probes were compared for 
significant differential expression between static (A) and flow (B) conditions. When the level of 
significance (logFC >0.5 or <-0.5, P.value <0.05 and adj.p.value <0.1) is fulfilled, the gene is 
marked in green, otherwise the gene is marked in red. 
gene p-val coef logFC P. Value 
adj. 
P.Val function 
comp. 
A-B 
Cda 1.3E-06 0.99 -1.89 0.00 0.02 pyrimidine metabolism (Demontis et al. 1998) up 
Nos3 5.9E-06 0.99 -1.77 0.00 0.00 atheroprotective effects (Fish and Marsden 2006) up 
Galnt18/ 
GalNac-
T15 
7E-06 0.99 -0.93 0.01 0.03 protein glycosylation (Cheng et al. 2004) up 
Sh2b3/ 
Lnk 8.2E-06 0.99 -0.70 0.01 0.03 
cell adhesion and 
migration (Devalliere et al. 
2012) 
up 
Tmem44  1.1E-05 0.98 -1.03 0.00 0.00 maybe sensory receptor (Moyer et al. 2009) up 
Snupn 1.4E-06 -0.99 0.29 0.02 0.05 nuclear protein transporter (Strasser et al. 2005) down 
Sowahb 1.8E-06 -0.99 0.09 0.19 0.31 cell–cell signaling (Mosavi et al. 2004) down 
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Table 23 continued: Functional correlation of gene-probes with Icam2. 
Rffl 5E-06 -0.99 0.97 0.00 0.01 
proteolysis, endocytic 
recycling (Ciechanover et 
al. 2000; Coumailleau et 
al. 2004) 
down 
Zswim4 7.5E-06 -0.99 0.59 0.01 0.04 regulation of transcription (Makarova et al. 2002) down 
Clip1/ 
Clip-170 8.6E-06 -0.98 0.43 0.01 0.04 
microtubule binding 
(Fukata et al. 2002) down 
 
3.4 Irradiation effects of heart endothelial cells after 
local heart irradiation 
3.4.1 Yield of endothelial cells after heart irradiation 
The number of isolated ECs was counted directly after isolation. The counts of 
ECs irradiated with 16 Gy were significantly reduced by 15 % compared with age-
matched control hearts (Figure 30). 
 
 
Figure 30: Number of isolated mouse heart ECs 16 weeks after local heart irradiation with 0 
(sham), 8 or 16 Gy. The amount of ECs from 16 Gy irradiated hearts was significantly lower than 
the amount of ECs from sham-irradiated hearts. Four biological replicates in each group were used 
for the statistical analysis. Asterisk represent significantly different values (p* < 0.05). 
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3.4.2 Proportion and cell surface density of markers after heart 
irradiation 
Primary ECs directly after isolation from un-irradiated and irradiated hearts were 
characterized by flow cytometric analysis using EC-specific antibodies directed 
against PECAM-1, endoglin, VE-cadherin, ICAM-1,  ICAM-2  and  mucosialin.  The  
 
 
 
 
Figure 31: Characterization of ECs isolated from mouse hearts 16 weeks after local heart 
irradiation with 0 (sham), 8 or 16 Gy. (A) The proportion of cells that stained positively for ECs-
specific markers (PECAM-1, endoglin, VE-cadherin, ICAM-1, ICAM-2 and mucosialin) was nearly 
100 % (97±2 %), independent of the radiation dose. The amount of ECs that stained positively for 
VCAM-1 was significantly increased after 8 Gy (44 %) compared to sham-irradiated ECs (33 %). 
(B) Mean fluorescence intensity values are shown for ECs-specific markers (PECAM-1, endoglin, 
VE-cadherin, ICAM-1, ICAM-2, mucosialin and VCAM-1). Cell surface densities were significantly 
increased for ICAM-1 (mfi: 204 and 220) and ICAM-2 (mfi: 184 and 183) after irradiation with 8 and 
16 Gy compared to sham-irradiated ECs (mfi: 142 and 108). Three biological replicates in each 
group were used for the statistical analysis. Asterisk represent significantly different values (p* < 
0.05). 
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leukocyte marker was not detectable on the population of separated ECs. The 
proportion of cells stained positively for PECAM-1, endoglin, VE-cadherin, ICAM-1, 
ICAM-2 and mucosialin is nearly 100 % (97±2 %) independent of the dose of 
irradiation (Figure 31A). In contrast, the proportion of ECs stained positively for 
VCAM-1 was significantly increased after 8 Gy (44 % vs. 33 %; p=0.03) compared 
to sham ECs. Analysis of the cell surface densities (Figure 31B) showed 
significant increase of ICAM-1 (mfi: 204 and 220 vs. 142; p=0.035 and 0.02) and 
ICAM-2 (mfi: 184 and 183 vs. 108; p=0.02 and p<0.05) 16 weeks after irradiation 
with 8 and 16 Gy compared to sham-irradiated ECs. 
 
3.5 Irradiation effects of heart and lung endothelial cells 
after thorax irradiation 
3.5.1 Surface markers of endothelial cells from non-irradiated 
hearts and lungs 
Primary ECs derived from non-irradiated hearts and lungs were examined directly 
after isolation by flow cytometric analysis using EC-specific antibodies directed 
against endoglin, VE-cadherin, mucosialin, PECAM-1, ICAM-1 and ICAM-2. The 
leukocyte marker CD45 was not detectable on the isolated EC population. Almost 
all lung and heart cells (97±2 %) stained positively for endoglin, VE-cadherin, 
mucosialin, PECAM-1, ICAM-1 and ICAM-2 (Figure 32A). In contrast, the 
proportion of ECs that stained positively for prominin-1 (13 % vs. 4 %; p=0.02) and 
VCAM-1 (28 % vs 13 %; p<0.05) was significantly higher on heart ECs compared 
to lung ECs. Significantly more ECs from lung stained positively for HCAM (53 % 
vs. 16 %; p=0.002) compared to heart ECs (Figure 32B). The percentage of ECs 
that stained positively for integrin β3 and VEGFR-2 showed no significant 
differences between lung and heart. Analysis of the cell surface densities of the 
markers showed that endoglin (mfi: 159 vs. 72; p=0.01), VEGFR-2 (mfi: 14 vs. 6; 
p=0.02), ICAM-2 (mfi: 135 vs. 91; p=0.006) and VCAM-1 (mfi: 29 vs. 10; p=0.002) 
were significantly higher expressed on heart ECs compared to lung ECs, whereas 
ICAM-1 (mfi: 240 vs. 110; p=0.007) was higher expressed on lung ECs compared 
to heart ECs (Figure 32C, D). 
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Figure 32: Characterization of ECs isolated from non-irradiated heart and lung. (A) Purity of ECs 
isolated from heart and lung indicated by EC-specific antibodies against endoglin, VE-cadherin, 
mucosialin, PECAM-1, ICAM-1 and ICAM-2. (B) Proportion of positively stained heart and lung 
ECs (HCAM, integrin β3, VEGFR-2, prominin-1 and VCAM-1). The amount of ECs that stained 
positively for prominin-1 and VCAM-1 was significantly higher on heart ECs (13 % and 28 %) 
compared to lung ECs (4 % and 13 %). HCAM was higher expressed on lung ECs (53 %) 
compared to heart ECs (16 %). (C, D) Mean fluorescence intensity values are shown for endoglin, 
VE-cadherin, mucosialin, PECAM-1, ICAM-1, ICAM-2, HCAM, integrin β3, VEGFR-2, prominin-1 
and VCAM-1. Cell surface densities were significantly increased for endoglin, VEGFR-2 and 
VCAM-1 on heart ECs compared to lung ECs, whereas ICAM-1 was significantly increased on lung 
ECs compared to heart ECs. Three biological replicates in each group were used for the statistical 
analysis. Asterisk represent significantly different values (p* < 0.05; p** < 0.01). 
 
3.5.2 Proportion of cell surface markers for heart and lung 
endothelial cells after irradiation 
The proportion of positively stained heart and lung ECs did not change 
significantly at any time after irradiation with 2 Gy. The proportion of ECs that 
stained positively for HCAM was increased (61 % and 41 % vs. 16 %; p=0.0008 
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and p=0.04) 10 and 15 weeks after 8 Gy for heart ECs (Figure 33). 10 weeks after 
irradiation with 8 Gy, the percentage of integrin β3-positive cells increased (40 % 
vs. 29 %; p=0.03) for heart ECs and 5 to 10 weeks (37 % and 39 % vs. 27 %; 
p=0.01 and p=0.003) after irradiation for lung ECs. While VEGFR-2 showed no 
significant difference, the percentage of prominin-1 positively stained cells was 
decreased (3 % and 6 % vs. 13 %; p=0.02 and p=0.04) 15 and 20 weeks for heart 
ECs and increased (13 % vs. 4 %; p=0.02) 20 weeks for lung ECs after 8 Gy. 
VCAM-1 was increased for heart ECs (50 %, 47 % and 52 % vs. 28 %; p=0.02, 
p=0.04 and p=0.01) 10, 15 and 20 weeks and for lung ECs (22 % and 29 % vs. 
13 %; p<0.05 and p=0.02) 15 and 20 weeks after 8 Gy (Sievert et al. 2015). 
 
 
 
 
 
 
Figure 33: Legend on next page. 
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Figure 33 continued: Positively stained ECs isolated from heart (left side) and lung (right side) 5, 
10, 15 and 20 weeks after irradiation with sham, 2 or 8 Gy. The proportion of cells that stained 
positively for HCAM, integrin β3, VEGFR-2, prominin-1 and VCAM-1 are shown. The amount of 
heart ECs that stained positively for HCAM was significantly increased (61 % and 41 % vs. 16 %) 
10 and 15 weeks after 8 Gy compared to sham-irradiated ECs. The amount of integrin β3-positive 
cells was increased for heart ECs (40 % vs. 29 %) 10 weeks and for lung ECs (37 % and 39 % vs. 
27 %) 5 to 10 weeks after 8 Gy. Prominin-1-positive cells were decreased (3 % and 6 % vs. 13 %) 
15 and 20 weeks for heart ECs and increased (13 % vs. 4 %) 20 weeks for lung ECs after 8 Gy. 
VCAM-1-positive cells were increased for heart ECs (50 %, 47 % and 52 % vs. 28 %) 10, 15 and 
20 weeks and for lung ECs (22 % and 29 % vs. 13 %) 15 and 20 weeks after 8 Gy. Three biological 
replicates in each group were used for the statistical analysis. Asterisk represent significantly 
different values (p* < 0.05; p** < 0.01; p*** < 0.001). 
 
3.5.3 Irradiation-induced alterations in the cell surface density of 
markers involved in endothelial cell proliferation 
To investigate the proliferation of ECs after irradiation, the cell surface was 
analyzed using antibodies directed against surface markers which are relevant for 
proliferation. The expression densities of these surface markers showed a delayed 
but significant increase for both heart and lung ECs between 5− 15 weeks after 
irradiation, followed by a decrease to basic levels (Figure 34). For heart ECs, the 
expression density of HCAM was increased (mfi: 27 vs. 8; p=0.02) 10 weeks after 
8 Gy, endoglin was elevated (mfi: 287 vs. 159; p=0.03) 10 weeks after 8 Gy and 
heart ECs     lung ECs 
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the expression density of VE-cadherin was enhanced (mfi: 467 and 533 vs. 337; 
p=0.03 and p=0.02) 10 weeks after 2 and 8 Gy. For lung ECs, the expression 
density of HCAM was increased (mfi: 22 and 20 vs. 9; p=0.03 and p=0.02) 10 and 
15 weeks after irradiation, integrin β3 was elevated (mfi: 18 vs. 8; p=0.007) 10 
weeks after irradiation, endoglin was enhanced (mfi: 146, 130 and 127 vs. 72; 
p=0.02, p<0.05 and p<0.05) 5, 10 and 15 weeks after irradiation and VEGFR-2 
was increased (mfi: 14 and 14 vs. 6; p=0.002 and p=0.002) 5 and 10 weeks after 
irradiation with 8 Gy. No significant changes were observed for integrin β3 and 
VEGFR-2 for irradiated heart ECS and for VE-cadherin for irradiated lung ECs 
(Sievert et al. 2015). 
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Figure 34: Legend on next page. 
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Figure 34 continued: Expression density (mean fluorescence intensity) of EC surface marker 
involved in cell proliferation isolated from heart (left side) and lung (right side) 5, 10, 15 and 20 
weeks after irradiation with sham, 2 or 8 Gy. Expression density of HCAM, integrin β3, endoglin, 
VE-cadherin and VEGFR-2 are shown. For heart ECs, the expression density of HCAM was 
increased (mfi: 27 vs. 8) 10 weeks after 8 Gy, endoglin was increased (mfi: 287 vs. 159) 10 weeks 
after 8 Gy and VE-cadherin was increased (mfi: 467 and 533 vs. 337) 10 weeks after 2 and 8 Gy. 
For lung EC, the expression density of HCAM was increased (mfi: 22 and 20 vs. 9) 10 and 15 
weeks after 8 Gy, integrin β3 was increased (mfi: 18 vs. 8) 10 weeks after 8 Gy, endoglin was 
increased (mfi: 146, 130 and 127 vs. 72) 5, 10 and 15 weeks after 8 Gy and VEGFR-2 was 
increased (mfi: 14 and 14 vs. 6) 5 and 10 weeks after irradiation with 8 Gy. Three biological 
replicates in each group were used for the statistical analysis. Asterisk represent significantly 
different values (p* < 0.05; p** < 0.01). 
 
3.5.4 Irradiation-induced alterations of endothelial progenitor cell 
surface markers 
To determine the role of endothelial progenitor cells, the expression density of 
surface markers mucosialin and prominin-1 was measured after irradiation. While 
the expression of prominin-1 remained unaltered low for heart and lung ECs, the 
mucosialin expression was increased (mfi: 40 and 54 vs. 14; p=0.04 and p<0.05) 
15 and 20 weeks after irradiation for lung ECs (Figure 35) (Sievert et al. 2015). 
 
 
200
300
400
500
600
700
5 10 15 20
m
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
weeks after irradiation
0 Gy
2 Gy
8 Gy
200
300
400
500
600
700
5 10 15 20
m
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
weeks after irradiation
0 Gy
2 Gy
8 Gy
0
5
10
15
20
25
30
5 10 15 20
m
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
weeks after irradiation
0 Gy
2 Gy
8 Gy
0
5
10
15
20
25
30
5 10 15 20
m
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
weeks after irradiation
0 Gy
2 Gy
8 Gy** ** 
* 
* 
VE-cadherin 
VEGFR-2 
Results 
80 
 
 
heart ECs      lung ECs 
  
 
  
 
Figure 35: Expression density (mean fluorescence intensity) of EC surface marker involved in 
endothelial progenitor cells from heart (left side) and lung (right side) 5, 10, 15 and 20 weeks after 
irradiation with sham, 2 or 8 Gy. Expression density of mucosialin and prominin-1 are shown. For 
lung ECs, the expression density of mucosialin was increased (mfi: 40 and 54 vs. 14) 15 and 20 
weeks after irradiation with 8 Gy. Three biological replicates in each group were used for the 
statistical analysis. Asterisk represent significantly different values (p* < 0.05). 
 
3.5.5 Irradiation-induced alterations of cell surface markers 
involved in inflammation 
To investigate the inflammatory involvement of cell adhesion molecules after 
irradiation, the cell surface was analyzed using antibodies directed against 
different adhesion molecules which are relevant for inflammation. For heart ECs, 
PECAM-1 was increased (mfi: 163 and 322 vs. 106; p=0.02 and p=0.0005) 10 
weeks after irradiation with 2 and 8 Gy and ICAM-2 was elevated (mfi: 273 and 
190 vs. 135; p=0.004 and p=0.01) 10 and 15 weeks after irradiation with 8 Gy 
(Figure 36). For lung ECs, PECAM-1 was increased (mfi: 160, 197, 147 and 151 
vs. 79; p=0.01, p<0.05, p<0.05 and p<0.05) 5, 10, 15 and 20 weeks after 
irradiation with 8 Gy and ICAM-2 was elevated (mfi: 135, 134 and 150 vs. 91; 
p=0.006, p=0.01 and p=0.02) 10, 15 and 20 weeks after irradiation with 8 Gy. 
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Analysis of heart and lung EC expression densities of both ICAM-1 and VCAM-1 
showed a significant increase 10− 20 weeks after 8 Gy compared to sham-
irradiated ECs. The expression density of ICAM-1 was enhanced for heart ECs 
(mfi: 309, 230 and 233 vs. 110; p<0.05, p<0.05 and p=0.04) and for lung ECs (mfi: 
715, 666 and 451 vs. 240; p=0.0002, p=0.0008 and p=0.04) 10, 15 and 20 weeks 
after 8 Gy. Furthermore, ICAM-1 was increased (mfi: 421 and 415; p=0.01 and 
p=0.01) 15 and 20 weeks after 2 Gy for lung ECs. VCAM-1 was elevated for heart 
ECs (mfi: 56, 43 and 49 vs. 29; p=0.002, p<0.05 and p=0.04) and for lung ECs 
(mfi: 25, 28 and 25 vs. 10; p<0.05, p=0.02 and p<0.05) 10, 15 and 20 weeks after 
8 Gy (Sievert et al. 2015). 
 
   heart ECs    lung ECs 
  
 
  
 
  
 
Figure 36: Legend on next page. 
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Figure 36 continued: Expression density (mean fluorescence intensity) of EC surface marker 
involved in cell adhesion from heart (left side) and lung (right side) 5, 10, 15 and 20 weeks after 
irradiation with sham, 2 or 8 Gy. Expression densities of PECAM-1, ICAM-1, ICAM-2 and VCAM-1 
are shown. For heart ECs, the expression density of PECAM-1 was increased (mfi: 163 and 322 
vs. 106) 10 weeks after irradiation with 2 and 8 Gy, ICAM-1 was increased (mfi: 309, 320 and 233 
vs. 110) 10, 15 and 20 weeks after 8 Gy, ICAM-2 was increased (mfi: 273 and 190 vs. 135) 10 and 
15 weeks after 8 Gy and VCAM-1 was increased (mfi: 56, 43 and 49 vs. 29) 10, 15 and 20 weeks 
after irradiation with 8 Gy. For lung ECs, the expression density of PECAM-1 was increased (mfi: 
160, 197, 147 and 151 vs. 79) 5, 10, 15 and 20 weeks after 8 Gy, ICAM-1 was increased (mfi: 715, 
666 and 451 vs. 240) 10, 15 and 20 weeks after 8 Gy and (mfi: 421 and 415) 15 and 20 weeks 
after 2 Gy, ICAM-2 was increased (mfi: 135, 134 and 150 vs. 91) 10, 15 and 20 weeks after 8 Gy 
and VCAM-1 was increased (mfi: 25, 28 and 25 vs. 10) 10, 15 and 20 weeks after irradiation with 8 
Gy. Three biological replicates in each group were used for the statistical analysis. Asterisk 
represent significantly different values (p* < 0.05; p** < 0.01; p*** < 0.001). 
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4. DISCUSSION 
The goal of the thesis was the investigation of alterations in primary ECs under 
non- pathological and pathological conditions and following radiation therapy. For 
that, a new isolation method for primary ECs of tumor and normal tissue was 
established. Differences in the morphology, function and expression pattern of 
surface markers on the different ECs were analyzed. The study of tumor ECs 
reveals immunological interactions and functional changes in the interplay of 
existing and evolving ECs from benign and malignant tissue. The results of 
microarray gene expression analysis demonstrate that high shear stress 
represents an important stimulus for gene expressions of heart ECs. The analysis 
of heart ECs after local irradiation may provide evidences to clarify the long clinical 
development and progression of radiation-induced damage. 
 
4.1 Reproducible method for the isolation of viable 
endothelial cells from different tissue 
By using the newly established EC-isolation technique (Figure 11), primary ECs 
could be isolated from young and old mice in the absence of attached magnetic 
beads. Without steric effect of beads, isolated ECs can be analysed directly after 
isolation. Furthermore ECs are able to become adherent, survive in cell culture 
and allow the characterization in the stationary phase without many cell divisions 
in vitro. The long maintenance of ECs in cell culture to get rid of the attached 
beads with sustained cell division is no longer required. In the present study, heart 
and lung were used as examples of stable, non-proliferating normal tissues, the 
repair blastema as a rapidly proliferating normal tissue, and CT26 and B16-F0 
tumors as proliferating malignant tissues. Isolated cells could be clearly identified 
as ECs from each individual tissue due to the expression of six different EC 
surface markers such as PECAM-1, endoglin, VE-cadherin, mucosialin, ICAM-1 
and ICAM-2. A panel of markers needs to be used because each individual marker 
alone can also be found on other cell types apart from ECs (Table 2). The high 
proportion of positively stained cells for PECAM-1, endoglin, VE-cadherin, 
mucosialin, ICAM-1 and ICAM-2 proves that the isolated cells in the study are 
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indeed ECs. The purity was nearly 100 % (97±2 % for technical reason: 
overlapping of isotype and antibody). Further purification steps are not necessary. 
The time required for ECs isolation starting from sacrifice of mice to receipt of pure 
ECs ranged between three and a half and four hours depending on the nature of 
tissues. 
 
4.2 Expression density of endothelial cell markers in 
benign and malignant tissue correlated with 
proliferation 
Whereas the proportion of positively stained cells for all EC-markers (PECAM-1, 
endoglin, VE-cadherin, mucosialin, ICAM-1 and ICAM-2) was nearly 100 %, 
independent from the tissue (normal, benign or malignant) from which the cells 
were isolated, their expression density was different. The expression density of 
proliferation markers such as endoglin and VE-cadherin is higher on freshly 
isolated ECs of proliferating tissues like tumor and repair blastema as compared to 
non-proliferating normal tissues such as heart and lung. The expression density of 
the progenitor marker mucosialin is elevated in tumor-derived ECs, but not in that 
of repair blastemas, whereas the adhesion molecules PECAM-1, ICAM-1 and 
ICAM-2 were found to be elevated in ECs of benign and malignant proliferating 
tissues compared to non-proliferating normal tissues. 
Endoglin expression is increased in ECs during wound healing, developing 
embryos, inflammatory tissues and solid tumors (Burrows et al. 1995; Arthur et al. 
2000). All of these processes are involved in angiogenesis and are associated with 
the receptor of the transforming growth factor-β complex (TGF-β). A high 
expression of endoglin on tumor ECs correlates with a reduced survival of patients 
(Fonsatti and Maio 2004; Dallas et al. 2008). ECs from VE-cadherin-deficient mice 
form primitive vascular structures which are unstable during further development 
and result in embryonic death (Vittet et al. 1997; Carmeliet et al. 1999; Crosby et 
al. 2005). Furthermore, antibodies against VE-cadherin reduced angiogenesis and 
tumor growth in vivo (Liao et al. 2000; Corada et al. 2002; Liao et al. 2002). As 
might be expected the proportion and expression density of the proliferation 
marker integrin β3 were up-regulated on tumor ECs compared to normal ECs. It 
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was shown that depletion of integrin β3 transiently inhibited tumor growth and 
angiogenesis in mice (Brooks et al. 1994; Steri et al. 2014). Thus, the present 
thesis shows that high expression densities of endoglin, VE-cadherin and integrin 
β3 on freshly isolated ECs correlate with increased angiogenic capacity. 
Additionally, endoglin has been described as being capable of preventing 
apoptosis in hypoxic ECs and leading to an enhanced survival of ECs under 
hypoxic stress (Li et al. 2003). This may explain the fact that endoglin is expressed 
at higher levels on ECs isolated from tumors with hypoxic regions compared to 
ECs isolated from repair blastema (Sievert et al. 2014). 
The expression density of the progenitor marker mucosialin in mouse embryonic 
blood vessels is high in pre-endothelial cells and in vessels formed by 
vasculogenesis and angiogenesis, but low in vessels which are involved in the 
process of coalescence to form larger vessels (Wood et al. 1997). In the early 
phase, mucosialin knockout mice with transplanted B16-F1 melanoma cells 
showed a decreased, and then later an increased tumor growth caused by a 
reduction of mucosialin knockout hematopoietic cells (Maltby et al. 2011). The fact 
that mucosialin is expressed at a higher level on tumor ECs could be due to 
circulating endothelial progenitor cells, which might be involved in the 
vasculogenesis of the tumor (Sievert et al. 2014). 
EC adhesion molecules PECAM-1, ICAM-1 and ICAM-2 were increased in 
proliferating tissue (repair blastema and tumor), compared to non-proliferating 
tissues. Primary ECs isolated from PECAM-1 deficient mice showed a decreased 
cell migration and a reduced capillary morphogenesis (Park et al. 2010). Blocking 
of PECAM-1 inhibited the vascularization and growth of tumors in mice and 
inhibited the tube formation of ECs, in vitro (Zhou et al. 1999). However, PECAM-1 
knockout mice developed a normal functional vascular system during embryonic 
development, but a decreased angiogenesis in inflammation (Solowiej et al. 2003). 
ICAM-1 is also up-regulated in various cell types by inflammatory cytokines and 
may increase leukocyte extravasation during inflammation (Hubbard and Rothlein 
2000). ICAM-1 inhibition in mouse melanomas using ICAM-1 antisense 
oligonucleotides resulted in fewer metastases in the lungs (Miele et al. 1994). 
Antibodies against ICAM-1 also blocked the invasion of metastatic human breast 
cancer cells in vitro (Rosette et al. 2005). In contrast to ICAM-1, the expression of 
ICAM-2 is not elevated by inflammatory cytokines (Xu et al. 1996). Experiments in 
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ICAM-2-deficient mice have shown that ICAM-2 on ECs is required for 
angiogenesis and is involved in cell migration and survival, but not in EC 
proliferation (Huang et al. 2005). The present thesis demonstrates that the 
expression of ICAM-2 is increased on ECs from growing tumors and repair 
blastemas, whereas the expression of ICAM-1 is increased mainly in physiological 
wound healing (Sievert et al. 2014). 
The higher expression of endoglin and mucosialin on ECs from the B16-F0 tumor 
correlates with the faster tumor growth compared to that of CT26 tumors. In 
contrast, the higher expression of ICAM-1 and ICAM-2 on ECs from CT26 may 
correlate with the higher metastatic behavior of CT26 compared to B16-F0 in lung, 
when cells were subcutaneously injected in syngeneic mice (Fidler 1975; Ikubo et 
al. 1999). 
 
4.3 Alteration of morphology and migration of tumor 
endothelial cells 
In this thesis, it was shown that tumor ECs are larger, have a significantly higher 
migratory capacity and distribute in a more chaotic pattern in cell culture compared 
to ECs derived from normal tissue. 
During angiogenesis or neovascularization, new blood vessels derived from 
existing vasculature. After basement membrane disruption, ECs proliferate and 
migrate towards an angiogenic stimulus which may be released from tumor cells 
or macrophages during inflammation, and finally reorganize into a three-
dimensionally tubular structure (Figure 2). The rapid proliferation of tumor ECs and 
their persistent stimulation result in the formation of abnormal tumor vessels with 
increased vessel diameter and vessel length (Jain 2001; McDonald and Choyke 
2003). Continual remodeling by persistent tumor growth and regression (cell 
apoptosis and necrosis) contribute to the instability of these networks (Jain 2003). 
The present thesis confirms the abnormal size of tumor ECs by microscopic 
pictures and FACS analysis. Not only ECs isolated from B16-F0 and CT26, but 
also ECs from the repair blastema were approximately twice the size of normal 
ECs isolated from heart and lung. 
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ECs migration involves three major mechanisms: chemotaxis, haptotaxis and 
mechanotaxis (Lamalice et al. 2007). Chemotaxis is the directional migration 
toward a gradient of soluble chemoattractants such as VEGF and bFGF. 
Haptotaxis is the directional migration towards a gradient of immobilized ligands in 
response to integrins. Mechanotaxis is the directional migration of ECs generated 
by mechanical forces based on fluid shear stress. ECs migration is the integrated 
result of these three mechanisms. The complex process of EC migration can be 
divided in several steps: sensing of the stimuli, extension and protrusion of 
lamellipodia, attachment of the protrusions to the extracellular matrix, contraction 
of the cell body to allow forward movement, rear release and recycling of adhesive 
and signaling components (Rousseau et al. 2000; Lamalice et al. 2007). The 
present thesis has analyzed the migration capacity of normal heart EC and 
abnormal tumor ECs in a non-proliferating state continuously for 33 hours in vitro. 
For both types of ECs, no cell divisions were detectable. Although the migration of 
heart ECs was significantly lower compared to that of tumor ECs, heart ECs were 
able to cover the area by migration to organize a complete monolayer. Tumor ECs 
have shown no increased covering of the area, despite their higher migration 
capacity. Obviously the abnormal behavior of tumor ECs is retained in vitro. 
 
4.4 Impairment of tube formation and flow alignment of 
tumor endothelial cells 
Primary ECs from non-proliferating and proliferating tissue differ in their functional 
properties in vitro. Tube formation assays showed that tumor ECs have a smaller 
number of branching points and loops compared to that of normal ECs. Further in 
contrast to normal tissue ECs, tumor-derived ECs show no tendency to align 
under flow conditions (Sievert et al. 2014). 
Tube formation is the measurement method of the ability of ECs to form three-
dimensional structures in matrigel in vitro. Matrigel is a solubilized tissue basement 
membrane matrix that was originally isolated from the Engelbreth-Holm-Swarm 
mouse sarcoma, composed mainly of laminin, collagen IV, heparan sulphate, 
proteoglycans, entactin and various growth factors such as TGF-β, fibroblast 
growth factor and tissue plasminogen activator (Kleinman et al. 1986; Mullen 
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2004). In matrigel ECs do not make intercellular lumens or perform proliferation 
(Nakatsu and Hughes 2008). The number of cells plated onto matrigel and the 
time of the assay are critical steps and depends on the EC cell type (Arnaoutova 
et al. 2009). Too few cells results in incomplete cell connection, whereas too many 
cells results in large areas of monolayer. In both cases tube formation cannot be 
observed. The point of image capture should be determined for each EC type. 
Normally the cells attach within the first hour and migrate towards each other over 
the next 2− 4 hours, followed by formation of capillary-like tubes, which mature 
within 6− 16 hours. After 24 hours, cells typically undergo apoptosis and tubes 
detach from the matrix (Arnaoutova and Kleinman 2010). In the present thesis, 
primary ECs in the second passage were used. Cells in the first passage directly 
after isolation exhibit too many dead cells. Due to the larger size of tumor ECs 
compared to normal ECs, less tumor ECs (20,000 tumor ECs vs. 80,000 heart 
ECs per well) were seeded into the matrigel. These numbers represent the 
minimum number of ECs that are required to allow a tube formation within a 
defined area. Both types of ECs formed three-dimensional structures in matrigel. 
The reduced number of branching points and loops per image of tumor ECs 
compared to heart ECs might be the result of different amounts of seeded ECs on 
matrigel. On the other hand, the increased diameter or migration as well as the 
increased expression of surface markers could also be the reason for reduced 
number of branching points and loops. However, the potential to form tubes in 
matrigel remains intact for abnormal tumor ECs. Regardless of the results, the 
tube formation assay is not limited to test vascular behavior of ECs. Non-ECs, 
including fibroblast and tumor cells (glioblastoma cells, melanoma cells, prostata 
and breast carcinoma cells) also form three-dimensional structures in matrigel 
(Donovan et al. 2001; Francescone et al. 2011). This capability was consistent 
with their vasculogenic behavior of tumor cells identified in tissue samples, a 
process known as vasculogenic mimicry (Maniotis et al. 1999; Sharma et al. 2002; 
Francescone et al. 2012). Vasculogenic mimicry describes the formation of fluid-
conducting channels by aggressive tumor cells. The formation of these channels 
does not arise from existing vessels (Folberg and Maniotis 2004). 
Because of their unique location, ECs are to be exposed to pressure (created by 
the hydrostatic forces of blood), to stretch or tension (created by intercellular 
connections between ECs that exert forces on the cell during vasomotion) and to 
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shear stress (created by frictional forces of blood flow). Of these forces, shear 
stress appears to be a particularly important hemodyamic force because it 
stimulates the release of vasoactive substances and changes gene expression 
and cell metabolism (Davies 1995; Traub and Berk 1998). Steady laminar flow 
with high shear stress promotes the release of factors from ECs (NO, PGl2
Traub and Berk 1998
, tPA, 
thrombomodulin) that inhibit thrombosis, coagulation, migration of leukocytes and 
smooth muscle proliferation. High shear stress results in elongated and aligned 
morphology. The proliferation/DNA synthesis as well as the expression of 
adhesion molecules (ICAM-1, VCAM-1) are low. In contrast, disturbed flow with 
low or reciprocating shear stress changes the profile of secreted factors and 
expressed surface molecules (angiotensin II, endothelin-I, PDGF, increased 
expression of ICAM-1 and VCAM-1) in a situation that favors the opposite effect. 
Low shear stress results in polygonal morphology and high proliferation/DNA 
synthesis ( ; Reinhart-King et al. 2008; Chiu and Chien 2011). 
It is known that several tumors exhibit decreased blood flow (Stewart et al. 2006; 
Komar et al. 2009). In the present study, heart and tumor ECs were cultured under 
constant flow conditions, starting with 3.5 dyn/cm2 for 1 day, followed with 7 
dyn/cm2 
4.5 Change of mRNA-expression of ECs under 
permanent high shear stress  
for four days. Whereas most heart ECs showed an alignment in the 
direction of the flow, tumor ECs did not align. This result is conform to the low flow 
rate in tumors and the increased expression of ICAM-1 and VCAM-1 on tumor 
ECs. 
 
It is known that gene expression induced by shear stress is time dependent 
(Resnick et al. 2003). To exclude the detection of transient activated genes, heart 
ECs were cultured for 4 days with 20 dyn/cm2. This long-term shearing of cultured 
heart ECs led to the modulation of the expression of a multiplicity of novel and 
unknown genes. The results of the differential gene expression and subsequent 
pathway enrichment analysis provide 24 pathways with a FDR < 0.1, which are 
obviously affected by shear stress and can be assigned to different specific cell 
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components and functions: Extracellular organisation, cell membrane, signal 
molecules, hemostasis, metabolism, developmental biology and smooth muscle 
contraction (Table 18). The enriched cell component "extracellular organisation" 
includes the pathways "extracellular matrix organisation", "collagen formation", 
"assembly of collagen fibrils and other multimeric structures", "elastic fibre 
formation", "molecules associated with elastic fibres", "integrin cell surface 
interactions", "non-integrin membran-ECM interactions", "chondroitin 
sulfate/dermatan sulfate metabolism" and "laminin interactions". The impact of 
these pathways and candidates is supported by numerous links to ECs and 
angiogenesis. Collagen is the most abundant protein of the extracellular matrix 
and is involved in vascular elongation, stabilisation and proliferation (Bonanno et 
al. 2000; Di Lullo et al. 2002; Bahramsoltani et al. 2014). It was shown that aligned 
collagen fibrils regulate EC orientation and migration (Amyot et al. 2008; Lai et al. 
2012). Elastic fibers are components of the extracellular matrix and confer 
resilience and flexibility (Midwood and Schwarzbauer 2002; Liu et al. 2004). 
Elastic fibre molecules are able to enhance EC attachment and stable monolayer 
formation (Williamson et al. 2007). The cell surface harbors integrin and non-
integrin receptors. Integrins are membrane-associated glycoproteins with a large 
extracellular, a transmembrane and a short cytoplasmic domain (Evans and 
Calderwood 2007). The extracellular domain binds directly to extracellular matrix 
proteins, whereas the cytoplasmic domain interacts with cytoskeletal proteins, 
resulting in signal transduction, cytoskeletal organization and cell motility (Shyy 
and Chien 2002). Non-integrin transmembrane proteoglycans also interact with 
extracellular matrix proteins and influenced cell adhesion and movement (Rosso et 
al. 2004). It was shown that the chondroitin sulfate proteoglycan mediates EC 
migration on fibrinogen and invasion into a fibrin matrix (Henke et al. 1996). 
Laminins contribute to cell differentiation, cell shape and movement (Colognato 
and Yurchenco 2000). 
The enriched cell component "cell membrane" is influenced by the pathway 
"cholesterol biosynthesis" and represents an interesting link to blood vessels. ECs 
maintain cholesterol homeostasis by down-regulation of cholesterol synthesis and 
low density lipoprotein receptors to avoid atherosclerotic plaques (Hassan et al. 
2006). 
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The impact of "signal molecules" is reflected by the affected pathways "signaling 
by Rho GTPase", "axon guidance", "signaling by VEGF", "NRAGE signals death 
through JNK", "Nitric oxide stimulates guanylate cyclase", "Netrin-1 signaling" and 
"semaphorin interactions". The relevance of these pathways is reported by 
numerous links to ECs and their functions. Members of the Rho family GTPases 
are important regulators of the cytoskeleton and cell motility and polarity 
(Raftopoulou and Hall 2004; Villalonga and Ridley 2006; Hanna and El-Sibai 
2013). So-called endothelial tip cells, which lead the sprouting and migration of 
ECs during angiogenesis, share many features with the axonal growth cone 
(Siemerink et al. 2013). Capillary tip cells and axon growth cones use common 
signals to regulate their guidance (Adams and Eichmann 2010). The guidance 
molecule netrin-1 appears to act as an angiogenic and survival factor for ECs 
(Castets et al. 2009; Tu et al. 2015). The guidance molecule semaphorins affects 
adhesion, cytoskeletal remodeling, cell motility and cell migration (Serini et al. 
2008; Gelfand et al. 2009; Sakurai et al. 2012). VEGFs and their receptors 
(VEGFRs) play an important role in angiogenesis by regulating proliferation and 
migration of ECs (Bernatchez et al. 1999; Holmes et al. 2007; Wang et al. 2008b). 
The NRAGE, a p75 neurotrophin receptor, mediates signaling processes leading 
to activation of the JNK pathway and cell death in a variety of cell types (Salehi et 
al. 2002). NO-sensitive guanylate cyclase is an important receptor for the signal 
molecule NO results in the conversion of GTP to cGMP, which activates cGMP-
dependent protein kinases, cGMP-regulated phosphodiesterases and cGMP-
gated ion channels (Friebe and Koesling 2003). It was shown that NGF induced a 
significant increase in proliferation and migration of human ECs (Raychaudhuri et 
al. 2001; Cantarella et al. 2002; Dolle et al. 2005). 
The cellular process of "hemostasis" includes the pathways "hemostasis", "platelet 
activation, signaling and aggregation" and "platelet homeostasis". The importance 
of these pathways for the endothelium has already been described. ECs play a 
key role in the regulation of the hemostasis balance and platelets aggregation at 
sites of blood vessel damage (Chen and Lopez 2005; Verhamme and Hoylaerts 
2006). 
The pathways "metabolism", "developmental biology" and "smooth muscle 
contraction" present specific additional categories and show important links to 
ECs. Metabolism of ECs such as glycolysis is different not only between quiescent 
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and angiogenic states but also between static and flow conditions (De Bock et al. 
2013; Sun and Feinberg 2015). The development of ECs is being performed by 
stem cells and endothelial progenitor cells respectively (Balconi et al. 2000; 
Yamamoto et al. 2003). It was shown, that shear stress promotes differentiation of 
endothelial progenitor cells into mature ECs (Obi et al. 2009). Interestingly, the 
present study shows that shear stress not only influences the effect of endothelial 
progenitor cells but also of mature ECs. The vascular endothelium modulates the 
reactivity of vascular smooth muscle via metabolical degrades of vasoactive 
substances, conversions of precursors into vasoactive products and secretions of 
vasoactive substances (Vanhoutte et al. 1986). Thus, the present study shows, 
that high shear stress (20 dyn/cm2
The functions of genes correlating with Icam1 expression range from membrane-
trafficking, proliferation, migration, morphogenesis, cytoskeletal reorganization and 
proteolysis. Syt17 is a member of the Synaptotagmin family responsible for 
membrane trafficking. Synaptotagmin contributes to endocytosis and exocytosis of 
synaptic vesicles (
) for 4 days significantly affected the EC gene 
expression related to a variety of endothelial pathways.  
Gene expression of Pecam1, Icam1 and Icam2 was higher on heart ECs under 
static conditions compared to flow conditions. This finding is consistent with the 
higher protein-expression on tumor ECs and confirms the hypothesis that these 
inflammation markers are involved in ECs dysfunction. For a functional 
characterization of cellular signaling and interactions, five gene-probes with an 
activating and five gene-probes with an inactivating expression with the measured 
expression of Pecam1, Vcam1, Icam1 and Icam2 were considered. Only genes 
which fulfill the level of significance for both, functional correlation and differential 
expression between static and flow conditions, were considered here in more 
detail. All gene-probes correlated with Pecam1 and Vcam1 expression didn't fulfill 
the significance for differential expression between static and flow conditions. In 
contrast, Icam1 was significantly correlated with all activated gene-probes Syt17, 
Ankrd13b, Fgf2, Basp1, Plxna4 and with all inactivated gene-probes Grcc10, 
Psmb9, Nus1, Ssh3 and Bace2. Also, Icam2 could be correlated with all activated 
gene-probes Cda, Nos3, Galnt18, Sh2b3, Tmem44 and with two inactivated gene-
probes Rffl and Zswim4. 
Schwarz 2004). Ankyrin repeat domain 13 (Ankrd13) regulates 
the internalization of ligand-activated EGFR in HeLa cells (Tanno et al. 2012). 
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Fibroblast growth factor 2 (Fgf2) regulates placental EC proliferation and signaling 
in ovine artery ECs (Wang et al. 2008a). Basp1 promotes actin dynamics including 
loss of stress fibers in transfected fibroblast (Wiederkehr et al. 1997). Plexin-A4 
(Plxna4) regulates the migration of sympathetic neurons (Waimey et al. 2008). 
Protein C10 (Grcc10) regulates ubiquitin-dependent proteolysis in keratocytes 
(Lee et al. 2009). The proteasome subunit beta type 9 (Psmb9) is a component of 
the ubiquitin-proteasome system and may play a role in maintaining normal 
cardiac function through regulation of signaling pathways and maintenance of 
normal sarcomere structure (Powell 2006; Nakamura et al. 2015). For HUVECs it 
was shown, that Nus1/Nogo-B receptor is essential for chemotaxis and 
morphogenesis (Miao et al. 2006). Slingshot homolog 3 (Ssh3) plays a critical role 
in regulating actin cytoskeletal reorganization (Ohta et al. 2003). Beta-site amyloid 
precursor protein cleaving enzyme 2 (Bace2) is a transmembrane aspartic 
protease (Bennett et al. 2000). Thus, the present study shows that these genes, 
although not always described for ECs, have a functional correlation with Icam1 
and are significantly involved in high shear stress response of heart ECs. This has 
an effect not only for the EC membrane (trafficking and morphogenesis) and 
cytoplasm (cytoskeletal reorganization and proteolysis), but also for EC functions 
(proliferation and migration). 
The functions of genes correlating with Icam2 expression range from cell 
adhesion, sensory property, atheroprotective effect, pyrimidine metabolism, 
protein glycosylation, proteolysis and regulation of transcription. Cytidine 
deaminase (Cda) is an enzyme involved in pyrimidine metabolism (Demontis et al. 
1998). It is known that shear stress increases the transcription of endothelial nitric 
oxide synthase (Nos3) and results in atheroprotective effects (Davis et al. 2004; 
Fish and Marsden 2006). Polypeptide N-acetylgalactosaminyltransferase 18 
(Galnt18) transfers N-acetyl-D-galactosamine to a serin or threonine residue on 
the polypeptide acceptor (Cheng et al. 2004). Sh2b adapter protein 3 (Sh2b3) is a 
regulator of integrin signaling that affects adhesion and migration of ECs 
(Devalliere et al. 2012). Tmem44 might be involved in sensory receptor (Moyer et 
al. 2009). E3 ubiquitin-protein ligase rififylin (Rffl) is involved in endocytic recycling 
and proteolysis (Ciechanover et al. 2000; Coumailleau et al. 2004). The zinc finger 
swim domain-containing protein 4 (Zswim4) acts as regulator of transcription 
(Makarova et al. 2002). Overall, the present study shows that these genes, 
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although not always described for ECs, have a functional correlation with Icam2 
and are also involved in high shear stress response of heart ECs. This has an 
effect for the EC membrane (adhesion, migration and sensor), cytoplasm (protein 
glycosylation and proteolysis), pyrimidine metabolism and transcription. 
 
4.6 Early and late radiation effects on heart endothelial 
cells 
The aim of this experiment was to quantify the expression and to study the time-
dependent alteration of proliferation and inflammation markers on ECs isolated 
from heart and lung after a single in vivo irradiation. Radiation-induced changes on 
the microvasculature and the development of atherosclerotic plaques in 
microvessels should be investigated. Heart and lung influence each other 
depending on the percentage and dose of cardiac and pulmonary irradiation. Heart 
irradiation reduces the tolerated dose of the lung and vice versa (Ghobadi et al. 
2012). This results in a significant increase in the breathing rate and a right 
ventricle hypertrophy. However, these documented effects do only occur at doses 
above 10 Gy for thorax irradiation (100 % heart and 100 % lung), and at doses 
above 20 Gy for local heart irradiation (100 % heart and approximately 25 % lung) 
(van Luijk et al. 2005; van Luijk et al. 2007; Gabriels et al. 2012). In the present 
thesis, the highest dose to the thorax was 8 Gy and to the heart 16 Gy. Therefore, 
the reciprocal influence of irradiation between heart and lung may presumably play 
only a minor role. 
The thesis shows that irradiation of the thorax of a mouse influences the 
expression of endothelial surface markers which were grouped in proliferation, 
progenitor cells development and inflammation in a dose- and time-dependent 
manner. While the expression density of most EC surface markers did not 
significantly change after irradiation with 2 Gy (except for VE-cadherin and 
PECAM-1 after 10 weeks for heart ECs and for ICAM-1 after 15 and 20 weeks for 
lung ECs), the majority of EC surface markers which are related to proliferation 
and inflammation showed significantly changes after 8 Gy. 
New blood vessels can be developed by angiogenesis, arteriogenesis or 
vasculogenesis. During angiogenesis, new blood vessels are formed from 
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preexisting ECs which are stimulated by growth factors or hypoxia. In contrast, 
arteriogenesis describes the proliferation of collateral arteries from preexisting ECs 
which are stimulated by shear stress even in the absence of hypoxia. During 
vasculogenesis, new blood vessels develop from endothelial progenitor cells that 
differentiate into mature ECs. 
The transient increase in the expression density of proliferation markers (HCAM, 
endoglin and VE-cadherin for heart ECs, HCAM, integrin β3, endoglin and 
VEGFR-2 for lung ECs) suggested a stimulated proliferation of ECs in response to 
radiation-induced damage at earlier time points. This process occurred earlier in 
lung ECs than in heart ECs. These markers are normally highly expressed in 
proliferating ECs. The drop of these markers to normal levels after about 15 weeks 
reveals that radiation-induced angiogenesis is a transient response in heart and 
lung tissues. The increased expression density of proliferation markers correlates 
with an increased microvascular density 20 weeks after 8 Gy irradiation in the 
same animals (Seemann et al. 2012). While the formation of new blood vessels 
via angiogenesis is presumably finalized about 15 weeks after irradiation with 8 Gy 
in the heart and lung endothelium, the enhanced proportion of lung ECs that 
stained positively for prominin-1 20 weeks after 8 Gy and the increased expression 
density of mucosialin 15−20 weeks after 8 Gy irradiation suggest that a continuous 
formation of new blood vessels via vasculogenesis is occurring in the lung of mice. 
New vessel formation via vasculogenesis appears to be not relevant for heart ECs 
at the indicated doses and time points. Moreover, the proportion of heart ECs that 
stained positively for prominin-1 was decreased at 15 and 20 weeks after 8 Gy. 
Interestingly, it has been reported that the level of microvascular density was 
reduced 40 weeks after heart irradiation with 16 Gy and 60 weeks after heart 
irradiation with 8 Gy (Seemann et al. 2012; Patties et al. 2015). The decreased 
level of prominin-1 for heart ECs might confirm the observed reduced proliferation 
and progressive loss of microvessels (Sievert et al. 2015). 
Specific adhesion molecules regulate different stages of leukocyte infiltration in 
inflammatory sites (Quarmby et al. 1999). Several in vivo studies have shown 
increased expression levels of inflammation markers after irradiation in Arteria 
saphena (Patties et al. 2014) or in the intestine (Molla et al. 2003). However, 
studies which analyse the alteration of inflammation markers on isolated 
microvascular ECs after heart or lung irradiation are missing. While the expression 
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density of most inflammation markers on ECs was not affected by irradiation at 2 
Gy (except for PECAM-1 after 10 weeks for heart ECs and for ICAM-1 after 15 
and 20 weeks for lung ECs), all inflammation markers were up-regulated by high 
dose irradiation at 8 Gy. Heart ECs showed a transient increase in the expression 
density of PECAM-1 and ICAM-2 and a persistent increase of ICAM-1 and VCAM-
1 starting from 10 weeks after 8 Gy. Lung ECs demonstrated a persistently 
increased density of PECAM-1, ICAM-1, ICAM-2 and VCAM-1 up to 20 weeks 
after irradiation with 8 Gy. The expression density of ICAM-1 and VCAM-1 was 
increased in both heart and lung ECs at 10, 15 and 20 weeks after 8 Gy. In 
contrast to ICAM-1, which is ubiquitously expressed on all ECs, VCAM-1 
expression is low on heart (30 %) and lung (15 %) ECs. The proportion of heart 
and lung ECs that stained positively for VCAM-1 was increased 10, 15 and 20 
weeks after thorax irradiation with 8 Gy (Sievert et al. 2015). 
In conclusion, irradiation of the thorax leads to the up-regulation of markers that 
may suggest a temporary proliferating and prolonged inflammatory response of 
heart and lung ECs. The temporary increase in proliferation is more pronounced in 
lung ECs compared to heart ECs. Further, the involvement of endothelial 
progenitor cells after irradiation might play a role in lung but not in heart ECs. Both 
effects confirm the late loss of microvessels in irradiated hearts. These results are 
shown as hypothetical model in Figure 37. The persistent increase of inflammation 
markers ICAM-1 and VCAM-1 up to 20 weeks after irradiation may suggest the 
predisposition for the development of atherosclerotic plaques in lung and heart 
ECs at later time points. These inflammatory markers may provide possible targets 
for therapeutic intervention for patients undergoing thoracic irradiation therapy 
(Sievert et al. 2015). 
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Figure 37: Hypothetical model of proliferation-, inflammatory- and progenitor cells- phases of ECs 
from different tissue. (A, B) Proliferation and inflammation surface markers were increased in 
proliferating tissue like repair blastema and tumor, compared to non-proliferating tissue. Progenitor 
cells may have an impact in tumors, but not in repair blastemas. (C, D) Local thorax irradiation with 
8 Gy increased temporary the proliferation of heart and lung ECs. This process was more 
pronounced in lung ECs (5-15 weeks) than in heart ECs (10 weeks). Inflammation was increased in 
heart and lung ECs starting between 5 and 10 weeks after irradiation. This process was more 
pronounced in lung ECs than in heart ECs up to 20 weeks. The involvement of progenitor cells 
after irradiation might play a role in lung but not in heart ECs. 
 
4.7 PERSPECTIVE 
The novel method presented here provides a powerful tool for the purification of 
viable primary microvascular ECs of different origins which can be used to analyze 
organ-specific immunological interactions and functional changes in the interplay 
of existing and evolving ECs from benign and malignant tissues. The clear 
identification of ECs from each individual tissue due to the expression of six 
different EC surface markers such as PECAM-1, endoglin, VE-cadherin, 
mucosialin, ICAM-1 and ICAM-2 provides the basis for further research. The 
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analysis of surface markers on primary tumor ECs could therefore contribute to 
understand the effects of anti-angiogenic therapies. ICAM-1 and VCAM-1 should 
be tested to establish both markers as possible targets for therapeutic intervention 
for patients undergoing thoracic irradiation therapy. 
 
4.7.1 Effects of anti-angiogenic therapy 
The increase of different markers on tumor ECs might have an impact on the 
proliferation rate of ECs, the permeability for metastasis or the involvement of 
circulating endothelial progenitor cells. A successful approach for therapeutic 
treatment would be a marker, which is generally highly expressed on proliferating 
tumor ECs, but not on normal non-proliferating ECs. Such a molecule would be an 
optimal vascular target that can be used not only for tumor imaging and prognosis, 
but also as therapeutic drug in human tumors. The use of angiogenesis inhibitors, 
most of them targeting the VEGF pro-angiogenic signaling pathway, is already 
evaluated in different clinical studies for different disease stages (metastatic, 
adjuvant, neoadjuvant) (Sessa et al. 2008; Vasudev and Reynolds 2014). The 
pioneers of the clinical proof-of-concept for angiogenesis inhibitors are 
bevacizumab, a humanised monoclonal antibody that binds specifically to VEGF-
A, and two tyrosine kinase inhibitors: sorafenib and sunitinib which block the 
activity of VEGFR1, VEGFR2 and VEGFR3. However, anti-angiogenic therapies 
result in transitory improvements, in the form of tumor stasis or shrinkage and in 
some cases increased survival. Inevitably, the tumor begins to re-grow. The 
improvement in progression-free survival and in overall survival is only a few 
months (Carmeliet and Jain 2011; Vasudev and Reynolds 2014). Moreover, 
several studies have shown that VEGF blockade damages healthy vessels and 
results in severe problems such as hemorrhagic and thrombotic events (Kubota 
2012). Two general modes of resistance to angiogenesis inhibitors, in particularly 
those targeting the VEGF pathways, are in discussion: The evasive resistance and 
the intrinsic pre-existing non-responsiveness. The evasive resistance is the 
adaption to evade the specific angiogenic blockade. Although the specific target of 
the anti-angiogenic drug remains inhibited, alternative ways are activated to 
sustain tumor growth (Bergers and Hanahan 2008; Loges et al. 2010). The 
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activation or upregulation of alternative pro-angiogenic signaling pathways within 
the tumor is enhanced after treatment with agents targeting VEGF. The 
recruitment of bone marrow-derived pro-angiogenic cells confers resistance. 
Myeloid cells, including tumor-associated macrophages, infiltrate tumors and 
mediate resistance. Tumor-associated fibroblasts are activated to support tumor 
growth and angiogenesis. Increased pericytes coverage of tumor vasculature also 
enhances resistance. A further way is the activation and enhancement of invasion 
and metastasis to provide access to normal tissue vasculature without 
neovascularization. In contrast, patients with intrinsic pre-existing non-
responsiveness are refractory to anti-angiogenic therapy and the disease 
progression continues unabated. The pre-existing multiplicity of redundant pro-
angiogenic signals, the pre-existing inflammatory cell-mediated vascular protection 
and the hypovascularity lead to the indifference of tumors for angiogenesis 
inhibitors (Bergers and Hanahan 2008). A successful anti-angiogenic therapy will 
require a greater understanding of how tumors become vascularized and how they 
evade the effects of anti-angiogenic therapies. It will be important to identify the 
circumstances that elicit resistance, alone and in the context of standard 
chemotherapy and radiotherapy. The analysis of surface markers on primary 
tumor ECs due to the new established method could contribute to understand the 
effects of anti-angiogenic therapies. 
 
4.7.2 Effects of radiation therapy 
The persistent increase of inflammation markers ICAM-1 and VCAM-1 up to 20 
weeks after thorax irradiation with 8 Gy and the increased expression of ICAM-1 
16 weeks after local heart irradiation with 8 Gy and 16 Gy may suggest the 
predisposition for the development of atherosclerotic plaques in lung and heart 
ECs of wild type mice (C57BL/6). To confirm this hypothesis, the analysis of ECs 
30 and 40 weeks after local heart irradiation with 8 and 16 Gy would be useful. It is 
known that local heart irradiation with 16 Gy leads to sudden death between 30 
and 40 weeks in 38 % of mice (Seemann et al. 2012). The reason for this was 
presumably the presence of amyloidosis in the hearts after irradiation with 16 Gy 
leading to heart failure (McCarthy and Kasper 1998). The prolonged involvement 
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of ICAM-1 and VCAM-1 on irradiated heart ECs would explain the late 
development of atherosclerotic plaques in hearts which could result in myocardial 
infarction. If this is the case, ICAM-1 and VCAM-1 may provide possible targets for 
therapeutic intervention in the future for patients undergoing thoracic irradiation 
therapy. 
This study demonstrates that high shear stress presents an important stimulus that 
has a profound impact on the gene expression of ECs. In order to analyze the 
relevance of changes of gene expression, microarray gene expression dataset has 
to be extended by including characterisation of isolated heart ECs 20 weeks after 
8 Gy in vivo irradiation. 
In contrast to C57BL/6 mice, which have low plasma levels of cholesterol, 
Apolipoprotein E-deficient (ApoE−/−) mice have increased cholesterol levels and 
develop age-related atherosclerosis. Therefore, ApoE−/−
Previously results about the effects of local heart irradiation in a mouse model with 
X−ray were performed with the help of a shielding plate such as lead. The 
irradiation field consists of a window in the lead plate. The rest of the mouse body 
was shielded with the lead plate. With this setting, approximately 30-40 % of the 
lung volume was included in the irradiation field. Recently, a small animal radiation 
research platform (SARRP, X-Strahl) is available which enables a high precision 
CT image-guided irradiation of organs and tumors in mice in mm-range following 
treatment planning. Thereby heart irradiation effects based on co-irradiation of the 
lung can be reduced. By using this instrument the irradiation of parts from heart 
and lung is possible in order to study effects of a partial normal tissue irradiation. 
 mice are presumably 
more suitable for the analysis of irradiated heart ECs and the involvement of 
ICAM-1 and VCAM-1 to atherosclerotic plaques. 
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7. APPENDIX 
 
Table 24: Different gene expression of heart ECs in response to high shear stress involved in 
extracellular matrix organisation. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log. Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
SDC4 2.6 6.2 up DDR1 0.8 1.7 up 
ITGA1 1.4 2.7 up COL6A3 1.4 2.7 up 
BMP2 2.9 7.6 up LAMA4 0.6 1.5 up 
LEPREL2 1.2 2.3 up COL5A1 0.7 1.6 up 
COL1A2 2.7 6.6 up ADAM17 0.5 1.4 up 
LOXL2 2.4 5.2 up COL28A1 0.5 1.5 up 
MMP14 1 1.9 up MFAP5 0.6 1.5 up 
ADAMTS14 2.1 4.2 up LAMA2 0.6 1.5 up 
BMP7 2.3 4.8 up ITGB5 0.5 1.4 up 
LOXL1 1.6 3 up FBLN2 -3.5 0.1 down 
CASP3 1 2 up CTSD -1.2 0.4 down 
LAMA3 1.2 2.3 up LTBP4 -2.3 0.2 down 
MFAP2 1.4 2.6 up KDR -1.5 0.4 down 
ITGA11 2.4 5.2 up PLEC -1.9 0.3 down 
MMP3 1.2 2.2 up ACAN -1.6 0.3 down 
COL1A1 1.7 3.3 up NID1 -0.9 0.5 down 
MMP17 1.1 2.2 up COL12A1 -1.1 0.5 down 
SPP1 3.8 14.3 up BMP1 -0.8 0.6 down 
MMP11 1.2 2.3 up COL5A2 -2.4 0.2 down 
NID2 1.4 2.6 up ITGB4 -1.2 0.4 down 
TGFB3 1.7 3.3 up TIMP2 -1.2 0.4 down 
EFEMP2 0.7 1.6 up COL4A1 -0.6 0.6 down 
TGFB2 1.7 3.2 up ADAM15 -1.3 0.4 down 
COL20A1 0.9 1.8 up CD47 -0.6 0.7 down 
EFEMP1 2.4 5.1 up ICAM4 -0.8 0.6 down 
JAM3 0.6 1.6 up COL4A2 -0.7 0.6 down 
ADAMTS2 1.3 2.5 up COL13A1 -1 0.5 down 
COL3A1 1.3 2.4 up SERPINE1 -0.8 0.6 down 
ITGA8 2.2 4.7 up ITGA6 -0.7 0.6 down 
VTN 0.8 1.7 up NCAM1 -0.7 0.6 down 
LOXL3 0.8 1.8 up HSPG2 -1.1 0.5 down 
COL4A3 0.6 1.5 up TGFB1 -0.8 0.6 down 
CTSS 1.6 3 up TLL1 -1.3 0.4 down 
LUM 2 4 up ELANE -0.7 0.6 down 
CTSL 0.7 1.6 up ICAM2 -0.9 0.6 down 
COL27A1 1 1.9 up THBS1 -0.7 0.6 down 
PCOLCE 0.7 1.6 up ITGA3 -0.5 0.7 down 
NTN4 1.3 2.5 up VCAN -0.6 0.7 down 
COL2A1 2.1 4.4 up JAM2 -0.8 0.6 down 
LTBP2 1.9 3.9 up ITGAM -0.7 0.6 down 
DDR2 0.9 1.9 up ICAM1 -1.6 0.3 down 
DCN 1.9 3.6 up PECAM1 -0.5 0.7 down 
PDGFB 1 2.1 up COL5A3 -1.1 0.5 down 
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Table 24 continued: Different gene expression of heart ECs in response to high shear stress 
involved in extracellular matrix organisation. 
SDC3 0.5 1.5 up BMP4 -0.7 0.6 down 
LTBP3 0.5 1.4 up LAMA5 -0.6 0.6 down 
CTSB 0.7 1.7 up     
 
Table 25: Different gene expression of heart ECs in response to high shear stress involved in 
assembly of collagen fibrils and other multimeric structures. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
COL1A2 2.7 6.6 up COL2A1 2.1 4.4 up 
LOXL2 2.4 5.2 up CTSB 0.7 1.7 up 
LOXL1 1.6 3 up COL6A3 1.4 2.7 up 
LAMA3 1.2 2.3 up COL5A1 0.7 1.6 up 
MMP3 1.2 2.2 up PLEC -1.9 0.3 down 
COL1A1 1.7 3.3 up BMP1 -0.8 0.6 down 
COL3A1 1.3 2.4 up COL5A2 -2.4 0.2 down 
LOXL3 0.8 1.8 up ITGB4 -1.2 0.4 down 
COL4A3 0.6 1.5 up COL4A1 -0.6 0.6 down 
CTSS 1.6 3 up COL4A2 -0.7 0.6 down 
CTSL 0.7 1.6 up ITGA6 -0.7 0.6 down 
COL27A1 1 1.9 up TLL1 -1.3 0.4 down 
PCOLCE 0.7 1.6 up COL5A3 -1.1 0.5 down 
 
Table 26: Different gene expression of heart ECs in response to high shear stress involved in 
hemostasis. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
NOS2 3.2 9.4 up SLC16A3 0.6 1.6 up 
ANGPT2 2.4 5.4 up RASGRP2 1.2 2.4 up 
KIF3A 1.7 3.2 up PLEK 0.6 1.5 up 
GNB4 2.2 4.5 up ZFPM1 -1.5 0.4 down 
ITGA1 1.4 2.7 up LRP8 -2 0.2 down 
SLC7A7 1.1 2.1 up VWF -2.3 0.2 down 
F2RL2 1.4 2.6 up SLC7A11 -2.1 0.2 down 
LCP2 2.5 5.7 up ITPR3 -2.1 0.2 down 
MMRN1 4.1 17.1 up GAS6 -1.5 0.4 down 
KLC3 0.8 1.8 up DOCK8 -1.2 0.4 down 
SH2B1 0.8 1.8 up DAGLA -1.1 0.5 down 
DGKK 3.3 9.9 up ABL1 -0.8 0.6 down 
LCK 1.6 3 up GATA3 -1.9 0.3 down 
PF4 2 4.1 up RAP1B -0.5 0.7 down 
ABCC4 1.4 2.7 up ZFPM2 -1 0.5 down 
SERPINB8 0.7 1.7 up S100A10 -1.3 0.4 down 
P2RY1 1.4 2.6 up MGLL -1 0.5 down 
AKT3 0.8 1.8 up PLAUR -1.7 0.3 down 
CABLES1 0.8 1.8 up SOD1 -0.6 0.7 down 
F2R 0.7 1.7 up TFPI -0.6 0.7 down 
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Table 26 continued: Different gene expression of heart ECs in response to high shear stress 
involved in hemostasis. 
TGFB3 1.7 3.3 up GNAQ -0.6 0.6 down 
PDE3B 1.2 2.3 up ANXA2 -0.7 0.6 down 
ITPR1 0.9 1.8 up NRAS -0.5 0.7 down 
PHF21A 0.9 1.9 up TEK -1.4 0.4 down 
MERTK 1.6 3 up PTK2 -0.7 0.6 down 
TGFB2 1.7 3.2 up HSPA5 -0.6 0.7 down 
JAM3 0.6 1.6 up GATA2 -0.8 0.6 down 
KIF2A 0.7 1.7 up CD47 -0.6 0.7 down 
F13A1 3 8.2 up NOS3 -1.8 0.3 down 
GNG2 1.1 2.1 up PLAT -2.5 0.2 down 
SLC8A2 0.6 1.6 up PIK3R3 -1.8 0.3 down 
KCNMB1 0.9 1.9 up FYN -0.8 0.6 down 
SLC7A8 0.7 1.6 up SERPINE1 -0.8 0.6 down 
ARRB1 2.3 4.9 up P2RX1 -0.6 0.6 down 
DOCK10 0.7 1.7 up ITGA6 -0.7 0.6 down 
PPP2R5A 1.3 2.4 up YWHAZ -0.7 0.6 down 
PDE10A 0.7 1.6 up SERPINC1 -0.6 0.7 down 
ITPK1 0.6 1.5 up PRCP -2 0.2 down 
SERPING1 1.7 3.2 up HDAC1 -0.6 0.6 down 
VEGFB 0.6 1.5 up HABP4 -0.7 0.6 down 
PIK3R2 0.5 1.4 up CD36 -2.5 0.2 down 
GNAI1 0.7 1.7 up PDE1B -1.2 0.4 down 
VEGFA 0.6 1.5 up KRAS -0.6 0.6 down 
EHD3 0.8 1.7 up TGFB1 -0.8 0.6 down 
IGF2 0.8 1.7 up DOCK11 -0.8 0.6 down 
GNG7 0.5 1.4 up KIF23 -0.9 0.5 down 
GRB14 0.8 1.8 up F3 -1.2 0.4 down 
GNG12 0.7 1.6 up GATA4 -0.7 0.6 down 
KIF26A 0.6 1.5 up KCNMB4 -0.6 0.7 down 
GNGT2 0.8 1.7 up THBS1 -0.7 0.6 down 
PIK3CB 0.9 1.8 up PRKAR2B -0.5 0.7 down 
WEE1 0.8 1.7 up SH2B3 -0.7 0.6 down 
PDGFB 1 2.1 up AMICA1 -0.8 0.6 down 
ANGPT4 0.7 1.6 up INPP5D -0.6 0.6 down 
FCER1G 1.2 2.3 up ITGA3 -0.5 0.7 down 
PRKAR1B 0.9 1.9 up JAM2 -0.8 0.6 down 
RHOB 1 1.9 up CAPZB -0.8 0.6 down 
PDE5A 0.7 1.6 up SLC8A3 -0.6 0.6 down 
GUCY1A3 1.2 2.3 up ITGAM -0.7 0.6 down 
PDE1A 0.9 1.9 up SELP -0.6 0.7 down 
CD84 0.5 1.5 up KIF20A -0.7 0.6 down 
MRVI1 0.8 1.8 up PECAM1 -0.5 0.7 down 
DOCK3 0.7 1.7 up KIF22 -0.5 0.7 down 
VAV1 0.7 1.6 up ITPR2 -0.5 0.7 down 
CLU 0.9 1.8 up SLC7A6 -0.5 0.7 down 
TRPC3 1.1 2.2 up PLA2G4A -1 0.5 down 
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Table 27: Different gene expression of heart ECs in response to high shear stress involved in 
cholesterol biosynthesis. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
SQLE -1.2 0.4 down HSD17B7 -0.9 0.5 down 
FDFT1 -0.9 0.5 down FDPS -1 0.5 down 
DHCR24 -1.3 0.4 down MVD -0.7 0.6 down 
IDI1 -1.2 0.4 down HMGCS1 -0.9 0.5 down 
NSDHL -0.8 0.6 down PMVK -0.5 0.7 down 
SC5D -0.8 0.6 down LSS -0.8 0.6 down 
DHCR7 -1.2 0.4 down HMGCR -0.9 0.5 down 
 
Table 28: Different gene expression of heart ECs in response to high shear stress involved in 
molecules associated with elastic fibres. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
BMP2 2.9 7.6 up LTBP2 1.9 3.9 up 
BMP7 2.3 4.8 up LTBP3 0.5 1.4 up 
MFAP2 1.4 2.6 up MFAP5 0.6 1.5 up 
TGFB3 1.7 3.3 up ITGB5 0.5 1.4 up 
EFEMP2 0.7 1.6 up FBLN2 -3.5 0.1 down 
TGFB2 1.7 3.2 up LTBP4 -2.3 0.2 down 
EFEMP1 2.4 5.1 up TGFB1 -0.8 0.6 down 
ITGA8 2.2 4.7 up BMP4 -0.7 0.6 down 
VTN 0.8 1.7 up     
 
Table 29: Different gene expression of heart ECs in response to high shear stress involved in axon 
guidance. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
SEMA6D 1 2 up MYH11 0.7 1.6 up 
ITGA1 1.4 2.7 up TRIO 0.9 1.8 up 
EPHA5 0.9 1.9 up CLTB -1.2 0.4 down 
SCN8A 0.9 1.9 up EZR -1.1 0.5 down 
EPHB3 0.8 1.7 up GIT1 -1.3 0.4 down 
DPYSL5 0.8 1.8 up EPHA4 -0.9 0.5 down 
FGFR1 0.9 1.9 up SPTBN2 -0.9 0.5 down 
TRPC4 1.2 2.3 up EPHB4 -1.4 0.4 down 
MYH10 0.9 1.9 up ABL1 -0.8 0.6 down 
SCN3B 1 2.1 up SLIT2 -0.8 0.6 down 
ARHGEF28 1.1 2.1 up KDR -1.5 0.4 down 
SRGAP2 1 2.1 up ALCAM -1.2 0.4 down 
KALRN 0.7 1.6 up NRP1 -1.5 0.4 down 
ST8SIA4 1.6 3.1 up ROBO3 -1.2 0.4 down 
APH1B 1.3 2.5 up EFNB2 -1.2 0.4 down 
RPS6KA5 0.7 1.6 up NRCAM -1.6 0.3 down 
SCN3A 2.1 4.4 up PLXNA4 -1.6 0.3 down 
PAK4 0.6 1.5 up PITPNA -0.6 0.7 down 
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Table 29 continued: Different gene expression of heart ECs in response to high shear stress 
involved in axon guidance. 
ABLIM1 1.2 2.3 up COL4A1 -0.6 0.6 down 
SCN2B 0.7 1.6 up NRAS -0.5 0.7 down 
TYROBP 2 3.9 up SEMA3E -0.9 0.5 down 
ITSN1 0.6 1.5 up CRMP1 -1.8 0.3 down 
TRPC1 0.6 1.5 up PTK2 -0.7 0.6 down 
AGAP2 1.9 3.8 up EFNB1 -0.7 0.6 down 
TREM2 1.4 2.6 up MSN -0.5 0.7 down 
MYL9 1.2 2.3 up COL4A2 -0.7 0.6 down 
COL4A3 0.6 1.5 up RPS6KA3 -0.6 0.7 down 
VEGFA 0.6 1.5 up FYN -0.8 0.6 down 
NTN4 1.3 2.5 up GSK3B -0.6 0.7 down 
CACNA1H 0.7 1.6 up NGEF -0.8 0.6 down 
CD72 0.6 1.5 up CDK5R1 -0.6 0.6 down 
DLG1 0.5 1.4 up SPTAN1 -0.7 0.6 down 
LIMK1 0.9 1.9 up PIP5K1C -0.8 0.6 down 
CSNK2A1 0.5 1.5 up SHB -0.9 0.5 down 
MYO10 1 1.9 up NCAM1 -0.7 0.6 down 
RHOB 1 1.9 up ARHGEF12 -0.5 0.7 down 
RND1 1.6 3 up KRAS -0.6 0.6 down 
COL6A3 1.4 2.7 up RPS6KA4 -0.6 0.7 down 
ARPC3 1 2 up NEO1 -0.6 0.6 down 
SRGAP3 0.7 1.6 up SRGAP1 -0.7 0.6 down 
ARHGEF7 0.5 1.4 up EPHA7 -0.7 0.6 down 
TRPC3 1.1 2.2 up NCK1 -0.7 0.6 down 
MYL12B 0.7 1.6 up RPS6KA2 -0.7 0.6 down 
PAK2 0.6 1.5 up PAK1 -0.7 0.6 down 
SLIT3 0.6 1.5 up UNC5B -0.7 0.6 down 
SCN5A 0.9 1.8 up      
Table 30: Different gene expression of heart ECs in response to high shear stress involved in 
elastic fibre formation. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
BMP2 2.9 7.6 up VTN 0.8 1.7 up 
LOXL2 2.4 5.2 up LOXL3 0.8 1.8 up 
BMP7 2.3 4.8 up LTBP2 1.9 3.9 up 
LOXL1 1.6 3 up LTBP3 0.5 1.4 up 
MFAP2 1.4 2.6 up MFAP5 0.6 1.5 up 
TGFB3 1.7 3.3 up ITGB5 0.5 1.4 up 
EFEMP2 0.7 1.6 up FBLN2 -3.5 0.1 down 
TGFB2 1.7 3.2 up LTBP4 -2.3 0.2 down 
EFEMP1 2.4 5.1 up TGFB1 -0.8 0.6 down 
ITGA8 2.2 4.7 up BMP4 -0.7 0.6 down 
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Table 31: Different gene expression of heart ECs in response to high shear stress involved in 
signaling by Rho GTPase. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
STARD13 1.5 2.8 up ARHGAP9 0.5 1.5 up 
ARHGAP18 1.7 3.3 up ARHGEF7 0.5 1.4 up 
BCR 1 2.1 up VAV1 0.7 1.6 up 
RALBP1 0.6 1.5 up ARHGEF17 0.8 1.7 up 
SRGAP2 1 2.1 up AKAP13 0.6 1.5 up 
KALRN 0.7 1.6 up TRIO 0.9 1.8 up 
PLEKHG5 0.9 1.9 up CHN2 -1.2 0.4 down 
ARHGAP26 0.9 1.9 up RHOQ -0.9 0.5 down 
PLEKHG2 0.9 1.9 up ARHGAP23 -0.8 0.6 down 
OPHN1 0.5 1.4 up RAC3 -0.7 0.6 down 
ARHGAP29 0.9 1.8 up MYO9A -0.7 0.6 down 
RHOJ 0.6 1.5 up ARHGAP31 -0.5 0.7 down 
ITSN1 0.6 1.5 up NGEF -0.8 0.6 down 
SYDE1 1 2 up ARHGAP11A -0.5 0.7 down 
PIK3R2 0.5 1.4 up ARHGEF12 -0.5 0.7 down 
ARHGEF4 0.7 1.6 up MCF2L -0.9 0.5 down 
TAGAP 0.6 1.5 up TIAM2 -0.6 0.7 down 
ARHGAP25 0.5 1.5 up SRGAP1 -0.7 0.6 down 
ARHGAP15 0.5 1.4 up RHOH -0.5 0.7 down 
RHOB 1 1.9 up ARHGDIG -0.5 0.7 down 
FAM13A 0.9 1.9 up ARHGEF18 -0.9 0.5 down 
SRGAP3 0.7 1.6 up     
 
Table 32: Different gene expression of heart ECs in response to high shear stress involved in 
collagen formation. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
LEPREL2 1.2 2.3 up COL2A1 2.1 4.4 up 
COL1A2 2.7 6.6 up CTSB 0.7 1.7 up 
LOXL2 2.4 5.2 up COL6A3 1.4 2.7 up 
ADAMTS14 2.1 4.2 up COL5A1 0.7 1.6 up 
LOXL1 1.6 3 up COL28A1 0.5 1.5 up 
LAMA3 1.2 2.3 up PLEC -1.9 0.3 down 
MMP3 1.2 2.2 up COL12A1 -1.1 0.5 down 
COL1A1 1.7 3.3 up BMP1 -0.8 0.6 down 
COL20A1 0.9 1.8 up COL5A2 -2.4 0.2 down 
ADAMTS2 1.3 2.5 up ITGB4 -1.2 0.4 down 
COL3A1 1.3 2.4 up COL4A1 -0.6 0.6 down 
LOXL3 0.8 1.8 up COL4A2 -0.7 0.6 down 
COL4A3 0.6 1.5 up COL13A1 -1 0.5 down 
CTSS 1.6 3 up ITGA6 -0.7 0.6 down 
CTSL 0.7 1.6 up TLL1 -1.3 0.4 down 
COL27A1 1 1.9 up COL5A3 -1.1 0.5 down 
PCOLCE 0.7 1.6 up     
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Table 33: Different gene expression of heart ECs in response to high shear stress involved in 
developmental biology. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
SEMA6D 1 2 up TCF12 0.6 1.5 up 
ITGA1 1.4 2.7 up TRIO 0.9 1.8 up 
FOXO1 1.1 2.2 up KLF4 -2.4 0.2 down 
EPHA5 0.9 1.9 up CLTB -1.2 0.4 down 
NR5A2 2.6 6 up EZR -1.1 0.5 down 
MEF2A 0.8 1.7 up GIT1 -1.3 0.4 down 
TCF4 1.4 2.7 up NCOR2 -1 0.5 down 
HIF3A 1.9 3.8 up EPHA4 -0.9 0.5 down 
SCN8A 0.9 1.9 up SPTBN2 -0.9 0.5 down 
EPHB3 0.8 1.7 up EPHB4 -1.4 0.4 down 
DPYSL5 0.8 1.8 up ABL1 -0.8 0.6 down 
FGFR1 0.9 1.9 up SLIT2 -0.8 0.6 down 
PCSK6 2 3.9 up KDR -1.5 0.4 down 
CEBPD 2.6 6 up ALCAM -1.2 0.4 down 
TRPC4 1.2 2.3 up NRP1 -1.5 0.4 down 
MYH10 0.9 1.9 up ROBO3 -1.2 0.4 down 
AKT3 0.8 1.8 up EFNB2 -1.2 0.4 down 
SCN3B 1 2.1 up NRCAM -1.6 0.3 down 
ARHGEF28 1.1 2.1 up LPL -1.3 0.4 down 
SRGAP2 1 2.1 up CCNC -0.7 0.6 down 
NFKB1 0.8 1.7 up PLXNA4 -1.6 0.3 down 
KALRN 0.7 1.6 up PITPNA -0.6 0.7 down 
HHEX 1 2 up COL4A1 -0.6 0.6 down 
ST8SIA4 1.6 3.1 up NRAS -0.5 0.7 down 
APH1B 1.3 2.5 up MAPK11 -1 0.5 down 
RPS6KA5 0.7 1.6 up SEMA3E -0.9 0.5 down 
SLC2A4 1.2 2.3 up CRMP1 -1.8 0.3 down 
SCN3A 2.1 4.4 up PTK2 -0.7 0.6 down 
PAK4 0.6 1.5 up EFNB1 -0.7 0.6 down 
CDK19 0.8 1.8 up BNIP2 -0.6 0.7 down 
ABLIM1 1.2 2.3 up MSN -0.5 0.7 down 
SCN2B 0.7 1.6 up COL4A2 -0.7 0.6 down 
MED14 0.6 1.5 up RPS6KA3 -0.6 0.7 down 
TYROBP 2 3.9 up FYN -0.8 0.6 down 
ITSN1 0.6 1.5 up CDON -0.7 0.6 down 
TRPC1 0.6 1.5 up FABP4 -0.8 0.6 down 
AGAP2 1.9 3.8 up GSK3B -0.6 0.7 down 
TREM2 1.4 2.6 up SREBF2 -0.7 0.6 down 
MYL9 1.2 2.3 up NGEF -0.8 0.6 down 
COL4A3 0.6 1.5 up CDK5R1 -0.6 0.6 down 
VEGFA 0.6 1.5 up SPTAN1 -0.7 0.6 down 
NTN4 1.3 2.5 up MEF2D -0.7 0.6 down 
CACNA1H 0.7 1.6 up PIP5K1C -0.8 0.6 down 
CD72 0.6 1.5 up SHB -0.9 0.5 down 
ACVR2B 0.9 1.9 up NCAM1 -0.7 0.6 down 
DLG1 0.5 1.4 up MED20 -0.5 0.7 down 
LIMK1 0.9 1.9 up CTNNB1 -1 0.5 down 
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Table 33 continued: Different gene expression of heart ECs in response to high shear stress 
involved in developmental biology. 
CSNK2A1 0.5 1.5 up CD36 -2.5 0.2 down 
MYO10 1 1.9 up ARHGEF12 -0.5 0.7 down 
RHOB 1 1.9 up CDK8 -0.5 0.7 down 
RND1 1.6 3 up KRAS -0.6 0.6 down 
COL6A3 1.4 2.7 up TGFB1 -0.8 0.6 down 
EGR2 0.8 1.8 up RPS6KA4 -0.6 0.7 down 
ARPC3 1 2 up NEO1 -0.6 0.6 down 
SRGAP3 0.7 1.6 up SRGAP1 -0.7 0.6 down 
ARHGEF7 0.5 1.4 up KLF5 -1 0.5 down 
TRPC3 1.1 2.2 up EPHA7 -0.7 0.6 down 
MYL12B 0.7 1.6 up NCK1 -0.7 0.6 down 
CEBPA 0.6 1.5 up MEF2C -0.8 0.6 down 
STAT3 0.6 1.5 up RPS6KA2 -0.7 0.6 down 
PAK2 0.6 1.5 up PAK1 -0.7 0.6 down 
SLIT3 0.6 1.5 up PPARG -0.6 0.7 down 
SCN5A 0.9 1.8 up UNC5B -0.7 0.6 down 
MYH11 0.7 1.6 up CCND3 -0.5 0.7 down 
 
Table 34: Different gene expression of heart ECs in response to high shear stress involved in 
signaling by NGF. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp.  
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
BCL2L11 1.7 3.2 up MAGED1 0.6 1.5 up 
FOXO1 1.1 2.2 up STAT3 0.6 1.5 up 
SHC3 1.4 2.6 up ADORA2A 0.9 1.9 up 
MEF2A 0.8 1.7 up AKAP13 0.6 1.5 up 
ADCYAP1R1 1.3 2.5 up HBEGF 0.8 1.8 up 
TRIB3 1.9 3.8 up TRIO 0.9 1.8 up 
FGFR1 0.9 1.9 up ITPR3 -2.1 0.2 down 
PCSK6 2 3.9 up CAMK4 -1.5 0.4 down 
LCK 1.6 3 up DUSP4 -1.6 0.3 down 
CASP3 1 2 up NGF -0.6 0.7 down 
AKT3 0.8 1.8 up FGFR3 -1.4 0.4 down 
NFKB1 0.8 1.7 up NRAS -0.5 0.7 down 
KALRN 0.7 1.6 up MAPK11 -1 0.5 down 
KIT 3.6 12.3 up SQSTM1 -0.9 0.5 down 
PLEKHG5 0.9 1.9 up PIK3R3 -1.8 0.3 down 
APH1B 1.3 2.5 up RPS6KA3 -0.6 0.7 down 
ITPR1 0.9 1.8 up FYN -0.8 0.6 down 
RPS6KA5 0.7 1.6 up MDM2 -0.8 0.6 down 
FGF23 2.2 4.6 up GSK3B -0.6 0.7 down 
GAB1 0.8 1.8 up NGEF -0.8 0.6 down 
PLEKHG2 0.9 1.9 up HDAC1 -0.6 0.6 down 
NFKBIA 0.6 1.5 up ARHGEF1 -0.6 0.7 down 
ITSN1 0.6 1.5 up IRS1 -0.6 0.7 down 
CDKN1B 0.9 1.8 up ARHGEF12 -0.5 0.7 down 
PIK3R2 0.5 1.4 up PDE1B -1.2 0.4 down 
RALGDS 1.9 3.7 up MCF2L -0.9 0.5 down 
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Table 34 continued: Different gene expression of heart ECs in response to high shear stress 
involved in signaling by NGF. 
ARHGEF4 0.7 1.6 up KRAS -0.6 0.6 down 
PDGFRA 0.5 1.4 up PTEN -0.6 0.7 down 
PIK3CB 0.9 1.8 up TIAM2 -0.6 0.7 down 
ADCY2 0.5 1.5 up MLST8 -0.6 0.7 down 
PDGFB 1 2.1 up PRKAR2B -0.5 0.7 down 
NTRK2 0.5 1.5 up RAPGEF1 -0.5 0.7 down 
PRKAR1B 0.9 1.9 up RTN4 -0.7 0.6 down 
PDE1A 0.9 1.9 up MEF2C -0.8 0.6 down 
FGF1 1 1.9 up RPS6KA2 -0.7 0.6 down 
SHC2 0.6 1.5 up CDKN1A -0.6 0.7 down 
ARHGEF7 0.5 1.4 up ARHGEF18 -0.9 0.5 down 
ADAM17 0.5 1.4 up ITPR2 -0.5 0.7 down 
VAV1 0.7 1.6 up DUSP6 -0.7 0.6 down 
ARHGEF17 0.8 1.7 up     
 
Table 35: Different gene expression of heart ECs in response to high shear stress involved in 
metabolism. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp.  
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
ETHE1 1.7 3.3 up SQLE -1.2 0.4 down 
SDC4 2.6 6.2 up ITPR3 -2.1 0.2 down 
ITPKC 1.8 3.6 up GGCT -1 0.5 down 
GNB4 2.2 4.5 up NQO1 -4.2 0.1 down 
GDA 3.3 10.2 up MTM1 -1.1 0.5 down 
LPIN3 1.5 2.8 up PGD -1.4 0.4 down 
CYP4B1 2.5 5.6 up FASN -1 0.5 down 
FMO3 4.5 22.2 up B4GALT1 -0.8 0.6 down 
B4GALT3 1.6 3.1 up NCOR2 -1 0.5 down 
DCTD 1.4 2.6 up NT5C2 -0.7 0.6 down 
PSME3 0.9 1.9 up GPX4 -0.7 0.6 down 
KCNG2 1.9 3.6 up FDFT1 -0.9 0.5 down 
ABCC3 1.7 3.3 up KDSR -0.7 0.6 down 
GXYLT2 0.9 1.9 up HYAL1 -1.3 0.4 down 
PCBD1 1.2 2.3 up GSTA2 -2.9 0.1 down 
PYGL 2 4.1 up B4GALT7 -1.1 0.5 down 
FMO2 5.8 56.9 up ELOVL1 -0.6 0.7 down 
TRIB3 1.9 3.8 up DHCR24 -1.3 0.4 down 
PAOX 0.9 1.8 up IDI1 -1.2 0.4 down 
GLUL 1.6 3 up LDLRAP1 -0.8 0.6 down 
ARSA 0.8 1.8 up TXNRD1 -1.1 0.5 down 
IPMK 1.5 2.7 up ENO1 -0.6 0.6 down 
CTH 1.3 2.5 up MOCS2 -0.7 0.6 down 
G0S2 2.7 6.7 up PPAP2B -2.3 0.2 down 
OAZ2 0.8 1.8 up MGLL -1 0.5 down 
FAM213B 0.9 1.9 up ACAN -1.6 0.3 down 
CCBL1 1.7 3.2 up ASS1 -1.5 0.4 down 
OXCT1 0.8 1.7 up NSDHL -0.8 0.6 down 
MMAA 0.6 1.6 up ME1 -1.3 0.4 down 
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Table 35 continued: Different gene expression of heart ECs in response to high shear stress 
involved in metabolism. 
NUDT16 0.6 1.6 up HYAL2 -1.2 0.4 down 
RPIA 0.9 1.8 up ABHD5 -1.2 0.4 down 
PRKAB2 0.9 1.9 up BMP1 -0.8 0.6 down 
HSD11B1 2.5 5.6 up ARNTL -1.2 0.4 down 
CERK 1.1 2.1 up SC5D -0.8 0.6 down 
SLC10A6 2.3 4.8 up DHCR7 -1.2 0.4 down 
GYS1 0.7 1.6 up AOX1 -1.9 0.3 down 
LDHB 1.1 2.1 up HSD17B7 -0.9 0.5 down 
ACSS1 2.4 5.1 up FDPS -1 0.5 down 
IDH2 1.1 2.1 up CPT1A -1.1 0.5 down 
ACP5 2.1 4.4 up RRM1 -0.5 0.7 down 
NUDT1 0.6 1.5 up ABCC1 -1.1 0.5 down 
GLS2 0.8 1.7 up CIAPIN1 -0.6 0.7 down 
PHYH 1 2 up LPL -1.3 0.4 down 
MARCKS 0.6 1.6 up SCO1 -0.5 0.7 down 
ITPR1 0.9 1.8 up GCLC -1 0.5 down 
BCKDHB 0.6 1.5 up GPX1 -0.6 0.6 down 
CHP1 0.7 1.7 up LDLR -1.3 0.4 down 
GMPR 1 2 up NUDT10 -1.1 0.5 down 
VAPA 0.6 1.6 up PSMB3 -0.6 0.6 down 
HMGCL 1.3 2.4 up DTYMK -0.8 0.6 down 
CD320 0.7 1.7 up GNAQ -0.6 0.6 down 
NDUFA6 0.7 1.6 up DDC -0.6 0.7 down 
MAOB 1.1 2.2 up CCNC -0.7 0.6 down 
NUP210 2.4 5.2 up BLVRA -0.5 0.7 down 
PAPSS2 0.9 1.8 up BPNT1 -0.7 0.6 down 
G6PC3 0.6 1.5 up ACER3 -0.9 0.5 down 
NAPRT1 1.2 2.3 up NME1 -1 0.5 down 
SLC2A4 1.2 2.3 up NR1D1 -1.4 0.4 down 
SYT5 1.9 3.7 up ETFA -0.5 0.7 down 
STARD6 1.1 2.1 up MVD -0.7 0.6 down 
SHMT1 0.6 1.5 up PDHX -0.5 0.7 down 
L2HGDH 0.6 1.5 up ETFB -0.6 0.6 down 
MOCOS 0.9 1.9 up NRF1 -0.5 0.7 down 
GSTZ1 0.5 1.5 up PDSS2 -0.5 0.7 down 
PPIP5K1 0.6 1.5 up ETFDH -0.6 0.7 down 
APOA2 0.8 1.7 up RAN -0.8 0.6 down 
PANK4 0.6 1.5 up PSMD5 -0.6 0.7 down 
CDK19 0.8 1.8 up ALOX12 -1.4 0.4 down 
DPEP1 2.2 4.7 up MTAP -0.7 0.6 down 
PNPLA2 0.8 1.8 up GSTO2 -1 0.5 down 
OPLAH 0.6 1.5 up LPCAT3 -0.7 0.6 down 
SLC44A1 0.6 1.5 up MGST3 -0.8 0.6 down 
MTMR14 0.6 1.5 up CUBN -0.7 0.6 down 
UGCG 1.2 2.3 up SLC25A15 -0.5 0.7 down 
MED14 0.6 1.5 up NFYC -0.6 0.7 down 
COX7A2L 0.6 1.6 up SLC26A2 -0.6 0.7 down 
GNG2 1.1 2.1 up CAT -0.8 0.6 down 
SMS 0.5 1.5 up SRD5A1 -0.7 0.6 down 
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Table 35 continued: Different gene expression of heart ECs in response to high shear stress 
involved in metabolism. 
PFKFB3 1.5 2.9 up SLC52A3 -0.9 0.5 down 
ACY3 0.9 1.9 up DEGS2 -0.5 0.7 down 
CDS2 0.6 1.6 up NOS3 -1.8 0.3 down 
PPP1R3C 1.5 2.8 up PSMD6 -0.6 0.7 down 
ARSI 0.5 1.4 up PRPS2 -0.6 0.7 down 
IDUA 0.9 1.8 up MTMR2 -0.8 0.6 down 
SUOX 0.7 1.7 up PIK3R3 -1.8 0.3 down 
PFKP 0.8 1.7 up ABCG1 -0.8 0.6 down 
MGST2 1.2 2.3 up CHST2 -1.2 0.4 down 
PLD1 0.6 1.5 up GOT2 -0.5 0.7 down 
ALDH1A1 1.6 3 up NUP155 -0.6 0.7 down 
UPP1 0.7 1.7 up MBOAT2 -1.2 0.4 down 
ENO3 0.8 1.7 up ELOVL4 -0.8 0.6 down 
LGMN 0.8 1.7 up HMGCS1 -0.9 0.5 down 
LUM 2 4 up COX5B -0.6 0.7 down 
ITPK1 0.6 1.5 up PITPNB -0.6 0.7 down 
ALDH6A1 0.5 1.4 up FABP4 -0.8 0.6 down 
ABCA1 2.6 6.1 up NNMT -1 0.5 down 
CHST7 1.1 2.1 up ADK -1.7 0.3 down 
ITPKA 0.6 1.5 up SREBF2 -0.7 0.6 down 
SLC6A12 2.5 5.8 up PCCB -0.6 0.7 down 
HLCS 0.6 1.5 up HMOX1 -1.3 0.4 down 
PIK3R2 0.5 1.4 up SLC25A12 -0.6 0.7 down 
GNAI1 0.7 1.7 up PMVK -0.5 0.7 down 
SGSH 0.6 1.5 up PIP5K1C -0.8 0.6 down 
PDP1 0.7 1.6 up MAT2A -0.8 0.6 down 
PLCE1 0.9 1.8 up PI4KA -0.5 0.7 down 
HEXA 1 1.9 up BDH1 -0.9 0.5 down 
CHST15 0.7 1.6 up SLC19A1 -0.7 0.6 down 
CERS4 0.6 1.6 up ASL -0.5 0.7 down 
LPCAT2 0.7 1.6 up MED20 -0.5 0.7 down 
NDUFC2 0.6 1.5 up HSPG2 -1.1 0.5 down 
CHST1 1.8 3.4 up INPP4B -1.2 0.4 down 
PSMB8 0.9 1.9 up CD36 -2.5 0.2 down 
GNG7 0.5 1.4 up NDUFB5 -0.5 0.7 down 
GPCPD1 0.7 1.6 up HEXB -0.7 0.6 down 
GNG12 0.7 1.6 up ACOX1 -0.8 0.6 down 
GPC3 0.7 1.6 up CDK8 -0.5 0.7 down 
GLS 0.8 1.7 up RRM2 -1.4 0.4 down 
TPI1 0.7 1.6 up PSMC5 -0.5 0.7 down 
LYVE1 1.8 3.5 up NUPL2 -0.6 0.7 down 
GNGT2 0.8 1.7 up PSMD9 -0.6 0.7 down 
PIK3CB 0.9 1.8 up LIPE -0.7 0.6 down 
RGL1 0.9 1.8 up HK1 -0.5 0.7 down 
VAPB 0.8 1.7 up AK1 -1.5 0.4 down 
ADCY2 0.5 1.5 up PTEN -0.6 0.7 down 
DCN 1.9 3.6 up PDSS1 -0.6 0.7 down 
SLC2A3 0.8 1.7 up ELOVL5 -0.7 0.6 down 
SGMS2 0.8 1.7 up SLC25A32 -0.6 0.7 down 
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Table 35 continued: Different gene expression of heart ECs in response to high shear stress 
involved in metabolism. 
SULT1A1 2.1 4.4 up PPIP5K2 -0.7 0.6 down 
PSMB9 1 1.9 up PTGS2 -1.7 0.3 down 
GPC4 0.6 1.5 up CDA -1.9 0.3 down 
GSTT2 0.6 1.5 up PIK3C2A -0.7 0.6 down 
ALDOC 0.9 1.8 up COQ7 -0.6 0.7 down 
SDC3 0.5 1.5 up SLC27A1 -0.5 0.7 down 
PRKAR1B 0.9 1.9 up IDH1 -0.9 0.5 down 
PLCB4 1.1 2.1 up TIAM2 -0.6 0.7 down 
SLC25A37 0.6 1.5 up ATIC -0.6 0.7 down 
ASNS 0.8 1.8 up NDUFAB1 -0.6 0.7 down 
GPC6 0.5 1.4 up ABCG2 -0.6 0.6 down 
PLB1 0.6 1.5 up PRKAR2B -0.5 0.7 down 
CYP7B1 0.9 1.9 up PRKD1 -0.6 0.6 down 
STARD5 0.7 1.7 up VAC14 -0.6 0.7 down 
SMPD3 1.2 2.2 up FLAD1 -0.5 0.7 down 
CSAD 0.6 1.6 up INPP5D -0.6 0.6 down 
FBP1 0.5 1.4 up UCP2 -2 0.2 down 
PFKFB4 0.5 1.4 up CMPK1 -0.6 0.6 down 
NUDT4 0.5 1.5 up VCAN -0.6 0.7 down 
LHB 0.6 1.5 up SLC19A2 -0.7 0.6 down 
ALOX5AP 0.8 1.7 up SLC25A16 -0.9 0.5 down 
APOE 1.7 3.1 up ARSJ -0.8 0.6 down 
KCNB1 1 1.9 up LSS -0.8 0.6 down 
SLC16A3 0.6 1.6 up UCP3 -2 0.3 down 
GCH1 0.6 1.5 up AKAP5 -1.1 0.5 down 
ANKRD1 1.1 2.1 up ASAH1 -0.6 0.6 down 
ITPKB 0.6 1.6 up SNAP25 -0.7 0.6 down 
CYP1A1 -7.1 0 down PFAS -0.6 0.7 down 
APRT -1.3 0.4 down HMGCR -0.9 0.5 down 
GSTO1 -3.1 0.1 down ACACB -1 0.5 down 
TEAD4 -1 0.5 down SLC35B3 -0.6 0.7 down 
ADA -2.4 0.2 down MINPP1 -0.5 0.7 down 
GSTA4 -1.6 0.3 down PPARG -0.6 0.7 down 
CYP1B1 -3 0.1 down ITPR2 -0.5 0.7 down 
PTGS1 -2.6 0.2 down PPAP2A -0.7 0.6 down 
ABCC5 -1 0.5 down PTGES -0.6 0.6 down 
GCLM -2.1 0.2 down BLVRB -0.6 0.7 down 
SPHK1 -1.6 0.3 down ADSS -0.6 0.6 down 
CKB -2.1 0.2 down TK1 -1 0.5 down 
CHPF2 -1.2 0.4 down PLA2G4A -1 0.5 down 
CHST11 -1 0.5 down HDC -1 0.5 down 
PLIN2 -1.8 0.3 down CSPG4 -0.8 0.6 down 
IPPK -1 0.5 down PFKFB2 -0.6 0.6 down 
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Table 36: Different gene expression of heart ECs in response to high shear stress involved in 
integrin cell surface interactions. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
ITGA1 1.4 2.7 up ICAM4 -0.8 0.6 down 
ITGA11 2.4 5.2 up COL4A2 -0.7 0.6 down 
SPP1 3.8 14.3 up COL13A1 -1 0.5 down 
JAM3 0.6 1.6 up ITGA6 -0.7 0.6 down 
ITGA8 2.2 4.7 up HSPG2 -1.1 0.5 down 
VTN 0.8 1.7 up ICAM2 -0.9 0.6 down 
COL4A3 0.6 1.5 up THBS1 -0.7 0.6 down 
LUM 2 4 up ITGA3 -0.5 0.7 down 
ITGB5 0.5 1.4 up JAM2 -0.8 0.6 down 
KDR -1.5 0.4 down ITGAM -0.7 0.6 down 
COL4A1 -0.6 0.6 down ICAM1 -1.6 0.3 down 
CD47 -0.6 0.7 down PECAM1 -0.5 0.7 down 
 
Table 37: Different gene expression of heart ECs in response to high shear stress involved in 
NRAGE signals death through JNK. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
BCL2L11 1.7 3.2 up MAGED1 0.6 1.5 up 
KALRN 0.7 1.6 up AKAP13 0.6 1.5 up 
PLEKHG5 0.9 1.9 up TRIO 0.9 1.8 up 
PLEKHG2 0.9 1.9 up NGF -0.6 0.7 down 
ITSN1 0.6 1.5 up NGEF -0.8 0.6 down 
ARHGEF4 0.7 1.6 up ARHGEF12 -0.5 0.7 down 
ARHGEF7 0.5 1.4 up MCF2L -0.9 0.5 down 
VAV1 0.7 1.6 up TIAM2 -0.6 0.7 down 
ARHGEF17 0.8 1.7 up ARHGEF18 -0.9 0.5 down 
 
Table 38: Different gene expression of heart ECs in response to high shear stress involved in 
netrin-1 signaling. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
TRPC4 1.2 2.3 up EZR -1.1 0.5 down 
ABLIM1 1.2 2.3 up SLIT2 -0.8 0.6 down 
TRPC1 0.6 1.5 up PITPNA -0.6 0.7 down 
AGAP2 1.9 3.8 up PTK2 -0.7 0.6 down 
NTN4 1.3 2.5 up FYN -0.8 0.6 down 
MYO10 1 1.9 up NEO1 -0.6 0.6 down 
TRPC3 1.1 2.2 up NCK1 -0.7 0.6 down 
SLIT3 0.6 1.5 up UNC5B -0.7 0.6 down 
TRIO 0.9 1.8 up     
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Table 39: Different gene expression of heart ECs in response to high shear stress involved in nitric 
oxide stimulates guanylate cyclase. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
NOS2 3.2 9.4 up GUCY1A3 1.2 2.3 up 
PDE3B 1.2 2.3 up PDE1A 0.9 1.9 up 
ITPR1 0.9 1.8 up MRVI1 0.8 1.8 up 
KCNMB1 0.9 1.9 up NOS3 -1.8 0.3 down 
PDE10A 0.7 1.6 up PDE1B -1.2 0.4 down 
PDE5A 0.7 1.6 up KCNMB4 -0.6 0.7 down 
 
Table 40: Different gene expression of heart ECs in response to high shear stress involved in non-
integrin membran-ECM interactions. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp.  
A-B 
SDC4 2.6 6.2 up LAMA2 0.6 1.5 up 
LAMA3 1.2 2.3 up ITGB5 0.5 1.4 up 
VTN 0.8 1.7 up ITGB4 -1.2 0.4 down 
NTN4 1.3 2.5 up ITGA6 -0.7 0.6 down 
DDR2 0.9 1.9 up HSPG2 -1.1 0.5 down 
PDGFB 1 2.1 up TGFB1 -0.8 0.6 down 
SDC3 0.5 1.5 up THBS1 -0.7 0.6 down 
DDR1 0.8 1.7 up LAMA5 -0.6 0.6 down 
LAMA4 0.6 1.5 up     
 
Table 41: Different gene expression of heart ECs in response to high shear stress involved in 
platelet homeostasis. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
NOS2 3.2 9.4 up PDE1A 0.9 1.9 up 
GNB4 2.2 4.5 up MRVI1 0.8 1.8 up 
PDE3B 1.2 2.3 up TRPC3 1.1 2.2 up 
ITPR1 0.9 1.8 up LRP8 -2 0.2 down 
GNG2 1.1 2.1 up ITPR3 -2.1 0.2 down 
SLC8A2 0.6 1.6 up NOS3 -1.8 0.3 down 
KCNMB1 0.9 1.9 up P2RX1 -0.6 0.6 down 
PPP2R5A 1.3 2.4 up PDE1B -1.2 0.4 down 
PDE10A 0.7 1.6 up KCNMB4 -0.6 0.7 down 
GNG7 0.5 1.4 up SLC8A3 -0.6 0.6 down 
GNG12 0.7 1.6 up PECAM1 -0.5 0.7 down 
GNGT2 0.8 1.7 up ITPR2 -0.5 0.7 down 
PDE5A 0.7 1.6 up PLA2G4A -1 0.5 down 
GUCY1A3 1.2 2.3 up     
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Table 42: Different gene expression of heart ECs in response to high shear stress involved in 
semaphorin interactions. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
SEMA6D 1 2 up PAK2 0.6 1.5 up 
ITGA1 1.4 2.7 up MYH11 0.7 1.6 up 
DPYSL5 0.8 1.8 up NRP1 -1.5 0.4 down 
MYH10 0.9 1.9 up PLXNA4 -1.6 0.3 down 
TYROBP 2 3.9 up SEMA3E -0.9 0.5 down 
TREM2 1.4 2.6 up CRMP1 -1.8 0.3 down 
MYL9 1.2 2.3 up FYN -0.8 0.6 down 
CD72 0.6 1.5 up GSK3B -0.6 0.7 down 
LIMK1 0.9 1.9 up CDK5R1 -0.6 0.6 down 
RHOB 1 1.9 up PIP5K1C -0.8 0.6 down 
RND1 1.6 3 up ARHGEF12 -0.5 0.7 down 
MYL12B 0.7 1.6 up PAK1 -0.7 0.6 down 
 
Table 43: Different gene expression of heart ECs in response to high shear stress involved in 
smooth muscle contraction. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
ITGA1 1.4 2.7 up ACTA2 0.9 1.8 up 
TPM3 1.3 2.5 up TPM1 0.6 1.5 up 
MYLK 1.6 3.1 up MYL12B 0.7 1.6 up 
LMOD1 1.4 2.7 up MYH11 0.7 1.6 up 
ACTG2 1.9 3.8 up ITGB5 0.5 1.4 up 
MYL9 1.2 2.3 up     
 
Table 44: Different gene expression of heart ECs in response to high shear stress involved in 
platelet activation, signaling and aggregation. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
GNB4 2.2 4.5 up RHOB 1 1.9 up 
F2RL2 1.4 2.6 up VAV1 0.7 1.6 up 
LCP2 2.5 5.7 up CLU 0.9 1.8 up 
MMRN1 4.1 17.1 up TRPC3 1.1 2.2 up 
DGKK 3.3 9.9 up RASGRP2 1.2 2.4 up 
LCK 1.6 3 up PLEK 0.6 1.5 up 
PF4 2 4.1 up VWF -2.3 0.2 down 
ABCC4 1.4 2.7 up ITPR3 -2.1 0.2 down 
P2RY1 1.4 2.6 up GAS6 -1.5 0.4 down 
AKT3 0.8 1.8 up DAGLA -1.1 0.5 down 
F2R 0.7 1.7 up RAP1B -0.5 0.7 down 
TGFB3 1.7 3.3 up MGLL -1 0.5 down 
ITPR1 0.9 1.8 up SOD1 -0.6 0.7 down 
TGFB2 1.7 3.2 up GNAQ -0.6 0.6 down 
F13A1 3 8.2 up PTK2 -0.7 0.6 down 
GNG2 1.1 2.1 up HSPA5 -0.6 0.7 down 
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Table 44 continued: Different gene expression of heart ECs in response to high shear stress 
involved in platelet activation, signaling and aggregation. 
ARRB1 2.3 4.9 up PIK3R3 -1.8 0.3 down 
SERPING1 1.7 3.2 up FYN -0.8 0.6 down 
VEGFB 0.6 1.5 up SERPINE1 -0.8 0.6 down 
PIK3R2 0.5 1.4 up YWHAZ -0.7 0.6 down 
GNAI1 0.7 1.7 up HABP4 -0.7 0.6 down 
VEGFA 0.6 1.5 up CD36 -2.5 0.2 down 
IGF2 0.8 1.7 up TGFB1 -0.8 0.6 down 
GNG7 0.5 1.4 up THBS1 -0.7 0.6 down 
GNG12 0.7 1.6 up SELP -0.6 0.7 down 
GNGT2 0.8 1.7 up PECAM1 -0.5 0.7 down 
PIK3CB 0.9 1.8 up ITPR2 -0.5 0.7 down 
PDGFB 1 2.1 up PLA2G4A -1 0.5 down 
FCER1G 1.2 2.3 up     
 
Table 45: Different gene expression of heart ECs in response to high shear stress involved in 
chondroitin sulfate/ dermatan sulfate metabolism. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
SDC4 2.6 6.2 up GPC6 0.5 1.4 up 
GXYLT2 0.9 1.9 up CHPF2 -1.2 0.4 down 
IDUA 0.9 1.8 up CHST11 -1 0.5 down 
CHST7 1.1 2.1 up HYAL1 -1.3 0.4 down 
HEXA 1 1.9 up B4GALT7 -1.1 0.5 down 
CHST15 0.7 1.6 up HSPG2 -1.1 0.5 down 
GPC3 0.7 1.6 up HEXB -0.7 0.6 down 
DCN 1.9 3.6 up VCAN -0.6 0.7 down 
GPC4 0.6 1.5 up CSPG4 -0.8 0.6 down 
SDC3 0.5 1.5 up     
 
Table 46: Different gene expression of heart ECs in response to high shear stress involved in 
laminin interactions. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
ITGA1 1.4 2.7 up ITGB4 -1.2 0.4 down 
LAMA3 1.2 2.3 up ITGA6 -0.7 0.6 down 
NID2 1.4 2.6 up HSPG2 -1.1 0.5 down 
LAMA4 0.6 1.5 up ITGA3 -0.5 0.7 down 
LAMA2 0.6 1.5 up LAMA5 -0.6 0.6 down 
NID1 -0.9 0.5 down     
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Table 47: Different gene expression of heart ECs in response to high shear stress involved in 
signaling by VEGF. 
Gene Log.Fold. Change 
Linear. 
Fold. 
Change 
Comp. 
A-B Gene 
Log.Fold. 
Change 
Linear. 
Fold. 
Change 
Comp. 
A-B 
TRIB3 1.9 3.8 up NRP1 -1.5 0.4 down 
HSPB1 0.8 1.7 up FLT1 -1.3 0.4 down 
AKT3 0.8 1.8 up NRAS -0.5 0.7 down 
PGF 1.8 3.6 up MAPK11 -1 0.5 down 
ITPR1 0.9 1.8 up PTK2 -0.7 0.6 down 
VEGFB 0.6 1.5 up NOS3 -1.8 0.3 down 
PIK3R2 0.5 1.4 up FYN -0.8 0.6 down 
VEGFA 0.6 1.5 up SHB -0.9 0.5 down 
ABI2 0.6 1.5 up CTNNB1 -1 0.5 down 
PIK3CB 0.9 1.8 up KRAS -0.6 0.6 down 
SHC2 0.6 1.5 up MLST8 -0.6 0.7 down 
VAV1 0.7 1.6 up NCK1 -0.7 0.6 down 
PAK2 0.6 1.5 up PAK1 -0.7 0.6 down 
SPHK1 -1.6 0.3 down ITPR2 -0.5 0.7 down 
ITPR3 -2.1 0.2 down JUP -1.9 0.3 down 
BAIAP2 -1.8 0.3 down FLT4 -0.8 0.6 down 
KDR -1.5 0.4 down     
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